Patent Grant
12138195
A person or animal may have limited or impaired mobility such that typical urination processes are challenging or impossible. For example, a person may experience or have a disability that impairs mobility. A person may have restricted travel conditions such as those experienced by pilots, drivers, and workers in hazardous areas. Additionally, sometimes bodily fluids collection is needed for monitoring purposes or clinical testing.
Urinary catheters, such as a Foley catheter, can be used to address some of these circumstances, such as incontinence. Unfortunately, urinary catheters can be uncomfortable, painful, and can lead to complications, such as infections. Additionally, bed pans, which are receptacles used for the toileting of bedridden patients are sometimes used. However, bedpans can be prone to discomfort, spills, and other hygiene issues.
In an embodiment, a fluid collection assembly is disclosed. The fluid collection assembly includes a fluid impermeable barrier defining, at least one opening, a chamber in fluid communication with the at least one opening, and at least one fluid outlet. The fluid collection assembly also includes at least one porous material disposed in the chamber. Further, the fluid collection assembly includes at least one conduit attached to the at least one fluid outlet. The fluid collection assembly additionally includes one or more leak prevention features configured to at least inhibit bodily fluids leaking from the chamber
Features from any of the disclosed embodiments may be used in combination with one another, without limitation. In addition, other features and advantages of the present disclosure will become apparent to those of ordinary skill in the art through consideration of the following detailed description and the accompanying drawings.
The drawings illustrate several embodiments of the present disclosure, wherein identical reference numerals refer to identical or similar elements or features in different views or embodiments shown in the drawings.
The drawings illustrate several embodiments of the present disclosure, wherein identical reference numerals refer to identical or similar elements or features in different views or embodiments shown in the drawings.
Embodiments are directed to bodily fluids collection assemblies that include one or more leak prevention features along with systems including and methods of using such bodily fluids collection assemblies. An example fluid collection assembly includes a fluid impermeable barrier defining at least one opening, a chamber in fluid communication with the at least one opening, and at least one fluid outlet. The fluid collection assembly also includes at least one porous material (e.g., at least one wicking material) disposed in the chamber. The fluid collection assembly also includes at least one conduit attached to the fluid outlet. During operation, the fluid collection assembly may receive bodily fluids (e.g., urine) from an individual (e.g., human) through the opening and into the chamber. The porous material may receive at least some of the bodily fluids that enter the chamber. A suction applied from the conduit to the chamber may direct the bodily fluids in chamber towards the conduit. The conduit may then remove the bodily fluids from the chamber.
The fluid collection assembly includes one or more leak prevention features. The leak prevention features decrease the likelihood that the fluid collection assembly leaks compared to a substantially similar fluid collection assembly that does not include the leak prevention features. For example, the bodily fluids may leak from the fluid collection assembly when the bodily fluids flow out of the chamber through the opening or the bodily fluids fail to enter the chamber. The leaked bodily fluids may cause the individual embarrassment and an create unsanitary environment. The bodily fluids may leak from the fluid collection assembly for a variety of reasons, examples of which include movement of the individual, oversaturation of the porous material, and/or the opening of the fluid collection assembly becoming spaced from the individual. The leak prevention features of the fluid collection assembly are configured to minimize or prevent at least some of the reasons that cause the fluid collection assembly to leak.
In an embodiment, the leak prevention features of the fluid collection assembly 100 includes forming the fluid collection assembly 100 to exhibit a generally non-cylindrical shape. For example, some conventional fluid collection assemblies exhibit a generally cylindrical shape (e.g., bent generally cylindrical shape). Generally, the conventional fluid collection assemblies exhibiting the generally cylindrical shape rely on the thighs of the individual contacting the sides of the conventional fluid collection assembly to maintain the conventional fluid collection assembly against the vulva. However, the thighs of thinner individuals may be unable to contact the sides of the conventional fluid collection assembly and/or separating the legs of the individual (e.g., for comfort or movement) may cause the thighs to cease contacting the sides of the conventional fluid collection assembly. When the thighs of the individual do not contact the sides of the conventional fluid collection assembly, at least a portion of the conventional fluid collection assembly may move away from the individual thereby creating a passageway through which bodily fluids may flow without entering the chamber of the conventional fluid collection assembly. As such, in the illustrated embodiment, the fluid collection assembly 100 exhibits a generally disk-like shape. The generally disk-like shape of the fluid collection assembly 100 has the technical effect of allowing the fluid collection assembly 100 to contact the thighs of the individual even when the individual is thin or is separating the thighs thereof.
The generally disk-like shape of the fluid collection assembly 100 allows the fluid collection assembly 100 to be relatively flat. In particular, the generally disk-like shape of the fluid collection assembly 100 allows the opening 104 and the portion of the porous material 110 adjacent to the opening 104 to be generally flat. The generally flat shape of the fluid collection assembly 100 allows the fluid collection assembly 100 to exhibit a relatively small thickness relative to conventional fluid collection assemblies. The thickness of the fluid collection assembly 100 is measured from an outer surface 120 of a portion of the fluid impermeable barrier 102 defining the opening 104 to an opposing portion of the outer surface 120 of the fluid impermeable barrier 102 in a direction that is perpendicular to a width W and length L of the opening 104. For example, the fluid collection assembly 100 may exhibit a thickness that is about 10 mm or less, about 7.5 mm or less, about 5 mm or less, or in ranges of about 2.5 mm to about 7.5 mm or about 5 mm to about 10 mm. Such thickness may make using the fluid collection assembly 100 more comfortable than conventional fluid collection assemblies which, for example, may exhibit a thickness greater than about 2 cm. It is noted that, in some embodiments, the fluid collection assembly 100 may exhibit a thickness that is greater than about 1 cm, such as at least about 2 cm or at least about 3 cm. The relatively flat shape of the fluid collection assembly 100 may also have the technical effect of allowing the fluid collection assembly 100 to collect bodily fluids from orifices other than a urethral opening, such as from a wound or sacral drainage. It is noted that other non-cylindrically shaped fluid collection assemblies disclosed herein other than the generally disk-like shaped fluid collection assembly 100 (e.g., the fluid collection assembly 200 of
The generally disk-like shape of the fluid collection assembly 100 allows the opening 104 to exhibit a larger width W than conventional fluid collection assemblies. For example, conventional fluid collection assemblies may exhibiting an opening exhibiting a length (e.g., maximum dimension of the opening) that is significantly greater than a width (e.g., a dimension of the opening that is measured perpendicular to the length) of the opening, such as the length of the opening being more than 2.5 times greater than the width. However, the generally disk-like shape of the fluid collection assembly 100 allows the opening 104 to exhibit a width W that is 50% (i.e., half of) to 100% (i.e., equal to) the length L. For example, the width W may be about 50% to about 70%, about 60% to about 80%, about 70% to about 90%, or about 80% to about 100% of the length L. The increased width W of the opening 104 relative to the length L may allow the fluid collection assembly 100 to receive more bodily fluid (i.e., prevent leaks) that flow in a directly that is generally parallel (e.g., ±30°) to the width W compared to convention fluid collection assemblies while receiving the same or substantially the same amount of bodily fluids that flow in a direction that is generally parallel to the length L. The increased width W of the opening 104 relative to the length L may also allow the fluid collection assembly 100 to accommodate larger displacements (e.g., caused by the individual moving) in a direction that is generally parallel to the width W without leaking than conventional fluid collection assemblies while being able to accommodate the same or substantially same displacements in a direction that is generally parallel to the length L. In other words, the larger width W of the opening 104 relative to the length L of the opening 104 is another leak prevention feature of the fluid collection assembly 100.
In an embodiment, the generally flat shape of the fluid collection assembly 100 and/or the relatively large width W of the opening 104 relative to the length L of the opening 104 allows the fluid collection assembly 100 to be secured to the individual by merely resting the fluid collection assembly 100 on the individual (e.g., resting the fluid collection assembly 100 adjacent to the urethral opening). In an embodiment, the generally flat shape of the fluid collection assembly 100 and/or the relatively large width W of the opening 104 relative to the length L of the opening 104 allows the fluid collection assembly 100 to be secured to the individual using an adhesive, straps, or underwear (e.g., the underwear includes a pocket that receives the fluid collection assembly 100 and/or the underwear is configured to press the fluid collection assembly 100 against the urethral opening).
As will be discussed in more detail below, the fluid collection assembly 100 may exhibit a shape that is not a generally disk-like shape. For example, the fluid collection assembly 100 may exhibit a generally semi-cylindrical shape (
Referring to
In an embodiment, the one or more leak prevention features includes at least one additional porous material 116 at least partially occupying an interior of the conduit 112. As used herein, the additional porous material 116 may be integrally formed with at least a portion of the porous material 110 that is disposed in the chamber 106 (e.g., the additional porous material 116 and at least a portion of the porous material 110 exhibit single piece construction) or the additional porous material 116 may be distinct from the porous material 110. When the conduit 112 is not at least partially occupied with the additional porous material 116, the conduit 112 may require a suction force to remove bodily fluids from the chamber 106. In some embodiments, the suction force applied to the conduit 112 is not continuous since the constant air flow may dry the skin and/or the suction force may cause hickeys. As such, the suction force may not be applied to the conduit 112 when discharge of the bodily fluids (e.g., urination) is not expected. However, unexpected bodily fluid discharge may saturate the porous material 110 and cause the fluid collection assembly 100 to leak when a suction force is not applied to the conduit 112 without the additional porous material 116. However, when the conduit 112 is at least partially occupied by the additional porous material 116, the additional porous material 116 may pull the bodily fluids into the conduit 112 via capillary action, absorption, and/or wicking even when a suction force is not applied to the conduit 112. Even though the additional porous material 116 may be unable to pull the fluid completely through the conduit 112 or may pull the bodily fluids through the conduit 112 more slowly than the suction force, the additional porous material 116 may increase the quantity of bodily fluids that the fluid collection assembly 100 may receive before the porous material 110 saturates and the fluid collection assembly 100 leaks.
The additional porous material 116 extends inwardly from the inlet 114 of the conduit 112. The additional porous material 116 is positioned in the conduit 112 to contact the porous material 110 or such that any gap between the porous material 110 and the additional porous material 116 is sufficiently small that only a small quantity of bodily fluids is necessary to bridge the gap. In an embodiment, the additional porous material 116 may extend through an entirety of the conduit 112 which allows the additional porous material 116 to pull the bodily fluids a far distance into the conduit 112, such as through an entirety of the conduit 112. In an embodiment, the additional porous material 116 only extends inwardly from the inlet 114 for a distance that is less than a length of the conduit 112. Only extending the additional porous material 116 through a portion of the conduit 112 may improve fluid flow in the conduit 112. For example, the additional porous material 116 may slightly obstruct fluid flow in the portions of the conduit 112.
In an embodiment, the one or more leak prevention features includes a plurality of fluid outlets 108 and at least one conduit 112 extending from each of the fluid outlets 108. For example, the conduit 112 preferentially removes bodily fluids that are closer to the inlet 114. The plurality of fluid outlets 108 and the conduit 112 attached to each of the fluid outlets 108 allows a larger volume of the bodily fluids that are present in the chamber 106 to be preferentially removed from the chamber 106. In other words, the plurality of fluid outlets 108 and the conduit 112 decrease the amount of bodily fluids that remain in the chamber 106 thereby decreasing the likelihood that the fluid collection assembly 100 leaks. Further, the plurality of conduits 112 better distribute any pressure that is applied from the fluid collection assembly 100 to the individual thereby decreasing the likelihood that the fluid collection assembly 100 causes pressure ulcers. The conduits 112 may also be flat tubes which may make the conduits 112 more comfortable against the skin.
As previously discussed, the fluid impermeable barrier 102 at least partially defines an opening 104 and a chamber 106 (e.g., interior region). For example, at least one inner surface 118 of the fluid impermeable barrier 102 at least partially defines the chamber 106 within the fluid collection assembly 100. The fluid impermeable barrier 102 temporarily stores the bodily fluids in the chamber 106. The fluid impermeable barrier 102 may be formed of any suitable fluid impermeable material(s), such as a fluid impermeable polymer (e.g., silicone, polypropylene, polyethylene, polyethylene terephthalate, a polycarbonate, etc.), a metal film, natural rubber, another suitable material, or combinations thereof. As such, the fluid impermeable barrier 102 substantially prevents the bodily fluids from passing through the fluid impermeable barrier 102. In an example, the fluid impermeable barrier 102 may be air permeable and fluid impermeable. In such an example, the fluid impermeable barrier 102 may be formed of a hydrophobic material that defines a plurality of pores. At least one or more portions of at least an outer surface 120 of the fluid impermeable barrier 102 may be formed from a soft and/or smooth material, thereby reducing chaffing. During use, the outer surface 120 of the fluid impermeable barrier 102 may contact the wearer. The fluid impermeable barrier 102 may be sized and shaped to fit in the gluteal cleft between the legs of a female user.
The opening 104 provides an ingress route for bodily fluids to enter the chamber 106. The opening 104 may be defined by the fluid impermeable barrier 102 such as by an inner edge of the fluid impermeable barrier 102. For example, the opening 104 is formed in and extends through the fluid impermeable barrier 102, from the outer surface 120 to the inner surface 118, thereby enabling the bodily fluids to enter the chamber 106 from outside of the fluid collection assembly 100. In an embodiment, the opening 104 may be an elongated hole (the length L is more than 50% greater than the width W, as shown in
The fluid collection assembly 100 may be positioned proximate to the female urethral opening and urine may enter the chamber 106 of the fluid collection assembly 100 via the opening 104. The fluid collection assembly 100 is configured to receive the bodily fluids into the chamber 106 via the opening 104. When in use, the opening 104 may extend from a first location above the urethral opening (e.g., at or near the top of the urethral opening or the pubic hair) to a second location below the urethral opening (e.g., at or near the anus or the vaginal opening).
In some examples, as previously discussed, the fluid impermeable barrier 102 may define an fluid outlet 108 sized to receive the conduit 112. The at least one conduit 112 may be disposed in the chamber 106 or otherwise in fluid communication with the chamber 106 via the fluid outlet 108. The fluid outlet 108 may be sized and shaped to form an at least substantially fluid tight seal against the conduit 112 or the at least one tube thereby substantially preventing the bodily fluids from escaping the chamber 106.
The fluid impermeable barrier 102 may include markings thereon, such as one or more markings to aid a user in aligning the fluid collection assembly 100 on the wearer. For example, a line on the fluid impermeable barrier 102 (e.g., opposite the opening 104) may allow a healthcare professional to align the opening 104 over the urethral opening of the individual wearing the fluid collection assembly 100. In examples, the markings may include one or more of alignment guide or an orientation indicator, such as a stripe or hashes. Such markings may be positioned to align the fluid collection assembly 100 to one or more anatomical features such as a pubic bone, etc.
As previously discussed, the fluid collection assembly 100 includes porous material 110 disposed in the chamber 106. The porous material 110 may cover at least a portion (e.g., all) of the opening 104. The porous material 110 is exposed to the environment outside of the chamber 106 through the opening 104. The permeable properties referred to herein may be wicking, capillary action, absorption, diffusion, or other similar properties or processes, and are referred to herein as “permeable” and/or “porous.” The porous material 110 may also wick the bodily fluids generally towards an interior of the chamber 106, as discussed in more detail below. The porous material 110 may include one or more of a fluid permeable membrane 122 or a fluid permeable support 124.
In an embodiment, at least a portion of the porous material 110 may be a wicking material configured to wick any of the bodily fluids away from the opening 104, thereby preventing bodily fluids from escaping the chamber 106. The wicking material may not include absorption of the bodily fluids into the wicking material. Put another way, substantially no absorption of the bodily fluids into the wicking material may take place after the wicking material is exposed to the bodily fluids. While no absorption is desired, the term “substantially no absorption” may allow for nominal amounts of absorption of the bodily fluids into the wicking material (e.g., absorbency), such as less than about 30 wt % of the dry weight of the wicking material, less than 20 wt %, less than 10 wt %, less than about 7 wt %, less than about 5 wt %, less than about 3 wt %, less than about 2 wt %, less than about 1 wt %, or less than about 0.5 wt % of the dry weight of the wicking material. In an embodiment, at least a portion of the porous material 100 may include an absorbent or adsorbent material.
The fluid collection assembly 100 may include the fluid permeable membrane 122 disposed in the chamber 106. The fluid permeable membrane 122 may cover at least a portion (e.g., all) of the opening 104. The fluid permeable membrane 122 may be composed to pull/push the bodily fluids away from the opening 104, thereby preventing the bodily fluids from escaping the chamber 106.
The fluid permeable membrane 122 may include any material that may be permeable to the bodily fluids. For example, the fluid permeable membrane 122 may include fabric, such as a gauze (e.g., a silk, linen, or cotton gauze), another soft fabric, or another smooth fabric. Forming the fluid permeable membrane 122 from gauze, soft fabric, and/or smooth fabric may reduce chaffing caused by the fluid collection assembly 100.
The fluid collection assembly 100 may include the fluid permeable support 124 disposed in the chamber 106. The fluid permeable support 124 is configured to support the fluid permeable membrane 122 since the fluid permeable membrane 122 may be formed from a relatively foldable, flimsy, or otherwise easily deformable material. For example, the fluid permeable support 124 may be positioned such that the fluid permeable membrane 122 is disposed between the fluid permeable support 124 and the fluid impermeable barrier 102. As such, the fluid permeable support 124 may support and maintain the position of the fluid permeable membrane 122. The fluid permeable support 124 may include any material that may be permeable to the bodily fluids, such as any of the fluid permeable membrane materials disclosed herein above. For example, the fluid permeable membrane material(s) may be utilized in a more dense or rigid form than in the fluid permeable membrane 122 when used as the fluid permeable support 124. The fluid permeable support 124 may be formed from any fluid permeable material that is less deformable than the fluid permeable membrane 122. For example, the fluid permeable support 124 may include a porous polymer (e.g., nylon, polyester, polyurethane, polyethylene, polypropylene, etc.) structure (e.g., spun fibers, such as spun nylon fibers) or an open cell foam. In some examples, the fluid permeable support 124 may be formed from a natural material, such as cotton, wool, silk, or combinations thereof. In such examples, the material may have a coating to prevent or limit absorption of the bodily fluids into the material, such as a water repellent coating. In some examples, the fluid permeable support 124 may be formed from fabric, felt, gauze, or combinations thereof. In some examples, the fluid permeable membrane 122 may be optional. For example, the porous material 110 may include only the fluid permeable support 124. In some examples, the fluid permeable support 124 may be optionally omitted from the fluid collection assembly 100. For example, the porous material 110 may only include the fluid permeable membrane 122.
In an embodiment, the fluid permeable membrane 122 and the fluid permeable support 124 are wicking materials. In such an embodiment, the fluid permeable support 124 may have a greater ability to wick the bodily fluids than the fluid permeable membrane 122, such as to move the bodily fluids inwardly from the outer surface 120 of the fluid collection assembly 100. In some examples, the wicking ability of the fluid permeable support 124 and the fluid permeable membrane 122 may be substantially the same.
As previously discussed, the fluid permeable membrane 122 and the fluid permeable support 124 may at least substantially completely fill the portions of the chamber 106 that are not occupied by the conduit 112. In an example, not shown, the fluid permeable membrane 122 and the fluid permeable support 124 may not substantially completely fill the portions of the chamber 106 that are not occupied by the conduit 112. In such an example, the fluid collection assembly 100 includes a fluid reservoir (e.g., fluid reservoir 336 illustrated in
The fluid reservoir is a substantially unoccupied portion of the chamber 106. The fluid reservoir may be defined between the fluid impermeable barrier 102 and one or both of the fluid permeable membrane 122 and fluid permeable support 124. The bodily fluids that are in the chamber 106 may flow through the fluid permeable membrane 122 and/or fluid permeable support 124 to the fluid reservoir. The fluid reservoir may retain of the bodily fluids therein. The bodily fluids that are in the chamber 106 may flow through the fluid permeable membrane 122 and/or fluid permeable support 124 and, optionally, to the fluid reservoir. The fluid impermeable barrier 102 may retain the bodily fluids in the fluid reservoir. The fluid reservoir may be located in a portion of the chamber 106 that is designed to be located in a gravimetrically low point of the fluid collection assembly when the device is worn. In some examples (not shown), the fluid collection assembly 100 may include multiple fluid reservoirs, such as fluid reservoirs that are located adjacent to each of the fluid outlets 108.
In an embodiment, not shown, the conduit 112 may be at least partially disposed in the chamber 106. The conduit 112 may be used to remove fluid form the chamber 106. The conduit 112 (e.g., a tube) includes the inlet 114 and an outlet (not shown) positioned downstream from the inlet 114. The outlet may be operably coupled to a suction source, such as a vacuum pump for withdrawing the bodily fluids form the chamber through the conduit 112. The conduit 112 fluidly couples the chamber 106 with the fluid storage container (not shown) or the vacuum source (not shown).
The conduit 112 may include a flexible material such as plastic tubing (e.g., medical tubing). Such plastic tubing may include a thermoplastic elastomer, polyvinyl chloride, ethylene vinyl acetate, polytetrafluoroethylene, etc., tubing. In some examples, the conduit 112 may include silicon or latex. In some examples, the conduit 112 may include one or more portions that are resilient, such as to by having one or more of a diameter or wall thickness that allows the conduit to be flexible. In an embodiment, the conduit 112 may include a plurality of conduits 112 extending from each of the fluid outlet 108. In such an embodiment, each of the conduits 112 may be connected to a common conduit 126 that is connected to the vacuum source or each of the conduits 112 may be connected to the same vacuum source or different vacuum sources.
In an example, the conduit 112 is configured to be at least insertable into the chamber 106. In such an example, the conduit 112 may include one or more markers (not shown) on an exterior thereof that are located to facilitate insertion of the conduit 112 into the chamber 106. For example, the conduit 112 may include one or more markings thereon that are configured to prevent over or under insertion of the conduit 112, such as when the conduit 112 defines an inlet 114 that is configured to be disposed in or adjacent to the reservoir. In another example, the conduit 112 may include one or more markings thereon that are configured to facilitate correct rotation of the conduit 112 relative to the chamber 106. The one or more markings may include a line, a dot, a sticker, or any other suitable marking.
As described in more detail below, the conduit 112 is configured to be coupled to, and at least partially extend between, one or more of the fluid storage container (Fluid storage container 1090 of
The inlet 114 and the outlet of the conduit 112 are configured to fluidly couple (e.g., directly or indirectly) the vacuum source (not shown) to the chamber 106 (e.g., the reservoir). As the vacuum source (
The fluid collection assembly 200 exhibits a generally elongated shape. The elongated shape of the fluid collection assembly 200 may allow the fluid collection assembly 200 to exhibit a size and shape that fits in the gluteal cleft between the legs of an individual, especially a non-thin individual. The elongated shape of the fluid collection assembly 200 allows the opening 204 to exhibit an elongated shape wherein a length L of the opening 204 is greater (e.g., at least about 1.5 times greater, at least about 2 times greater, or at least 3 times greater) than the width W of the opening 204. The opening 204 may have an elongated shape because the space between the legs of a female is relatively small when the legs of the female are closed, thereby only permitting the flow of the bodily fluids along a path that corresponds to the elongated shape of the opening 204 (e.g., longitudinally extending opening). The opening 204 in the fluid impermeable barrier 202 may exhibit a length that is measured along the longitudinal axis of the fluid collection assembly 200 that may be at least about 10% of the length of the fluid collection assembly 200, such as about 25% to about 50%, about 40% to about 60%, about 50% to about 75%, about 65% to about 85%, or about 75% to about 95% of the length of the fluid collection assembly 200.
The leak prevention feature of the fluid impermeable barrier 202 may include the cross-sectional shape of the fluid impermeable barrier 202.
In an embodiment, the concavely curved cross-sectional shape of the fluid impermeable barrier 202 allows the conduit 212 to be positioned adjacent to a back surface 218 of the fluid impermeable barrier 202. Since the conduit 212 is positioned adjacent to the back surface 218, any air flow caused by a suction force applied to the conduit 212 is concentrated between the inlet of the conduit 212 and the opening 204. This concentration of the air flow may increase the amount of bodily fluids that are sucked into the conduit 212 and are removed from the chamber 206. Meanwhile, a substantially similar fluid collection assembly that includes a conduit spaced from the back surface may cause some of the air to flow between the conduit and the back surface of the fluid impermeable barrier thereby decreasing the amount of air flow between the opening and the conduit and the amount of bodily fluids received by the conduit.
The porous material 210 of the fluid impermeable barrier 202 includes a fluid permeable membrane 222 and a fluid permeable support 224. In an embodiment, the porous material 210 may include at least one absorbent layer 230 positioned between the fluid permeable membrane 222 and the fluid impermeable support 224. The absorbent layer 230 may be a leak prevention feature of the fluid impermeable barrier 202. For example, the fluid permeable membrane 222 may be a wicking material. Disposing the absorbent layer 230 downstream from the fluid permeable membrane 222 may help pull bodily fluids through the fluid permeable membrane 222. As such the absorbent layer 230 may increase the flow rate of bodily fluids through the fluid permeable membrane 222 and through the chamber 206 as a whole thereby decreasing leaking caused by oversaturation of the porous material 210. The absorbent layer 230 may include any suitable absorbent material, such as, super absorbent polymers, absorbent materials used in diapers, absorbent materials used in astronaut underwear, sponge-like material, one or more hydrophilic materials, etc.
It is noted that the fluid collection assembly 200 may exhibit shapes other than the concavely curved cross-sectional shape illustrated in
The fluid collection assembly 300 exhibits a generally cylindrical shape. The elongated shape of the fluid collection assembly 300 may allow the fluid collection assembly 300 to exhibit a size and shape that fits in the gluteal cleft between the legs of an individual, especially a non-thin individual. The elongated shape of the fluid collection assembly 300 allows the opening 304 to exhibit an elongated shape wherein a length of the opening 304 is significantly greater than the width of the opening 304. The opening 304 may have an elongated shape because the space between the legs of a female is relatively small when the legs of the female are closed, thereby only permitting the flow of the bodily fluids along a path that corresponds to the elongated shape of the opening 304 (e.g., longitudinally extending opening). Further, the curved outermost surface of the fluid collection assembly 300, and more particularly the curved outermost surface 328 of the porous material 310, will press against the labia folders.
Referring to
The open terminal end 340 of the conduit 312 may substantially only remove bodily fluids when the bodily fluids are present in the fluid reservoir 336 in sufficient quantity that the bodily fluids contact the open terminal end 340. As such, solely relying on the open terminal end 340 to remove bodily fluids may delay removal of the bodily fluids from the chamber 306 since the bodily fluids must first flow into the fluid reservoir 336 in sufficient quantity to be removed and at least some of the bodily fluids may not be removed from the chamber 306 when the quantity of bodily fluids in the fluid reservoir 336 are insufficient to contact the open terminal end 340, both of which may increase the likelihood that the fluid collection assembly 300 leaks. As such, the one or more leak prevention features of the fluid collection assembly 300 may include at least one conduit inlet 342 formed in the conduit 312 (e.g., the conduit 312 includes a plurality of inlets, namely the open terminal end 340 and the at least one conduit inlet 342). The conduit inlet 342 includes an inlet formed in the conduit 312 between the outlet portion 338 and the open terminal end 340 that is in fluid communication with an interior 362 (e.g., passageway) of the conduit 312. As used herein, the conduit inlet 342 refer to inlets formed in the conduit 312 that are distinct from the open terminal end 340. The conduit inlet 342 allows the conduit 312 to remove bodily fluids from the chamber 306 that are spaced from the fluid reservoir 336 in addition to the bodily fluids that are present in the fluid reservoir 336. In an embodiment, not shown, the open terminal end 340 of the conduit 312 may be omitted and the conduit 312 may only include one or more conduit inlets 342.
In an embodiment, the conduit inlet 342 may include a one-way valve (not shown). The one-way valve may be configured to allow the bodily fluids to flow from an exterior (e.g., the chamber 306) of the conduit 312 into an interior 362 of the conduit 312 and restrict the flow of the bodily fluids from the interior 362 to the exterior of the conduit 312. The one-way valve may prevent bodily fluids that are received upstream from one of the conduit inlet 342 from exiting the conduit 312. Allowing the bodily fluids to exit the conduit 312 at a location downstream from where the bodily fluids were received may increase the likelihood that the fluid collection assembly 300 leaks. The one-way valve may include any suitable one-way valve. In an example, the one-way valve is a flap formed in the interior 362 of the conduit 312. The flap may be configured to open when the flow of the bodily fluids is from the exterior to the interior 362 of the conduit 312 and close when the flow of the bodily fluids is from the interior 362 to the exterior of the conduit 312. In an example, the one-way valve includes a ball valve that substantially only permits the bodily fluids to flow from the exterior to the interior 362 of the conduit 312.
The conduit inlets 342 may also allow the fluid collection assembly 300 to be used when the individual using the fluid collection assembly 300 is in different positions. For example, when the individual is lying down, the fluid reservoir 336 is the gravimetrically lowest point of the chamber 306. As such, gravity pulls the bodily fluids towards the fluid reservoir 336 in addition to the permeability of the porous material 310 and the suction force. However, switching the position of the individual from the lying position to another position (e.g., sitting or standing position) may change the gravimetrically low point of the chamber 306.
In an embodiment, the conduit 312 may include valve (not shown) that closes at least one of the inlets of the conduit 312 (e.g., the open terminal end 340 or one of the conduit inlets 342) when the inlet is not at or near the gravimetrically low point of the chamber 306. The valve may close the inlet when the inlet is not at or near the gravimetrically low point of the chamber 306 since the inlet is more likely to pull air into the conduit 312 when the inlet is not at or near the gravimetrically low point of the chamber 306 and decreases the overall efficiency of the conduit 312. In an example, the valve may include a ball valve that is configured to close an inlet of the conduit 312 when the inlet is not at or near the gravimetrically low point of the chamber 306 and open the inlet of the conduit 312 when the inlet is at or near the gravimetrically low point of the chamber 306. For instance, a ball of the ball valve may press against the inlet of the conduit 312 when the inlet is not at or near the gravimetrically low point of the chamber 306 and the ball of move into a recess thereby opening the inlet when the inlet is at or near the gravimetrically low point of the chamber 306.
The conduit inlets illustrated in
The first conduit 312c exhibits a first length measured from the first outlet portion 338c to the first open terminal end 340c. The second conduit 312d exhibits a second length measured from the second outlet portion 338d to the second open terminal end 340d. The third conduit 312e exhibits a third length measured from the third outlet portion 338e to the third open terminal end 340e. In an embodiment, as illustrated, the first distance is greater than the second distance and the second distance is greater than the third distance. The different distances of the first, second, and third conduits 312c, 312d, 312e causes the first, second, and third open terminal ends 340c, 340d, 340e to be positioned in different locations of a chamber. Similar to the different locations of the inlets of the conduits discussed in
In an embodiment, the first, second, and third conduits 312c, 312d, 312e may intersect and form a common conduit or intersect at the fluid storage container. In such an embodiment, a suction force applied to one of the first, second, and third conduits 312c, 312d, 312e is also applied to the other ones of the first, second, and third conduits 312c, 312d, 312e. As such, each of the first, second, and third conduits 312c, 312d, 312e may include any of the valves discussed so that the first, second, and third conduits 312c, 312d, 312e to pull the bodily fluids therein and minimize the amount of air pulled therein. In an embodiment, the first, second, and third conduits 312c, 312d, 312e may each be connected to separate vacuum sources thereby eliminating the need for valves. However, many locations (e.g., hospitals) may not include multiple vacuum sources and/or the multiple vacuum sources may increase the cost of using a fluid collection assembly that includes the first, second, and third conduits 312c, 312d, 312e. In an embodiment, the first, second, and third conduits 312c, 312d, 312e may be connected to a suction control apparatus that controls the amount of suction that is applied to each of the first, second, and third conduits 312c, 312d, 312e.
As previously discussed, the conduits discussed with regards to
The fluid collection assembly 400 includes at least one fluid reservoir 436 that is substantially unoccupied. As previously discussed, the fluid reservoir 436 extends at least partially along the length of the conduit 412. The fluid reservoir 436 may be a leak prevention feature since the fluid reservoir 436 may facilitate quick removal of any bodily fluids that are present in the chamber 406. For example, the conduit 412 may define a plurality of inlets 414 longitudinally spaced from each other, which allows the conduit 412 to remove bodily fluids from a plurality of different locations in the chamber 406. At least one of the plurality of inlets 414 of the conduit 412 may be adjacent to the fluid reservoir 436. The fluid reservoir 436 may allow the bodily fluids to quickly and easily flow to the plurality of inlets 414. For instance, the fluid reservoir 436 may allow the bodily fluids to accumulate adjacent to at least one of the inlets 414 when the individual is in a sitting position. The fluid reservoir 436 may then allow the bodily fluids to quickly and easily flow to another one(s) of the inlets 414 when the individual moves, such as moves from the sitting position to a standing position. Thus, the fluid reservoir 436 allows for the quick removal of bodily fluids from the chamber 406, even when the individual moves.
In the illustrated embodiment, the fluid reservoir 436 is defined by and positioned between the fluid impermeable barrier 402 and the conduit 412. For example, the fluid impermeable barrier 402 may include a bulge 450 extending outwardly from the rest of the fluid impermeable barrier 402. The bulge 450 may partially define the fluid reservoir 436. In an embodiment, the fluid reservoir 436 is defined between at least the porous material 410 and the conduit 412, between at least the fluid impermeable barrier 402 and the porous material 410, or within the porous material 410.
In an embodiment, the one or more leak prevention features of any of the fluid collection assemblies disclosed herein may include a leak prevention layer that forms a portion of the porous material. The leak prevention layer is configured to encourage flow of the bodily fluids therein in a first direction and discourage flow of the bodily fluids therein in a second direction that is opposite the first direction thereby inhibiting the bodily fluids from leaking from the chamber.
Each of the sheets 554 define a plurality of void spaces 556 extending therethrough. The void spaces 556 may include apertures (as shown), a plurality of interconnected pores, etc. The plurality of void spaces 556 are configured to control the flow rate of the bodily fluids flowing therethrough. Generally, the void spaces 556 are configured such that the flow rate of the bodily fluids increases the further downstream the bodily fluids flow (e.g., with further distance from the first sheet 554a and/or the urethral opening) which encourages the bodily fluids to flow in the downstream direction. The void spaces 556 also discourage the bodily fluids flowing in an upstream direction (e.g., a direction opposite the downstream direction) since the flow rate of the bodily fluids flowing in an upstream direction generally decreases. For example, referring to
In an embodiment, the rate at which the bodily fluids flow through each of the sheets 554 may depend on the collective cross-sectional area of the void spaces 556 (e.g., the sum of the cross-sectional area of each of the void spaces 556 along a selected plane). Generally, increasing the collective cross-sectional area of the void spaces 556 increases the flow rate of the bodily fluids and decreasing the collective cross-sectional area of the void spaces 556 decreases the flow rate of the bodily fluids. As such, the collective cross-sectional area of the void spaces 556 generally increases in the downstream direction.
In an embodiment, the collective cross-sectional area of the void spaces 556 depends on the number density of void spaces 556 that are formed in each of the sheets 554 in a selected area. In such an embodiment, the number density of void spaces 556 formed in each sheet 554 generally increases in the downstream direction. For example, as illustrated, the first sheet 554a may exhibit a first number density of the void spaces 556, the second sheet 554b may exhibit a second number density of void spaces 556 that is greater than the first number density, and the third sheet 554c may exhibit a third number density of void spaces 556 that is greater than the second number density.
In an embodiment, the collective cross-sectional area of the void spaces 556 depends on the average cross-sectional area of each of the void spaces 556 that are formed in each of the sheets 554 in a selected area. In such an embodiment, the average cross-sectional area of each of the void spaces 556 formed in each sheet 554 generally increases in the downstream direction. For example, as illustrated, each of the void spaces 556 of the first sheet 554a may exhibit a first average cross-sectional area, each of the void spaces 556 of the second sheet 554b may exhibit a second average cross-sectional area that is greater than the first average cross-sectional area, and each of the void spaces 556 of the third sheet 554c may exhibit a third average cross-sectional area that is greater than the second average cross-sectional area.
In an embodiment, each of the sheets 554 are not attached to each other or only selected portions of the sheets 554 are attached to each other. In such an embodiment, passageways 558 are allowed to form between adjacent sheets 554. For example, as illustrated, the void spaces 556 of adjacent sheets 554 may not align with each other. Without the passageways 558, the bodily fluid may be unable to flow through void spaces 556 that are not aligned with each other, especially if the sheets 554 are formed from a fluid impermeable material or a material exhibiting limited fluid permeability. Thus, without the passageways 558, the leak prevention layer 552 may be unable to encourage the bodily fluids to flow in the downstream direction.
In an embodiment, the leak prevention layer 552 may be formed from wicking materials (e.g., at least one hydrophobic material). In an embodiment, the leak prevent layer 552 may be formed from any of the same materials as the fluid permeable membranes or the fluid permeable supports disclosed herein. In an embodiment, the leak prevention layer 552 may be formed from non-wicking material, such as at least one non-polyester polymer, at least one hydrophilic material, or any other absorbent or adsorbent material.
The porous material 510a includes the leak prevention layer 552a and at least one additional layer 560a. The additional layer 560a may include, for example, a fluid permeable membrane, a fluid permeable support, or an absorption layer. The leak prevention layer 552a extends at least partially across the opening 504a. As such, the leak prevention layer 552a may contact or otherwise be positioned proximate to the a urethral opening of the individual during operation. The additional layer 560a may be positioned downstream from the leak prevention layer 552a and support the leak prevention layer 552a.
The porous material 510b includes the leak prevention layer 552b, a fluid permeable membrane 522, and at least one additional layer 560b. The additional layer 560b may include, for example, a fluid permeable support, or an absorption layer. The fluid permeable membrane 522 may be selected to be softer or otherwise more comfortable when contacting the vulva of an individual than the leak prevention layer 552b. As such, the fluid permeable membrane 522 extends at least partially across the opening 504b thereby preventing the leak prevention layer 552b from contacting the vulva. Instead, the fluid permeable membrane 522 may contact or otherwise be positioned proximate to the a urethral opening of the individual during operation. The leak prevention layer 552 may be positioned between the fluid permeable membrane 522 and the additional layer 560b thereby allowing the additional layer 560b to be positioned downstream from and support the leak prevention layer 552b.
The fluid collection assembly 600 also includes a fluid reservoir 636 that is substantially unoccupied. The conduit 612 includes at least one inlet 614 (e.g., open terminal end or conduit inlet) that is adjacent to or positioned in the fluid reservoir 636. The conduit 612 may not extend all the way into the fluid reservoir 636 to prevent the fluid impermeable barrier 602 from being suctioned to and completely obstructing the inlet 614. Generally, the conduit 612 is only able to remove bodily fluids that accumulate in the fluid reservoir 636 once the bodily fluids contact or are adjacent to the inlet 614, otherwise the inlet 614 merely pull air into the conduit 612. In other words, the conduit 612 may only remove bodily fluids from the fluid reservoir 636 when a certain quantity of bodily fluids are present in the fluid reservoir 636. As such, there may be a delay from when the bodily fluids enter the fluid reservoir 636 and when the conduit 612 begins to remove the bodily fluids from the fluid reservoir 636. Further, bodily fluids may remain in the fluid reservoir 636 long after the individual discharges the bodily fluids. The delay in removing the bodily fluids and leaving some bodily fluids in the fluid reservoir 636 may increase the likelihood that the fluid collection assembly 600 leaks.
The fluid collection assembly 600 may include a leak prevention feature that is configured to minimize any delay in removing the bodily fluids and minimize the amount of bodily fluids that remain the fluid reservoir 636. The leak prevention feature may include an additional porous material 616 that is partially disposed in at least a portion of an interior 662 of conduit 612. The additional porous material 616 also extends from the inlet 614 into the fluid reservoir 636, such as from the inlet 614 to the fluid impermeable barrier 602. During operation, the bodily fluids that enter the fluid reservoir 636 contact the addition porous material 616 before the bodily fluids contact or are adjacent to the inlet 614 of the conduit 612. The additional porous material 616 pulls the bodily fluids into the interior 662 of the conduit 612 via wicking, capillary action, or absorption. The conduit 612 may remove the bodily fluids that are pulled into the interior 662 of the conduit 612. Thus, the additional porous material 616 may decrease the delay between the bodily fluids entering the fluid reservoir and removing the bodily fluids from the fluid reservoir 636. Further, the additional porous material 616 may continue to pull the bodily fluids from the fluid reservoir 636 even when the individual ceases to discharge bodily fluids into the chamber 606. For example, the additional porous material 616 may remove the bodily fluids from the fluid reservoir 636 until all or substantially all of the bodily fluids are removed from the fluid reservoir 636. Thus, the additional porous material 616 decreases the likelihood that the fluid collection assembly 600 leaks the bodily fluids.
In an embodiment, the one or more leak prevention features of any of the fluid collection assemblies disclosed herein include one or more features that are configured to allow the fluid collection assemblies to conform to a shape of a vulva and a region about the vulva. For example, the shape, size, and topography of the vulva and the region about the vulva may vary. These variations may cause gaps to form between the fluid collection assembly and the vulva and the region about the vulva and bodily fluids may leak through these gaps. As such, the leak prevention features may be configured to cause the fluid collection assembly to better conform to the shape, size, and topography of the vulva and the region about the vulva to eliminate or at least minimize any gaps between the fluid collection assembly and the vulva and the region about the vulva. For example,
The conduit 712 exhibits a “crinkle” structure. For example, the conduit 712 may include one or more peaks 764 (e.g., a plurality of circumferentially extending peaks 764 or single helically extending peak 764). The conduit 712 may also include one or more valleys 766 (e.g., a plurality of circumferentially extending valleys 766 or a single helically extending valley 766) disposed between portions of the peaks 764 spaced apart along a longitudinal direction of the conduit 712. The conduit 712 may be configured to be bent. The peaks 764 and valleys 766 may allow the conduit 712 to more freely bend when an external force is applied thereto and to maintain the bent shape after the external force is removed. The bent shape of the conduit 712 also causes the rest of the fluid collection assembly 700 to bend. Thus, the conduit 712 may allow the fluid collection assembly 700 to be conformed to a shape that generally corresponds to the shape of the vulva and the region about the vulva and to maintain said shape thereby inhibiting or preventing leaks.
In an embodiment, the valleys 766 remain substantially unoccupied. For example, the porous material 710 may not extend into the valleys 766 which may prevent the porous material 710 from inhibiting the conduit 712 from bending or prevent the conduit 712 from maintaining the shape thereof after the external force is removed. Also, configuring the porous material 710 to not extend into the valleys 766 may allow the porous material 710 to be formed using an extruding process instead of other more complicated processes. In an embodiment, the valleys 766 are occupied by the porous material 710.
The fluid collection assembly 800 includes a shape memory material 872. The shape memory material 872 may include a shape memory polymer or a metal (e.g., shape memory metal). Suitable shape memory materials are composed to adopt an intermediate or permanent shape in response to a stimuli. The stimuli may include an external physical force (e.g., bending force), heat, electrical bias, or a magnetic field. While the term “shape memory” is used to describe some of the “shape memory materials” herein, it should be understood that, in some examples, the material modified by the term “shape memory” may not necessarily need to return to a preselected shape upon application of a stimuli, as understood as the classical definition of the “shape memory material.” Rather, at least some of the shape memory materials herein may simply hold a selected shape when bent, set, or cured into a specific shape and/or when cooled in a specific shape, regardless of the stimuli applied thereto after. The shape memory materials may be returned to the original shape or changed to a new shape by application of stimuli. For example, a metal wire bent to a first shape may be utilized as the shape memory material, whereinafter the metal wire may be modified to a second shape via physical force applied thereto or via heating. For example, the shape memory material 872 may include a shape memory alloy (e.g., nitinol), a shape memory polymer, copper, aluminum, steel, iron, or any other suitable material that is bendable and maintains its shape after being bent. In the illustrated embodiment, the shape memory material 872 is a wire exhibiting a general zig-zag shape. The generally zig-zag shape of the shape memory material 872 allows the shape memory material 872 to change the shape of a greater portion of fluid collection assembly 800 than if the shape memory material 872 was a generally straight or curved wire while exhibiting a lesser weight than if the shape memory material 872 was a plate.
In an embodiment, as illustrated, the shape memory material 872 may be attached to the bottom surface 870 of the fluid impermeable barrier 802. The shape memory material 872 may be attached to the bottom surface 870 via an adhesive or any other suitable attachment technique. When the shape memory material 872 is attached to the bottom surface 870, a coating may be applied to the shape memory material 872 to prevent the shape memory material 872 from chaffing the individual. In an embodiment, the shape memory material 872 may be disposed in the fluid impermeable barrier 802 or attached to an inner surface of the fluid impermeable barrier 802. In an embodiment, the shape memory material 872 is disposed in or attached to the at least one porous material or the conduit of the fluid collection assembly.
The composition of the shape memory material 872 and examples of different shape memory materials that may form a leak prevention feature are disclosed in International Application No. WO 2021/016026 filed on Jul. 15, 2020, the disclosure of which is incorporated herein, in its entirety, by this reference.
Some conventional fluid collection assemblies include a conduit exhibiting an outer diameter that is greater than about 1 cm that extends through substantially all of the fluid collection assembly. Such conventional fluid collection assemblies may exhibit a fluid reservoir that may hold about 10 milliliters (“ml”) to about 14 ml of bodily fluids and may hold about 24 ml of bodily fluids in the chamber before leaking. Some individuals may discharge more than 24 ml of bodily fluids in the first second of urination which may cause the fluid collection assembly to leak, especially if there is any delay in removing the bodily fluids from the chamber. However, it is currently believed by the inventors that the diameter of the conduit may be decreased without decreasing the amount of bodily fluids that are removed from the chamber thereby increasing the amount of bodily fluids that may be held in the chamber. In other words, the one or more leak prevention features of any of the fluid collection assemblies disclosed herein may include using a conduit exhibiting a diameter that is about 5 mm to about 9 mm, such as in ranges of about 5 mm to about 6 mm, about 5.5 mm to about 6.5 mm, about 6 mm to about 7 mm, about 6.5 mm to about 7.5 mm, about 7 mm to about 8 mm, about 7.5 mm to about 8.5 mm, or about 8 mm to about 9 mm. In an example, a fluid collection assembly including a conduit exhibiting an outer diameter of about 9 mm may hold about 2% more bodily fluids before leaking than a substantially similar fluid collection assembly including a conduit exhibiting an outer diameter of about 1 cm (this number inherently depends on the length, diameter, and shape of the fluid collection assembly and the porosity of the porous material). The 2% increase in the amount of bodily fluids that are held in the chamber may be sufficient to prevent the fluid collection assembly from leaking. In an example, a fluid collection assembly including a conduit exhibiting an outer diameter of about 7.5 mm may hold about 5% more bodily fluids before leaking than a substantially similar fluid collection assembly including a conduit exhibiting an outer diameter of about 1 cm. The 5% increase in the amount of bodily fluids that are held in the chamber may be sufficient to prevent the fluid collection assembly from leaking. In an example, a fluid collection assembly including a conduit exhibiting an outer diameter of about 5 mm may hold about 9% more bodily fluids before leaking than a substantially similar fluid collection assembly including a conduit exhibiting an outer diameter of about 1 cm. The 9% increase in the amount of bodily fluids that are held in the chamber may be sufficient to prevent the fluid collection assembly from leaking.
In an embodiment, the one or more leak prevention features used in any of the fluid collection assemblies disclosed herein may include pre-moistening the at least one porous material before the fluid collection assemblies receive bodily fluids. Pre-moistening the porous material may include moistening the porous material with a non-bodily fluid, such as water, saline, or another suitable liquid. Pre-moistening the porous material may improve flow of the bodily fluids through the porous material. For example, the flow of the bodily fluids through a dry porous material may be slower than the flow of the bodily fluids through a moistened porous material (e.g., a pre-moistened porous material or a previously used porous material).
The fluid collection assemblies shown in
The sheath 976 includes (e.g., may be formed from) a fluid impermeable barrier 902 that is sized and shaped to fit into the hollowed region of the receptacle 974. For example, the sheath 976 may be generally tubular or cup-shaped, as shown. The generally tubular or cup-shaped fluid impermeable barrier 902 may at least partially define the outer surface 920 of the sheath 976. The fluid impermeable barrier 902 may be similar or identical to any of the fluid impermeable barriers disclosed herein, in one or more aspects. For example, the fluid impermeable barrier 902 may be constructed of any of the materials disclosed herein for the fluid impermeable barrier 102. The fluid impermeable barrier 902 at least partially defines the chamber 906. For example, the inner surface 918 of the fluid impermeable barrier 902 at least partially defines the perimeter of the chamber 906. The chamber 906 may be similar or identical to any of the chambers disclosed herein in one or more aspects. For example, the chamber 906 may at least temporarily retain bodily fluids therein. As shown, the fluid collection assembly 900 may include at least one porous material 910 therein. The porous material 910 may be similar or identical to any of the porous materials disclosed herein in one or more aspects. For example, the porous material 910 may include one or more of a fluid permeable membrane 922, a fluid permeable support 924, an absorbent layer (not shown), or a leak prevention layer (not shown). The fluid impermeable barrier 902 may also define an opening 904 extending through the fluid impermeable barrier 902 that is configured to have a male urethral opening (e.g., penis) positioned therethrough.
The sheath 976 and fluid impermeable barrier 902 may also include at least one vacuum relief hole 982 that allows the chamber 906 to remain substantially at atmospheric pressure. The vacuum relief hole 982 may be located at any point on the sheath 976, such as near or nearer the opening 980. In some examples (not shown), the vacuum relief hole 982 may extend through the cap 984 or be disposed beneath the cap 984. In some examples, the fluid collection assembly 900 may not include the vacuum relief hole 982, such as when a more complete seal as desired for the chamber 906.
The sheath 976 also includes at least a portion of the conduit 912 therein, such as at least partially disposed in the chamber 906 of the conduit 912 only disposed in the fluid outlet 908. For example, the conduit 912 may extend from the sheath 976 at the distal region 934 to a proximal region 932 at least proximate to the opening 980. The proximal region 932 may be disposed near or on the skin around the male urethral opening (e.g., on the penis or pubic area therearound). Accordingly, when a patient lays on their back, bodily fluids (e.g., urine) may aggregate near the opening 980 against the skin of the subject. The bodily fluids may be removed from the chamber 906 via the conduit 912.
In some examples, the fluid impermeable barrier 902 may be constructed of a material and/or have a thickness that allows the sheath 976 to collapse when placed under vacuum, such as to remove air around a penis in the fluid collection assembly 900 during use. In such examples, the conduit 912 may extend only to or into the distal region 934 in the chamber 906 (e.g., not through to the area adjacent the opening).
In an example, portions of the chamber 906 may be substantially empty due to the varying sizes and rigidity of the male penis. However, in some examples, the outermost regions of the chamber 906 (e.g., periphery of the interior regions of the sheath 976) may include porous material 910 (e.g., one or more of the fluid permeable membrane 922 and fluid permeable support 924). For example, the porous material 910 may be bonded to the inner surface 918 of the fluid impermeable barrier 902. The porous material 910 may be positioned (e.g., at the distal end of the chamber 906) to blunt a stream of urine from the male urethral opening thereby limiting splashing and/or to direct the bodily fluids to a selected region of the chamber 906. Since the chamber 906 is substantially empty (e.g., substantially all of the chamber 906 forms a reservoir), the bodily fluids are likely to pool at a gravimetrically low point of the chamber 906. The gravimetrically low point of the chamber 906 may be at an intersection of the skin of an individual and the fluid collection assembly 900, a corner formed in the sheath 976, or another suitable location depending on the orientation of the wearer.
The porous material 910 may include one or more of the fluid permeable membrane 922 or the fluid permeable support 924. The fluid permeable membrane 922 and the fluid permeable support 924 may be similar or identical to any of the fluid permeable membranes or fluid permeable supports as respectively disclosed herein, in one or more aspects such as material make-up or wicking ability. One or more of the fluid permeable membrane 922 or the fluid permeable support 924 may be disposed between the fluid impermeable barrier 902 and a penis inserted into the chamber 906. The fluid permeable membrane 922 may be positioned between the fluid impermeable barrier 902 and a penis inserted into the chamber 906, such as between the fluid permeable support 924 and penis of a wearer as shown. The fluid permeable support 924 may be positioned between the fluid permeable membrane 922 and the fluid impermeable barrier 902. The inner surface 918, optionally including the end of the chamber 906 substantially opposite the opening 904, may be covered with one or both the fluid permeable membrane 922 or the fluid permeable support 924. The fluid permeable support 924 or the fluid permeable membrane 922 may be affixed (e.g., adhered) to the fluid impermeable barrier 902. The fluid permeable support 924 or the fluid permeable membrane 922 may be affixed to each other. In some examples, the porous material 910 only includes the fluid permeable membrane 922 or the fluid permeable support 924.
In some examples, the fluid collection assembly 900 includes a cap 984 at a distal region 934. The cap 984 defines an interior channel through which the bodily fluids may be removed from the fluid collection assembly 900. The interior channel is in fluid communication with the chamber 906. The cap 984 may be disposed over at least a portion of the distal region 934 of one or more of the fluid impermeable barrier 902 or the porous material 910. The cap 984 may be made of a polymer, rubber, or any other fluid impermeable material. The cap 984 may be attached to one or more of the fluid impermeable barrier 902, the porous material 910, or the conduit 912. The cap 984 may have a laterally extending flange 986 and a longitudinally extending flange 988. The laterally extending flange 986 may cover at least a portion of the distal region 934 of the fluid collection assembly 900. The longitudinally extending flange 988 may laterally extend a distance from the sheath 976. The longitudinally extending flange 972 is sized and configured to receive and fluidly seal against the conduit 912, such as within the interior channel. The conduit 912 may extend a distance within or through the cap 984, such as to the porous material 910, through the porous material 910, or to a point set-off from the porous material 910. In the latter example, as depicted in
The reservoir 936 is an unoccupied portion of device such as in the cap 984 and is void of other material. In some examples, the reservoir 936 is defined at least partially by the porous material 910 and the cap 984. During use, the bodily fluids that are in the chamber 906 may flow through the porous material 910 to the reservoir 936. The reservoir 936 may store at least some of the bodily fluids therein and/or position the bodily fluids for removal by the conduit 912. In some examples, at least a portion of the porous material 910 may extend continuously between at least a portion of the opening of the interior channel and chamber 906 to move any bodily fluid from the opening directly to the reservoir 936.
In some examples (not shown), the fluid impermeable barrier 902 may be disposed on or over the cap 984, such as enclosing the cap 984 within the chamber 906.
In some examples, the sheath 976 may include at least a portion of the conduit 912 therein, such as at least partially disposed in the chamber 906. For example, the conduit 912 may extend from the sheath 976 to a region at least proximate to the opening 980. The inlet of the conduit 912 may be positioned adjacent to the annular base 978. The inlet of the conduit 912 may be positioned to be adjacent or proximate to the gravimetrically low point of the chamber 906, such as adjacent to the annular base 978. For example, the inlet may be co-extensive with or offset from the opening 980. In examples, the inlet may be positioned adjacent to the distal region 944 of the sheath 976.
The proximal region 932 may be disposed near or on the skin around the male urethral opening (e.g., around the penis) and the inlet of the conduit 912 may be positioned in the proximal region 932. The outlet of the conduit 912 may be directly or indirectly coupled to a vacuum source. Accordingly, the bodily fluids may be removed from the proximal region 932 of the chamber 906 via the conduit 912.
The receptacle 974, the sheath 976, the cap 984, and the conduit 912 may be attached together using any suitable method. For example, at least two of the receptacle 974, the sheath 976, the cap 984, or the conduit 912 may be attached together using at least one of an interference fit, an adhesive, stitching, welding (e.g., ultrasonic welding), tape, any other suitable method, or combinations thereof.
In some examples (not shown), the fluid collection assembly 900 may have a one piece design, with one or more of the sheath 976, the receptacle 974, and the cap 984 being a single, integrally formed piece.
Also as shown, the conduit 912 may be at least partially disposed with the chamber 906 of a fluid collection assembly 900. The conduit 912 may extend from the distal region 944 to the proximal region 932. For example, the conduit 912 may extend through the cap 984 to a point adjacent to the receptacle 974. The conduit 912 is sized and positioned to be coupled to a fluid storage container or the vacuum source (
The fluid collection assembly 900 may include any of the leak prevention features disclosed herein. In an example, as shown, the one or more leak prevent features of the fluid collection assembly 900 may include the porous material 910 having least one additional layer 1052. The additional layer 1052 may be an absorbent layer similar to the absorbent layer 230 of
Further examples of fluid collection assemblies that are configured to collect bodily fluids from males are disclosed in U.S. patent application Ser. No. 16/433,773 filed on Jun. 6, 2019, the disclosure of which is incorporated herein, in its entirety, by this reference.
In some examples, the vacuum source may be remotely located from the fluid collection assembly 900. In such examples, the conduit 912 may be fluidly connected to the fluid storage container, which may be disposed between the vacuum source and the fluid collection assembly 900.
During operation, a male using the fluid collection assembly 900 may discharge bodily fluids into the chamber 906. The bodily fluids may pool or otherwise be collected in the chamber 906. At least some of the bodily fluids may be pulled through the interior of the conduit 912 via the inlet. The bodily fluids may be drawn out of the fluid collection assembly 900 via the vacuum/suction provided by the vacuum source. During operation, the aperture 962 may substantially maintain the pressure in the chamber 906 at atmospheric pressure even though the bodily fluids are introduced into and subsequently removed from the chamber 906.
The suction force may be applied to the outlet of the conduit 1012 by the vacuum source 1092 either directly or indirectly. The suction force may be applied indirectly via the fluid storage container 1090. For example, the outlet of the conduit 1012 may be disposed within the fluid storage container 1090 and an additional conduit 1012 may extend from the fluid storage container 1090 to the vacuum source 1092. Accordingly, the vacuum source 1092 may apply suction to the fluid collection assembly 1000 via the fluid storage container 1090. The suction force may be applied directly via the vacuum source 1092. For example, the outlet of the conduit 1012 may be disposed within the vacuum source 1092. An additional conduit 1012 may extend from the vacuum source 1092 to a point outside of the fluid collection assembly 1000, such as to the fluid storage container 1090. In such examples, the vacuum source 1092 may be disposed between the fluid collection assembly 1000 and the fluid storage container 1090.
The fluid collection assemblies 1000 may be similar or identical to any of the fluid collection assemblies disclosed herein in one or more aspects. The fluid collection assembly 1000 may be shaped and sized to be positioned adjacent to a female urethral opening or have a male urethral opening positioned therethrough (e.g., receive a penis therein). For example, the fluid collection assembly 1000 may include a fluid impermeable barrier at least partially defining a chamber (e.g., interior region) of the fluid collection assembly 1000. The fluid impermeable barrier also defines an opening extending therethrough from the external environment. The opening may be positioned adjacent to a female urethral opening or have a male urethral opening positioned therethrough. The fluid collection assembly 1000 may include a fluid permeable membrane disposed within the fluid impermeable barrier. The fluid collection assembly 1000 may include at least one porous material disposed in the chamber such as one or more of a fluid permeable support and a fluid permeable membrane. The fluid collection assembly 1000 includes the shape memory material on or incorporated in one or more components thereof. The shape memory material is sized, shaped, and positioned to retain a selected geometric configuration as disclosed herein. The conduit 1012 may extend into the fluid collection assembly 1000 at a first end (e.g., proximal) region, through one or more of the fluid impermeable barrier, fluid permeable membrane, or the fluid permeable support to a second end (e.g., distal) region of the fluid collection assembly 1000. The conduit 1012 includes an inlet and an outlet, the outlet being fluidly coupled to the fluid storage container and the inlet being positioned in a portion of the chamber selected to be at a gravimetrically low point of the fluid collection assembly 1000 when worn.
The fluid storage container 1090 is sized and shaped to retain the bodily fluids therein. The fluid storage container 1090 may include a bag (e.g., drainage bag), a bottle or cup (e.g., collection jar), or any other enclosed container for storing bodily fluids such as urine. In some examples, the conduit 1012 may extend from the fluid collection assembly 1000 and attach to the fluid storage container 1090 at a first point therein. An additional conduit 1012 may attach to the fluid storage container 1090 at a second point thereon and may extend and attach to the vacuum source 1092. Accordingly, a vacuum (e.g., suction) may be drawn through fluid collection assembly 1000 via the fluid storage container 1090. The bodily fluids, such as urine, may be drained from the fluid collection assembly 1000 using the vacuum source 1092.
The vacuum source 1092 may include one or more of a manual vacuum pump, and electric vacuum pump, a diaphragm pump, a centrifugal pump, a displacement pump, a magnetically driven pump, a peristaltic pump, or any pump configured to produce a vacuum. The vacuum source 1092 may provide a vacuum or suction to remove the bodily fluids from the fluid collection assembly 1000. In some examples, the vacuum source 1092 may be powered by one or more of a power cord (e.g., connected to a power socket), one or more batteries, or even manual power (e.g., a hand operated vacuum pump). In some examples, the vacuum source 1092 may be sized and shaped to fit outside of, on, or within the fluid collection assembly 1000. For example, the vacuum source 1092 may include one or more miniaturized pumps or one or more micro pumps. The vacuum sources 1092 disclosed herein may include one or more of a switch, a button, a plug, a remote, or any other device suitable to activate the vacuum source 1092.
While various aspects and embodiments have been disclosed herein, other aspects and embodiments are contemplated. The various aspects and embodiments disclosed herein are for purposes of illustration and are not intended to be limiting.
Terms of degree (e.g., “about,” “substantially,” “generally,” etc.) indicate structurally or functionally insignificant variations. In an example, when the term of degree is included with a term indicating quantity, the term of degree is interpreted to mean ±10%, ±5%, ±2% or 0% of the term indicating quantity. In an example, when the term of degree is used to modify a shape, the term of degree indicates that the shape being modified by the term of degree has the appearance of the disclosed shape. For instance, the term of degree may be used to indicate that the shape may have rounded corners instead of sharp corners, curved edges instead of straight edges, one or more protrusions extending therefrom, is oblong, is the same as the disclosed shape, etc.
This application is a continuation of PCT International Application No. PCT/US2021/026607 filed on Apr. 9, 2021, which claims priority to U.S. Provisional Application 63/008,112 filed on Apr. 10, 2020, the disclosure of each of which are incorporated herein, in its entirety, by this reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 737443 | Mooers | Aug 1903 | A |
| 1032841 | Koenig | Jul 1912 | A |
| 1178644 | Johnson | Apr 1916 | A |
| 1742080 | Jones | Dec 1929 | A |
| 1979899 | Obrien et al. | Nov 1934 | A |
| 2241010 | Chipley | May 1941 | A |
| 2262772 | Peder | Nov 1941 | A |
| 2326881 | Packer | Aug 1943 | A |
| 2379346 | Farrell | Jun 1945 | A |
| 2485555 | Bester | Oct 1949 | A |
| 2613670 | Edward | Oct 1952 | A |
| 2616426 | Adele | Nov 1952 | A |
| 2644234 | Earl | Jul 1953 | A |
| 2648335 | Chambers | Aug 1953 | A |
| 2859786 | Tupper | Nov 1958 | A |
| 2944551 | Carl | Jul 1960 | A |
| 2968046 | Duke | Jan 1961 | A |
| 2971512 | Reinhardt | Feb 1961 | A |
| 3032038 | Swinn | May 1962 | A |
| 3077883 | Hill | Feb 1963 | A |
| 3087938 | Hans et al. | Apr 1963 | A |
| 3169528 | Knox et al. | Feb 1965 | A |
| 3171506 | Therkel | Mar 1965 | A |
| 3194238 | Breece | Jul 1965 | A |
| 3198994 | Hildebrandt et al. | Aug 1965 | A |
| 3221742 | Egon | Dec 1965 | A |
| 3312221 | Overment | Apr 1967 | A |
| 3312981 | McGuire et al. | Apr 1967 | A |
| 3349768 | Keane | Oct 1967 | A |
| 3362590 | Gene | Jan 1968 | A |
| 3366116 | Huck | Jan 1968 | A |
| 3398848 | Donovan | Aug 1968 | A |
| 3400717 | Bruce et al. | Sep 1968 | A |
| 3406688 | Bruce | Oct 1968 | A |
| 3424163 | Gravdahl | Jan 1969 | A |
| 3425471 | Yates | Feb 1969 | A |
| 3511241 | Lee | May 1970 | A |
| 3512185 | Ellis | May 1970 | A |
| 3520300 | Flower | Jul 1970 | A |
| 3528423 | Lee | Sep 1970 | A |
| 3613123 | Langstrom | Oct 1971 | A |
| 3648700 | Warner | Mar 1972 | A |
| 3651810 | Ormerod | Mar 1972 | A |
| 3661155 | Lindan | May 1972 | A |
| 3683918 | Pizzella | Aug 1972 | A |
| 3699815 | Holbrook | Oct 1972 | A |
| 3726277 | Hirschman | Apr 1973 | A |
| 3742952 | Magers et al. | Jul 1973 | A |
| 3757355 | Allen et al. | Sep 1973 | A |
| 3788324 | Lim | Jan 1974 | A |
| 3843016 | Bornhorst et al. | Oct 1974 | A |
| 3863638 | Rogers et al. | Feb 1975 | A |
| 3863798 | Kurihara et al. | Feb 1975 | A |
| 3864759 | Horiuchi | Feb 1975 | A |
| 3881486 | Fenton | May 1975 | A |
| 3881489 | Hartwell | May 1975 | A |
| 3915189 | Holbrook et al. | Oct 1975 | A |
| 3998228 | Poidomani | Dec 1976 | A |
| 3999550 | Martin | Dec 1976 | A |
| 4015604 | Csillag | Apr 1977 | A |
| 4020843 | Kanall | May 1977 | A |
| 4022213 | Stein | May 1977 | A |
| 4027776 | Douglas | Jun 1977 | A |
| 4064962 | Hunt | Dec 1977 | A |
| 4116197 | Bermingham | Sep 1978 | A |
| 4180178 | Turner | Dec 1979 | A |
| 4187953 | Turner | Feb 1980 | A |
| 4194508 | Anderson | Mar 1980 | A |
| 4200102 | Duhamel | Apr 1980 | A |
| 4202058 | Anderson | May 1980 | A |
| 4203503 | Bertotti et al. | May 1980 | A |
| 4209076 | Bertotti et al. | Jun 1980 | A |
| 4233025 | Larson et al. | Nov 1980 | A |
| 4233978 | Hickey | Nov 1980 | A |
| 4246901 | Frosch et al. | Jan 1981 | A |
| 4253542 | Ruspa et al. | Mar 1981 | A |
| 4257418 | Hessner | Mar 1981 | A |
| 4270539 | Frosch | Jun 1981 | A |
| 4281655 | Terauchi | Aug 1981 | A |
| 4292916 | Bradley et al. | Oct 1981 | A |
| 4330239 | Gannaway | May 1982 | A |
| 4352356 | Tong | Oct 1982 | A |
| 4360933 | Kimura et al. | Nov 1982 | A |
| 4365363 | Windauer | Dec 1982 | A |
| 4375841 | Vielbig | Mar 1983 | A |
| 4387726 | Denard | Jun 1983 | A |
| 4425130 | Desmarais | Jan 1984 | A |
| 4446986 | Bowen et al. | May 1984 | A |
| 4453938 | Brendling | Jun 1984 | A |
| 4457314 | Knowles | Jul 1984 | A |
| 4476879 | Jackson | Oct 1984 | A |
| 4526688 | Schmidt et al. | Jul 1985 | A |
| 4528703 | Kraus | Jul 1985 | A |
| D280438 | Wendt | Sep 1985 | S |
| 4551141 | McNeil | Nov 1985 | A |
| 4553968 | Komis | Nov 1985 | A |
| 4581026 | Schneider | Apr 1986 | A |
| 4589516 | Inoue et al. | May 1986 | A |
| 4601716 | Smith | Jul 1986 | A |
| 4610675 | Triunfol | Sep 1986 | A |
| 4620333 | Ritter | Nov 1986 | A |
| 4626250 | Schneider | Dec 1986 | A |
| 4627846 | Ternstroem | Dec 1986 | A |
| 4631061 | Martin | Dec 1986 | A |
| 4650477 | Johnson | Mar 1987 | A |
| 4655754 | Richmond et al. | Apr 1987 | A |
| 4656675 | Fajnsztajn | Apr 1987 | A |
| 4681570 | Dalton | Jul 1987 | A |
| 4681577 | Stern et al. | Jul 1987 | A |
| 4692160 | Nussbaumer | Sep 1987 | A |
| 4707864 | Ikematsu et al. | Nov 1987 | A |
| 4713065 | Koot | Dec 1987 | A |
| 4713066 | Komis | Dec 1987 | A |
| 4723953 | Pratt et al. | Feb 1988 | A |
| 4735841 | Sourdet | Apr 1988 | A |
| 4743236 | Manschot | May 1988 | A |
| 4747166 | Kuntz | May 1988 | A |
| 4752944 | Conrads et al. | Jun 1988 | A |
| 4769215 | Ehrenkranz | Sep 1988 | A |
| 4771484 | Mozell | Sep 1988 | A |
| 4772280 | Rooyakkers | Sep 1988 | A |
| 4790830 | Hamacher | Dec 1988 | A |
| 4790835 | Elias | Dec 1988 | A |
| 4791686 | Taniguchi et al. | Dec 1988 | A |
| 4795449 | Schneider | Jan 1989 | A |
| 4798603 | Meyer et al. | Jan 1989 | A |
| 4799928 | Crowley | Jan 1989 | A |
| 4804377 | Hanifl et al. | Feb 1989 | A |
| 4812053 | Bhattacharjee | Mar 1989 | A |
| 4813943 | Smith | Mar 1989 | A |
| 4820297 | Kaufman et al. | Apr 1989 | A |
| 4846818 | Keldahl et al. | Jul 1989 | A |
| 4846909 | Klug et al. | Jul 1989 | A |
| 4865595 | Heyden | Sep 1989 | A |
| 4880417 | Yabrov et al. | Nov 1989 | A |
| 4882794 | Stewart | Nov 1989 | A |
| 4883465 | Brennan | Nov 1989 | A |
| 4886498 | Newton | Dec 1989 | A |
| 4886508 | Washington | Dec 1989 | A |
| 4886509 | Mattsson | Dec 1989 | A |
| 4889532 | Metz et al. | Dec 1989 | A |
| 4889533 | Beecher | Dec 1989 | A |
| 4890691 | Ching-ho | Jan 1990 | A |
| 4903254 | Haas | Feb 1990 | A |
| 4904248 | Vaillancourt | Feb 1990 | A |
| 4905692 | More | Mar 1990 | A |
| 4936838 | Cross et al. | Jun 1990 | A |
| 4955922 | Terauchi | Sep 1990 | A |
| 4957487 | Gerow | Sep 1990 | A |
| 4965460 | Tanaka et al. | Oct 1990 | A |
| 4987849 | Sherman | Jan 1991 | A |
| 5002541 | Conkling et al. | Mar 1991 | A |
| 5004463 | Nigay | Apr 1991 | A |
| 5031248 | Kemper | Jul 1991 | A |
| 5045077 | Blake | Sep 1991 | A |
| 5045283 | Patel | Sep 1991 | A |
| 5049144 | Payton | Sep 1991 | A |
| 5053339 | Patel | Oct 1991 | A |
| 5057092 | Webster | Oct 1991 | A |
| 5058088 | Haas et al. | Oct 1991 | A |
| 5071347 | McGuire | Dec 1991 | A |
| 5078707 | Peter | Jan 1992 | A |
| 5084037 | Barnett | Jan 1992 | A |
| 5100396 | Zamierowski | Mar 1992 | A |
| 5112324 | Wallace | May 1992 | A |
| 5147301 | Ruvio | Sep 1992 | A |
| 5176667 | Debring | Jan 1993 | A |
| 5195997 | Carns | Mar 1993 | A |
| 5196654 | Diflora et al. | Mar 1993 | A |
| 5203699 | McGuire | Apr 1993 | A |
| 5244458 | Takasu | Sep 1993 | A |
| 5246454 | Peterson | Sep 1993 | A |
| 5267988 | Farkas | Dec 1993 | A |
| 5275307 | Freese | Jan 1994 | A |
| 5282795 | Finney | Feb 1994 | A |
| 5294983 | Ersoz et al. | Mar 1994 | A |
| 5295983 | Kubo | Mar 1994 | A |
| 5300052 | Kubo | Apr 1994 | A |
| 5304749 | Crandell | Apr 1994 | A |
| 5312383 | Kubalak | May 1994 | A |
| 5318550 | Cermak et al. | Jun 1994 | A |
| 5330459 | Lavon et al. | Jul 1994 | A |
| 5340840 | Park et al. | Aug 1994 | A |
| 5382244 | Telang | Jan 1995 | A |
| 5409014 | Napoli et al. | Apr 1995 | A |
| 5411495 | Willingham | May 1995 | A |
| 5423784 | Metz | Jun 1995 | A |
| 5456246 | Schmieding et al. | Oct 1995 | A |
| 5466229 | Elson | Nov 1995 | A |
| 5478334 | Bernstein | Dec 1995 | A |
| 5499977 | Marx | Mar 1996 | A |
| 5543042 | Filan et al. | Aug 1996 | A |
| D373928 | Green | Sep 1996 | S |
| 5582604 | Ahr et al. | Dec 1996 | A |
| 5592950 | Kopelowicz | Jan 1997 | A |
| 5605161 | Cross | Feb 1997 | A |
| 5618277 | Goulter | Apr 1997 | A |
| 5628735 | Skow | May 1997 | A |
| 5636643 | Argenta et al. | Jun 1997 | A |
| 5637104 | Ball et al. | Jun 1997 | A |
| 5674212 | Osborn, III | Oct 1997 | A |
| 5678564 | Lawrence | Oct 1997 | A |
| 5678654 | Uzawa | Oct 1997 | A |
| 5687429 | Rahlff | Nov 1997 | A |
| 5695485 | Duperret et al. | Dec 1997 | A |
| 5700254 | Mcdowall et al. | Dec 1997 | A |
| 5701612 | Daneshvar | Dec 1997 | A |
| 5705777 | Flanigan et al. | Jan 1998 | A |
| 5752944 | Dann et al. | May 1998 | A |
| 5772644 | Bark et al. | Jun 1998 | A |
| 5792132 | Garcia | Aug 1998 | A |
| 5827243 | Palestrant | Oct 1998 | A |
| 5827247 | Kay | Oct 1998 | A |
| 5827250 | Fujioka et al. | Oct 1998 | A |
| 5827257 | Fujioka et al. | Oct 1998 | A |
| D401699 | Herchenbach et al. | Nov 1998 | S |
| 5859393 | Cummins et al. | Jan 1999 | A |
| 5865378 | Hollinshead et al. | Feb 1999 | A |
| 5876393 | Ahr et al. | Mar 1999 | A |
| 5887291 | Bellizzi | Mar 1999 | A |
| 5891125 | Plumley | Apr 1999 | A |
| 5894608 | Birbara | Apr 1999 | A |
| D409303 | Oepping | May 1999 | S |
| 5911222 | Lawrence | Jun 1999 | A |
| 5957904 | Holland | Sep 1999 | A |
| 5968026 | Osborn et al. | Oct 1999 | A |
| 5972505 | Phillips et al. | Oct 1999 | A |
| 6039060 | Rower | Mar 2000 | A |
| 6050983 | Moore et al. | Apr 2000 | A |
| 6059762 | Boyer et al. | May 2000 | A |
| 6063064 | Tuckey et al. | May 2000 | A |
| 6098625 | Winkler | Aug 2000 | A |
| 6105174 | Karlsten et al. | Aug 2000 | A |
| 6113582 | Dwork | Sep 2000 | A |
| 6117163 | Bierman | Sep 2000 | A |
| 6123398 | Arai | Sep 2000 | A |
| 6129718 | Wada et al. | Oct 2000 | A |
| 6131964 | Sareshwala | Oct 2000 | A |
| 6152902 | Christian et al. | Nov 2000 | A |
| 6164569 | Hollinshead et al. | Dec 2000 | A |
| 6177606 | Etheredge et al. | Jan 2001 | B1 |
| 6209142 | Mattsson et al. | Apr 2001 | B1 |
| 6220050 | Cooksey | Apr 2001 | B1 |
| 6244311 | Hand et al. | Jun 2001 | B1 |
| 6248096 | Dwork et al. | Jun 2001 | B1 |
| 6263887 | Dunn | Jul 2001 | B1 |
| 6283246 | Nishikawa | Sep 2001 | B1 |
| 6311339 | Kraus | Nov 2001 | B1 |
| 6336919 | Davis et al. | Jan 2002 | B1 |
| 6338729 | Wada et al. | Jan 2002 | B1 |
| 6352525 | Wakabayashi | Mar 2002 | B1 |
| 6394988 | Hashimoto | May 2002 | B1 |
| 6398742 | Kim | Jun 2002 | B1 |
| 6406463 | Brown | Jun 2002 | B1 |
| 6409712 | Dutari et al. | Jun 2002 | B1 |
| 6416500 | Wada et al. | Jul 2002 | B1 |
| 6423045 | Wise et al. | Jul 2002 | B1 |
| 6428521 | Droll | Aug 2002 | B1 |
| 6428522 | Dipalma et al. | Aug 2002 | B1 |
| 6446454 | Lee et al. | Sep 2002 | B1 |
| 6475198 | Lipman et al. | Nov 2002 | B1 |
| 6479726 | Cole et al. | Nov 2002 | B1 |
| 6491673 | Palumbo et al. | Dec 2002 | B1 |
| 6508794 | Palumbo et al. | Jan 2003 | B1 |
| 6524292 | Dipalma et al. | Feb 2003 | B1 |
| 6540729 | Wada et al. | Apr 2003 | B1 |
| 6547771 | Robertson et al. | Apr 2003 | B2 |
| 6569133 | Cheng et al. | May 2003 | B2 |
| D476518 | Doppelt | Jul 2003 | S |
| 6592560 | Snyder et al. | Jul 2003 | B2 |
| 6610038 | Dipalma et al. | Aug 2003 | B1 |
| 6618868 | Minnick | Sep 2003 | B2 |
| 6620142 | Flueckiger | Sep 2003 | B1 |
| 6629651 | Male et al. | Oct 2003 | B1 |
| 6635038 | Scovel | Oct 2003 | B2 |
| 6652495 | Walker | Nov 2003 | B1 |
| 6666850 | Ahr et al. | Dec 2003 | B1 |
| 6685684 | Falconer | Feb 2004 | B1 |
| 6695828 | Dipalma et al. | Feb 2004 | B1 |
| 6700034 | Lindsay et al. | Mar 2004 | B1 |
| 6702793 | Sweetser et al. | Mar 2004 | B1 |
| 6706027 | Harvie | Mar 2004 | B2 |
| 6732384 | Scott | May 2004 | B2 |
| 6736977 | Hall et al. | May 2004 | B1 |
| 6740066 | Wolff | May 2004 | B2 |
| 6764477 | Chen et al. | Jul 2004 | B1 |
| 6783519 | Samuelsson | Aug 2004 | B2 |
| 6796974 | Palumbo et al. | Sep 2004 | B2 |
| 6814547 | Childers et al. | Nov 2004 | B2 |
| 6849065 | Schmidt et al. | Feb 2005 | B2 |
| 6857137 | Otto | Feb 2005 | B2 |
| 6885690 | Aggerstam et al. | Apr 2005 | B2 |
| 6888044 | Fell et al. | May 2005 | B2 |
| 6893425 | Dunn et al. | May 2005 | B2 |
| 6912737 | Ernest et al. | Jul 2005 | B2 |
| 6918899 | Harvie | Jul 2005 | B2 |
| 6979324 | Bybordi et al. | Dec 2005 | B2 |
| 7018366 | Easter | Mar 2006 | B2 |
| 7066411 | Male et al. | Jun 2006 | B2 |
| 7122023 | Hinoki | Oct 2006 | B1 |
| 7125399 | Miskie | Oct 2006 | B2 |
| 7131964 | Harvie | Nov 2006 | B2 |
| 7135012 | Harvie | Nov 2006 | B2 |
| 7141043 | Harvie | Nov 2006 | B2 |
| D533972 | La | Dec 2006 | S |
| 7160273 | Greter et al. | Jan 2007 | B2 |
| 7171699 | Ernest et al. | Feb 2007 | B2 |
| 7171871 | Kozak | Feb 2007 | B2 |
| 7179951 | Krishnaswamy-Mirle et al. | Feb 2007 | B2 |
| 7181781 | Trabold | Feb 2007 | B1 |
| 7186245 | Cheng et al. | Mar 2007 | B1 |
| 7192424 | Cooper | Mar 2007 | B2 |
| 7219764 | Forbes | May 2007 | B1 |
| 7220250 | Suzuki | May 2007 | B2 |
| D562975 | Otto | Feb 2008 | S |
| 7335189 | Harvie | Feb 2008 | B2 |
| 7358282 | Krueger et al. | Apr 2008 | B2 |
| 7390320 | Machida | Jun 2008 | B2 |
| 7438706 | Koizumi et al. | Oct 2008 | B2 |
| 7488310 | Yang | Feb 2009 | B2 |
| 7491194 | Oliwa | Feb 2009 | B1 |
| D591106 | Dominique et al. | Apr 2009 | S |
| 7513381 | Heng et al. | Apr 2009 | B2 |
| 7520872 | Biggie et al. | Apr 2009 | B2 |
| D593801 | Wilson et al. | Jun 2009 | S |
| 7540364 | Sanderson | Jun 2009 | B2 |
| 7549512 | Newberry | Jun 2009 | B2 |
| 7585293 | Vermaak | Sep 2009 | B2 |
| 7588560 | Dunlop | Sep 2009 | B1 |
| 7665359 | Barber | Feb 2010 | B2 |
| 7682347 | Parks et al. | Mar 2010 | B2 |
| 7687004 | Allen | Mar 2010 | B2 |
| 7695459 | Gilbert et al. | Apr 2010 | B2 |
| 7695460 | Wada et al. | Apr 2010 | B2 |
| 7699818 | Gilbert | Apr 2010 | B2 |
| 7699831 | Bengtson | Apr 2010 | B2 |
| 7722584 | Tanaka et al. | May 2010 | B2 |
| 7727206 | Gorres | Jun 2010 | B2 |
| 7740620 | Gilbert et al. | Jun 2010 | B2 |
| 7749205 | Tazoe | Jul 2010 | B2 |
| 7755497 | Wada | Jul 2010 | B2 |
| 7766887 | Burns et al. | Aug 2010 | B2 |
| D625407 | Koizumi et al. | Oct 2010 | S |
| 7806879 | Brooks et al. | Oct 2010 | B2 |
| 7811272 | Lindsay et al. | Oct 2010 | B2 |
| 7815067 | Matsumoto et al. | Oct 2010 | B2 |
| 7833169 | Hannon | Nov 2010 | B2 |
| 7857806 | Karpowicz et al. | Dec 2010 | B2 |
| 7866942 | Harvie | Jan 2011 | B2 |
| 7871385 | Levinson et al. | Jan 2011 | B2 |
| 7875010 | Frazier et al. | Jan 2011 | B2 |
| 7901389 | Mombrinie | Mar 2011 | B2 |
| 7927320 | Goldwasser et al. | Apr 2011 | B2 |
| 7927321 | Marland | Apr 2011 | B2 |
| 7931634 | Swiecicki et al. | Apr 2011 | B2 |
| 7939706 | Okabe | May 2011 | B2 |
| 7946443 | Stull et al. | May 2011 | B2 |
| 7947025 | Buglino et al. | May 2011 | B2 |
| 7963419 | Burney et al. | Jun 2011 | B2 |
| 7976519 | Bubb et al. | Jul 2011 | B2 |
| 7993318 | Olsson et al. | Aug 2011 | B2 |
| 8015627 | Baker et al. | Sep 2011 | B2 |
| 8016071 | Martinus et al. | Sep 2011 | B1 |
| 8028460 | Williams | Oct 2011 | B2 |
| 8047398 | Dimartino et al. | Nov 2011 | B2 |
| 8083094 | Caulfield et al. | Dec 2011 | B2 |
| 8128608 | Thevenin | Mar 2012 | B2 |
| 8181651 | Pinel | May 2012 | B2 |
| 8181819 | Burney et al. | May 2012 | B2 |
| 8211063 | Bierman | Jul 2012 | B2 |
| 8221369 | Parks et al. | Jul 2012 | B2 |
| 8241262 | Mahnensmith | Aug 2012 | B2 |
| 8277426 | Wilcox et al. | Oct 2012 | B2 |
| 8287508 | Sanchez | Oct 2012 | B1 |
| 8303554 | Tsai et al. | Nov 2012 | B2 |
| 8322565 | Caulfield et al. | Dec 2012 | B2 |
| 8337477 | Parks et al. | Dec 2012 | B2 |
| D674241 | Bickert et al. | Jan 2013 | S |
| 8343122 | Gorres | Jan 2013 | B2 |
| 8343125 | Kawazoe et al. | Jan 2013 | B2 |
| 8353074 | Krebs | Jan 2013 | B2 |
| 8353886 | Bester et al. | Jan 2013 | B2 |
| D676241 | Merrill | Feb 2013 | S |
| 8388588 | Wada et al. | Mar 2013 | B2 |
| D679807 | Burgess et al. | Apr 2013 | S |
| 8425482 | Khoubnazar | Apr 2013 | B2 |
| 8434586 | Pawelski et al. | May 2013 | B2 |
| 8449510 | Martini et al. | May 2013 | B2 |
| D684260 | Lund et al. | Jun 2013 | S |
| 8470230 | Caulfield et al. | Jun 2013 | B2 |
| 8479941 | Matsumoto et al. | Jul 2013 | B2 |
| 8479949 | Henkel | Jul 2013 | B2 |
| 8500719 | Simpson et al. | Aug 2013 | B1 |
| 8512301 | Ma | Aug 2013 | B2 |
| 8529530 | Koch et al. | Sep 2013 | B2 |
| 8535284 | Joder et al. | Sep 2013 | B2 |
| 8546639 | Wada | Oct 2013 | B2 |
| 8551075 | Bengtson | Oct 2013 | B2 |
| 8568376 | Delattre et al. | Oct 2013 | B2 |
| D694404 | Burgess et al. | Nov 2013 | S |
| 8585683 | Bengtson | Nov 2013 | B2 |
| 8652112 | Johannison et al. | Feb 2014 | B2 |
| 8669412 | Fernkvist et al. | Mar 2014 | B2 |
| D702973 | Norland et al. | Apr 2014 | S |
| 8703032 | Menon et al. | Apr 2014 | B2 |
| D704330 | Cicatelli | May 2014 | S |
| D704510 | Mason et al. | May 2014 | S |
| D705423 | Walsh Cutler | May 2014 | S |
| D705926 | Burgess et al. | May 2014 | S |
| 8714394 | Wulf | May 2014 | B2 |
| 8715267 | Bengtson et al. | May 2014 | B2 |
| 8757425 | Copeland | Jun 2014 | B2 |
| 8777032 | Biesecker et al. | Jul 2014 | B2 |
| 8808260 | Koch et al. | Aug 2014 | B2 |
| 8864730 | Conway et al. | Oct 2014 | B2 |
| 8881923 | Higginson | Nov 2014 | B2 |
| 8882731 | Suzuki et al. | Nov 2014 | B2 |
| 8936585 | Carson et al. | Jan 2015 | B2 |
| D729581 | Boroski | May 2015 | S |
| 9028460 | Medeiros | May 2015 | B2 |
| 9056698 | Noer | Jun 2015 | B2 |
| 9078792 | Ruiz | Jul 2015 | B2 |
| 9145879 | Pirovano et al. | Sep 2015 | B2 |
| 9173602 | Gilbert | Nov 2015 | B2 |
| 9173799 | Tanimoto | Nov 2015 | B2 |
| 9187220 | Biesecker et al. | Nov 2015 | B2 |
| 9199772 | Krippendorf | Dec 2015 | B2 |
| 9233020 | Matsumiya | Jan 2016 | B2 |
| 9248058 | Conway et al. | Feb 2016 | B2 |
| 9308118 | Dupree et al. | Apr 2016 | B1 |
| 9309029 | Incorvia et al. | Apr 2016 | B2 |
| 9333281 | Giezendanner et al. | May 2016 | B2 |
| 9381108 | Longoni et al. | Jul 2016 | B2 |
| 9382047 | Schmidtner et al. | Jul 2016 | B2 |
| 9402424 | Roy | Aug 2016 | B2 |
| 9456937 | Ellis | Oct 2016 | B2 |
| 9480595 | Baham et al. | Nov 2016 | B2 |
| 9517865 | Albers et al. | Dec 2016 | B2 |
| D777941 | Piramoon | Jan 2017 | S |
| 9533806 | Ding et al. | Jan 2017 | B2 |
| 9550611 | Hodge | Jan 2017 | B2 |
| 9555930 | Campbell et al. | Jan 2017 | B2 |
| 9623159 | Locke | Apr 2017 | B2 |
| D789522 | Burgess et al. | Jun 2017 | S |
| 9687849 | Bruno et al. | Jun 2017 | B2 |
| 9694949 | Hendricks et al. | Jul 2017 | B2 |
| 9709048 | Kinjo | Jul 2017 | B2 |
| 9713547 | Lee et al. | Jul 2017 | B2 |
| 9732754 | Huang et al. | Aug 2017 | B2 |
| 9752564 | Arceno et al. | Sep 2017 | B2 |
| 9788992 | Harvie | Oct 2017 | B2 |
| D804907 | Sandoval | Dec 2017 | S |
| 9868564 | McGirr et al. | Jan 2018 | B2 |
| D814239 | Arora | Apr 2018 | S |
| D817484 | Lafond | May 2018 | S |
| 10037640 | Gordon | Jul 2018 | B2 |
| 10058470 | Phillips | Aug 2018 | B2 |
| 10098990 | Koch et al. | Oct 2018 | B2 |
| D835264 | Mozzicato et al. | Dec 2018 | S |
| D835779 | Mozzicato et al. | Dec 2018 | S |
| D840533 | Mozzicato et al. | Feb 2019 | S |
| D840534 | Mozzicato et al. | Feb 2019 | S |
| 10225376 | Perez Martinez | Mar 2019 | B2 |
| 10226376 | Sanchez | Mar 2019 | B2 |
| 10258517 | Maschino et al. | Apr 2019 | B1 |
| D848612 | Mozzicato et al. | May 2019 | S |
| 10307305 | Hodges | Jun 2019 | B1 |
| 10335121 | Desai | Jul 2019 | B2 |
| D856512 | Cowart et al. | Aug 2019 | S |
| 10376406 | Newton | Aug 2019 | B2 |
| 10376407 | Newton | Aug 2019 | B2 |
| 10390989 | Sanchez | Aug 2019 | B2 |
| D858144 | Fu | Sep 2019 | S |
| 10406039 | Villarreal | Sep 2019 | B2 |
| 10407222 | Allen | Sep 2019 | B2 |
| 10478356 | Griffin | Nov 2019 | B2 |
| 10500108 | Maschino et al. | Dec 2019 | B1 |
| 10538366 | Pentelovitch et al. | Jan 2020 | B2 |
| 10569938 | Zhao et al. | Feb 2020 | B2 |
| 10577156 | Dagnelie et al. | Mar 2020 | B2 |
| RE47930 | Cho | Apr 2020 | E |
| 10618721 | Vazin | Apr 2020 | B2 |
| D884390 | Wang | May 2020 | S |
| 10669079 | Freedman et al. | Jun 2020 | B2 |
| D892315 | Airy | Aug 2020 | S |
| 10730672 | Bertram et al. | Aug 2020 | B2 |
| 10737848 | Philip et al. | Aug 2020 | B2 |
| 10765854 | Law et al. | Sep 2020 | B2 |
| 10766670 | Kittmann | Sep 2020 | B2 |
| 10799386 | Harrison | Oct 2020 | B1 |
| 10806642 | Tagomori et al. | Oct 2020 | B2 |
| D901214 | Hu | Nov 2020 | S |
| 10849799 | Nishikawa et al. | Dec 2020 | B2 |
| 10857025 | Davis et al. | Dec 2020 | B2 |
| 10865017 | Cowart et al. | Dec 2020 | B1 |
| 10889412 | West et al. | Jan 2021 | B2 |
| 10913581 | Stahlecker | Feb 2021 | B2 |
| D912244 | Rehm et al. | Mar 2021 | S |
| 10952889 | Newton | Mar 2021 | B2 |
| 10973378 | Ryu et al. | Apr 2021 | B2 |
| 10973678 | Newton | Apr 2021 | B2 |
| 10974874 | Ragias et al. | Apr 2021 | B2 |
| 11000401 | Ecklund et al. | May 2021 | B2 |
| D923365 | Wang | Jun 2021 | S |
| 11026829 | Harvie | Jun 2021 | B2 |
| 11027900 | Liu | Jun 2021 | B2 |
| 11045346 | Argent et al. | Jun 2021 | B2 |
| D928946 | Sanchez | Aug 2021 | S |
| 11160695 | Febo et al. | Nov 2021 | B2 |
| 11160697 | Maschino et al. | Nov 2021 | B2 |
| 11168420 | Kinugasa et al. | Nov 2021 | B2 |
| 11179506 | Barr et al. | Nov 2021 | B2 |
| 11226376 | Yamauchi et al. | Jan 2022 | B2 |
| 11253407 | Miao et al. | Feb 2022 | B2 |
| 11326586 | Milner et al. | May 2022 | B2 |
| 11369508 | Ecklund et al. | Jun 2022 | B2 |
| 11369524 | Hubbard et al. | Jun 2022 | B2 |
| 11376152 | Sanchez | Jul 2022 | B2 |
| 11382786 | Sanchez | Jul 2022 | B2 |
| 11382788 | Hjorth et al. | Jul 2022 | B2 |
| 11389318 | Radl et al. | Jul 2022 | B2 |
| 11395871 | Radl et al. | Jul 2022 | B2 |
| 11399990 | Suyama | Aug 2022 | B2 |
| 11426303 | Davis | Aug 2022 | B2 |
| 11504265 | Godinez et al. | Nov 2022 | B2 |
| 11529252 | Glithero | Dec 2022 | B2 |
| 11547788 | Radl et al. | Jan 2023 | B2 |
| 11806266 | Sanchez et al. | Nov 2023 | B2 |
| 11839567 | Davis et al. | Dec 2023 | B2 |
| D1010109 | Ecklund et al. | Jan 2024 | S |
| 11857716 | Lee et al. | Jan 2024 | B2 |
| 11865030 | Davis et al. | Jan 2024 | B2 |
| 11890221 | Ulreich et al. | Feb 2024 | B2 |
| 11925575 | Newton | Mar 2024 | B2 |
| 11938053 | Austermann et al. | Mar 2024 | B2 |
| 11944740 | Hughett et al. | Apr 2024 | B2 |
| 20010037097 | Cheng et al. | Nov 2001 | A1 |
| 20010054426 | Knudson et al. | Dec 2001 | A1 |
| 20020019614 | Woon | Feb 2002 | A1 |
| 20020026161 | Grundke | Feb 2002 | A1 |
| 20020087131 | Wolff | Jul 2002 | A1 |
| 20020091364 | Prabhakar | Jul 2002 | A1 |
| 20020189992 | Schmidt et al. | Dec 2002 | A1 |
| 20020193760 | Thompson | Dec 2002 | A1 |
| 20030004436 | Schmidt et al. | Jan 2003 | A1 |
| 20030032931 | Grundke et al. | Feb 2003 | A1 |
| 20030032944 | Cawood | Feb 2003 | A1 |
| 20030073964 | Palumbo et al. | Apr 2003 | A1 |
| 20030120178 | Heki | Jun 2003 | A1 |
| 20030157859 | Ishikawa | Aug 2003 | A1 |
| 20030181880 | Schwartz | Sep 2003 | A1 |
| 20030195484 | Harvie | Oct 2003 | A1 |
| 20030204173 | Burns et al. | Oct 2003 | A1 |
| 20030233079 | Parks et al. | Dec 2003 | A1 |
| 20040006321 | Cheng et al. | Jan 2004 | A1 |
| 20040015141 | Cheng et al. | Jan 2004 | A1 |
| 20040056122 | Male et al. | Mar 2004 | A1 |
| 20040084465 | Luburic | May 2004 | A1 |
| 20040127872 | Petryk | Jul 2004 | A1 |
| 20040128749 | Scott | Jul 2004 | A1 |
| 20040143229 | Easter | Jul 2004 | A1 |
| 20040147863 | Diaz et al. | Jul 2004 | A1 |
| 20040147894 | Mizutani et al. | Jul 2004 | A1 |
| 20040158221 | Mizutani et al. | Aug 2004 | A1 |
| 20040176731 | Cheng et al. | Sep 2004 | A1 |
| 20040176746 | Forral | Sep 2004 | A1 |
| 20040191919 | Unger et al. | Sep 2004 | A1 |
| 20040207530 | Nielsen | Oct 2004 | A1 |
| 20040236292 | Tazoe | Nov 2004 | A1 |
| 20040243075 | Harvie | Dec 2004 | A1 |
| 20040254547 | Okabe | Dec 2004 | A1 |
| 20050010182 | Parks et al. | Jan 2005 | A1 |
| 20050033248 | Machida | Feb 2005 | A1 |
| 20050065471 | Kuntz | Mar 2005 | A1 |
| 20050070861 | Okabe | Mar 2005 | A1 |
| 20050070862 | Tazoe | Mar 2005 | A1 |
| 20050082300 | Modrell et al. | Apr 2005 | A1 |
| 20050097662 | Leimkuhler et al. | May 2005 | A1 |
| 20050101924 | Elson et al. | May 2005 | A1 |
| 20050119630 | Harvie | Jun 2005 | A1 |
| 20050137557 | Swiecicki et al. | Jun 2005 | A1 |
| 20050154360 | Harvie | Jul 2005 | A1 |
| 20050177070 | Levinson et al. | Aug 2005 | A1 |
| 20050197639 | Mombrinie | Sep 2005 | A1 |
| 20050273920 | Marinas | Dec 2005 | A1 |
| 20050277904 | Chase et al. | Dec 2005 | A1 |
| 20050279359 | Leblanc et al. | Dec 2005 | A1 |
| 20060004332 | Marx | Jan 2006 | A1 |
| 20060015080 | Mahnensmith | Jan 2006 | A1 |
| 20060015081 | Suzuki | Jan 2006 | A1 |
| 20060016778 | Park | Jan 2006 | A1 |
| 20060069359 | Dipalma et al. | Mar 2006 | A1 |
| 20060079854 | Kay et al. | Apr 2006 | A1 |
| 20060111648 | Vermaak | May 2006 | A1 |
| 20060155214 | Wightman | Jul 2006 | A1 |
| 20060171997 | Gruenbacher et al. | Aug 2006 | A1 |
| 20060200102 | Cooper | Sep 2006 | A1 |
| 20060229575 | Boiarski | Oct 2006 | A1 |
| 20060229576 | Conway et al. | Oct 2006 | A1 |
| 20060231648 | Male et al. | Oct 2006 | A1 |
| 20060235266 | Nan | Oct 2006 | A1 |
| 20060235359 | Marland | Oct 2006 | A1 |
| 20060241553 | Harvie | Oct 2006 | A1 |
| 20060269439 | White | Nov 2006 | A1 |
| 20060277670 | Baker et al. | Dec 2006 | A1 |
| 20070006368 | Key et al. | Jan 2007 | A1 |
| 20070010797 | Nishtala et al. | Jan 2007 | A1 |
| 20070016152 | Karpowicz et al. | Jan 2007 | A1 |
| 20070038194 | Wada | Feb 2007 | A1 |
| 20070055209 | Patel et al. | Mar 2007 | A1 |
| 20070073252 | Forgrave | Mar 2007 | A1 |
| 20070117880 | Elson et al. | May 2007 | A1 |
| 20070118993 | Bates | May 2007 | A1 |
| 20070135786 | Schmidt et al. | Jun 2007 | A1 |
| 20070137718 | Rushlander et al. | Jun 2007 | A1 |
| 20070149935 | Dirico | Jun 2007 | A1 |
| 20070191804 | Coley | Aug 2007 | A1 |
| 20070214553 | Carromba | Sep 2007 | A1 |
| 20070225663 | Watt et al. | Sep 2007 | A1 |
| 20070225666 | Otto | Sep 2007 | A1 |
| 20070225668 | Otto | Sep 2007 | A1 |
| 20070266486 | Ramirez | Nov 2007 | A1 |
| 20070282309 | Bengtson et al. | Dec 2007 | A1 |
| 20080004576 | Tanaka et al. | Jan 2008 | A1 |
| 20080015526 | Reiner et al. | Jan 2008 | A1 |
| 20080015527 | House | Jan 2008 | A1 |
| 20080033386 | Okabe | Feb 2008 | A1 |
| 20080041869 | Backaert | Feb 2008 | A1 |
| 20080091153 | Harvie | Apr 2008 | A1 |
| 20080091158 | Yang | Apr 2008 | A1 |
| 20080114327 | Barge | May 2008 | A1 |
| 20080167634 | Kouta et al. | Jul 2008 | A1 |
| 20080183157 | Walters | Jul 2008 | A1 |
| 20080215031 | Belfort et al. | Sep 2008 | A1 |
| 20080234642 | Patterson et al. | Sep 2008 | A1 |
| 20080269703 | Collins et al. | Oct 2008 | A1 |
| 20080281282 | Finger et al. | Nov 2008 | A1 |
| 20080287894 | Van Den Heuvel | Nov 2008 | A1 |
| 20080312550 | Nishtala et al. | Dec 2008 | A1 |
| 20090025717 | Pinel | Jan 2009 | A1 |
| 20090048570 | Jensen | Feb 2009 | A1 |
| 20090056003 | Ivie et al. | Mar 2009 | A1 |
| 20090069761 | Vogel | Mar 2009 | A1 |
| 20090069765 | Wortham | Mar 2009 | A1 |
| 20090192482 | Dodge, II | Jul 2009 | A1 |
| 20090234312 | OToole et al. | Sep 2009 | A1 |
| 20090251510 | Noro et al. | Oct 2009 | A1 |
| 20090264840 | Virginio | Oct 2009 | A1 |
| 20090270822 | Medeiros | Oct 2009 | A1 |
| 20090281510 | Fisher | Nov 2009 | A1 |
| 20100004612 | Thevenin | Jan 2010 | A1 |
| 20100058660 | Williams | Mar 2010 | A1 |
| 20100121289 | Parks et al. | May 2010 | A1 |
| 20100158168 | Murthy et al. | Jun 2010 | A1 |
| 20100160882 | Lowe | Jun 2010 | A1 |
| 20100174250 | Hu et al. | Jul 2010 | A1 |
| 20100185168 | Graauw | Jul 2010 | A1 |
| 20100198172 | Wada et al. | Aug 2010 | A1 |
| 20100211032 | Tsai | Aug 2010 | A1 |
| 20100234820 | Tsai et al. | Sep 2010 | A1 |
| 20100241104 | Gilbert | Sep 2010 | A1 |
| 20100263113 | Shelton et al. | Oct 2010 | A1 |
| 20100310845 | Bond et al. | Dec 2010 | A1 |
| 20110028920 | Johannison | Feb 2011 | A1 |
| 20110028922 | Kay et al. | Feb 2011 | A1 |
| 20110034889 | Smith | Feb 2011 | A1 |
| 20110036837 | Shang | Feb 2011 | A1 |
| 20110040267 | Wada | Feb 2011 | A1 |
| 20110040271 | Rogers | Feb 2011 | A1 |
| 20110054426 | Stewart et al. | Mar 2011 | A1 |
| 20110060299 | Wada et al. | Mar 2011 | A1 |
| 20110060300 | Weig | Mar 2011 | A1 |
| 20110077495 | Gilbert | Mar 2011 | A1 |
| 20110077606 | Wilcox et al. | Mar 2011 | A1 |
| 20110087337 | Forsell | Apr 2011 | A1 |
| 20110137273 | Muellejans et al. | Jun 2011 | A1 |
| 20110145993 | Rader et al. | Jun 2011 | A1 |
| 20110152802 | Dicamillo et al. | Jun 2011 | A1 |
| 20110164147 | Takahashi et al. | Jul 2011 | A1 |
| 20110172620 | Khambatta | Jul 2011 | A1 |
| 20110172625 | Wada | Jul 2011 | A1 |
| 20110202024 | Cozzens | Aug 2011 | A1 |
| 20110238023 | Slayton | Sep 2011 | A1 |
| 20110240648 | Tucker | Oct 2011 | A1 |
| 20110251572 | Nishtala et al. | Oct 2011 | A1 |
| 20110265889 | Tanaka et al. | Nov 2011 | A1 |
| 20110276020 | Mitsui | Nov 2011 | A1 |
| 20120035577 | Tomes et al. | Feb 2012 | A1 |
| 20120041400 | Christensen | Feb 2012 | A1 |
| 20120059328 | Dikeman et al. | Mar 2012 | A1 |
| 20120066825 | Birbara et al. | Mar 2012 | A1 |
| 20120103347 | Wheaton | May 2012 | A1 |
| 20120137420 | Gordon et al. | Jun 2012 | A1 |
| 20120165768 | Sekiyama et al. | Jun 2012 | A1 |
| 20120165786 | Chappa et al. | Jun 2012 | A1 |
| 20120210503 | Anzivino, Sr. | Aug 2012 | A1 |
| 20120233761 | Huang | Sep 2012 | A1 |
| 20120245541 | Suzuki et al. | Sep 2012 | A1 |
| 20120245542 | Suzuki | Sep 2012 | A1 |
| 20120245547 | Wilcox et al. | Sep 2012 | A1 |
| 20120253303 | Suzuki | Oct 2012 | A1 |
| 20120271259 | Ulert | Oct 2012 | A1 |
| 20120296305 | Barraza Khaled et al. | Nov 2012 | A1 |
| 20120316522 | Carter et al. | Dec 2012 | A1 |
| 20120330256 | Wilcox et al. | Dec 2012 | A1 |
| 20130006206 | Wada | Jan 2013 | A1 |
| 20130045651 | Esteves et al. | Feb 2013 | A1 |
| 20130053804 | Soerensen et al. | Feb 2013 | A1 |
| 20130096523 | Chang et al. | Apr 2013 | A1 |
| 20130138064 | Stroebech et al. | May 2013 | A1 |
| 20130150813 | Gordon et al. | Jun 2013 | A1 |
| 20130245496 | Wells et al. | Sep 2013 | A1 |
| 20130245586 | Jha | Sep 2013 | A1 |
| 20130292537 | Dirico | Nov 2013 | A1 |
| 20130330501 | Aizenberg et al. | Dec 2013 | A1 |
| 20140005647 | Shuffler et al. | Jan 2014 | A1 |
| 20140031774 | Bengtson | Jan 2014 | A1 |
| 20140039432 | Dunbar et al. | Feb 2014 | A1 |
| 20140157499 | Suzuki et al. | Jun 2014 | A1 |
| 20140171889 | Hopman et al. | Jun 2014 | A1 |
| 20140182051 | Tanimoto | Jul 2014 | A1 |
| 20140196189 | Lee et al. | Jul 2014 | A1 |
| 20140276501 | Cisko | Sep 2014 | A1 |
| 20140303582 | Wright et al. | Oct 2014 | A1 |
| 20140316381 | Reglin | Oct 2014 | A1 |
| 20140325746 | Block | Nov 2014 | A1 |
| 20140348139 | Gomez Martinez | Nov 2014 | A1 |
| 20140352050 | Yao et al. | Dec 2014 | A1 |
| 20140371628 | Desai | Dec 2014 | A1 |
| 20150045757 | Lee et al. | Feb 2015 | A1 |
| 20150047114 | Ramirez | Feb 2015 | A1 |
| 20150048089 | Robertson | Feb 2015 | A1 |
| 20150135423 | Sharpe et al. | May 2015 | A1 |
| 20150157300 | Ealovega et al. | Jun 2015 | A1 |
| 20150209194 | Heyman | Jul 2015 | A1 |
| 20150290425 | Macy et al. | Oct 2015 | A1 |
| 20150320583 | Harvie | Nov 2015 | A1 |
| 20150329255 | Rzepecki | Nov 2015 | A1 |
| 20150342799 | Michiels et al. | Dec 2015 | A1 |
| 20150359660 | Harvie | Dec 2015 | A1 |
| 20150366699 | Nelson | Dec 2015 | A1 |
| 20160029998 | Brister et al. | Feb 2016 | A1 |
| 20160030228 | Jones | Feb 2016 | A1 |
| 20160038356 | Yao et al. | Feb 2016 | A1 |
| 20160058322 | Brister et al. | Mar 2016 | A1 |
| 20160060001 | Wada et al. | Mar 2016 | A1 |
| 20160100976 | Conway et al. | Apr 2016 | A1 |
| 20160106604 | Timm | Apr 2016 | A1 |
| 20160113809 | Kim | Apr 2016 | A1 |
| 20160183689 | Miner | Jun 2016 | A1 |
| 20160256022 | Le | Sep 2016 | A1 |
| 20160270982 | Raycheck et al. | Sep 2016 | A1 |
| 20160278662 | Brister et al. | Sep 2016 | A1 |
| 20160357400 | Penha et al. | Dec 2016 | A1 |
| 20160366699 | Zhang et al. | Dec 2016 | A1 |
| 20160367226 | Newton | Dec 2016 | A1 |
| 20160367411 | Justiz et al. | Dec 2016 | A1 |
| 20160367726 | Gratzer | Dec 2016 | A1 |
| 20160374848 | Sanchez | Dec 2016 | A1 |
| 20170007438 | Harvie | Jan 2017 | A1 |
| 20170014560 | Minskoff et al. | Jan 2017 | A1 |
| 20170100276 | Joh | Apr 2017 | A1 |
| 20170128638 | Giezendanner et al. | May 2017 | A1 |
| 20170143534 | Sanchez | May 2017 | A1 |
| 20170165405 | Muser et al. | Jun 2017 | A1 |
| 20170189225 | Voorhees et al. | Jul 2017 | A1 |
| 20170202692 | Laniado | Jul 2017 | A1 |
| 20170216081 | Accosta | Aug 2017 | A1 |
| 20170246026 | Laniado | Aug 2017 | A1 |
| 20170252014 | Siller Gonzalez et al. | Sep 2017 | A1 |
| 20170252202 | Sanchez et al. | Sep 2017 | A9 |
| 20170266031 | Sanchez | Sep 2017 | A1 |
| 20170266658 | Bruno et al. | Sep 2017 | A1 |
| 20170281399 | VanMiddendorp | Oct 2017 | A1 |
| 20170312116 | Laniado | Nov 2017 | A1 |
| 20170325788 | Ealovega et al. | Nov 2017 | A1 |
| 20170333244 | Laniado | Nov 2017 | A1 |
| 20170042748 | Griffin | Dec 2017 | A1 |
| 20170348139 | Newton | Dec 2017 | A1 |
| 20170354532 | Holt | Dec 2017 | A1 |
| 20170354551 | Gawley et al. | Dec 2017 | A1 |
| 20170367873 | Grannum | Dec 2017 | A1 |
| 20180002075 | Lee | Jan 2018 | A1 |
| 20180008451 | Stroebech | Jan 2018 | A1 |
| 20180008804 | Laniado | Jan 2018 | A1 |
| 20180021218 | Brosch et al. | Jan 2018 | A1 |
| 20180028349 | Newton | Feb 2018 | A1 |
| 20180037384 | Archeny et al. | Feb 2018 | A1 |
| 20180049910 | Newton | Feb 2018 | A1 |
| 20180064572 | Wiltshire | Mar 2018 | A1 |
| 20180104131 | Killian | Apr 2018 | A1 |
| 20180127187 | Sewell | May 2018 | A1 |
| 20180193215 | Davies et al. | Jul 2018 | A1 |
| 20180200101 | Su | Jul 2018 | A1 |
| 20180228642 | Davis | Aug 2018 | A1 |
| 20180256384 | Kasirye | Sep 2018 | A1 |
| 20180271694 | Fernandez et al. | Sep 2018 | A1 |
| 20180317892 | Catlin | Nov 2018 | A1 |
| 20190001030 | Braga et al. | Jan 2019 | A1 |
| 20190021899 | Vlet | Jan 2019 | A1 |
| 20190038451 | Harvie | Feb 2019 | A1 |
| 20190046102 | Kushnir et al. | Feb 2019 | A1 |
| 20190100362 | Meyers et al. | Apr 2019 | A1 |
| 20190133814 | Tammen et al. | May 2019 | A1 |
| 20190142624 | Sanchez | May 2019 | A1 |
| 20190224036 | Sanchez | Jul 2019 | A1 |
| 20190247222 | Ecklund et al. | Aug 2019 | A1 |
| 20190247223 | Brun et al. | Aug 2019 | A1 |
| 20190282391 | Johannes et al. | Sep 2019 | A1 |
| 20190314189 | Acosta | Oct 2019 | A1 |
| 20190314190 | Sanchez | Oct 2019 | A1 |
| 20190321587 | Mcmenamin et al. | Oct 2019 | A1 |
| 20190344934 | Faerber et al. | Nov 2019 | A1 |
| 20190365307 | Laing et al. | Dec 2019 | A1 |
| 20190365561 | Newton et al. | Dec 2019 | A1 |
| 20200008985 | Nguyen et al. | Jan 2020 | A1 |
| 20200016012 | Dutkiewicz | Jan 2020 | A1 |
| 20200030595 | Boukidjian et al. | Jan 2020 | A1 |
| 20200046544 | Godinez | Feb 2020 | A1 |
| 20200055638 | Lau et al. | Feb 2020 | A1 |
| 20200070392 | Huber et al. | Mar 2020 | A1 |
| 20200085609 | Schelch et al. | Mar 2020 | A1 |
| 20200085610 | Cohn et al. | Mar 2020 | A1 |
| 20200086090 | Von Weymarn-Schärli et al. | Mar 2020 | A1 |
| 20200107518 | Hiroshima et al. | Apr 2020 | A1 |
| 20200129322 | Leuckel | Apr 2020 | A1 |
| 20200171217 | Braga et al. | Jun 2020 | A9 |
| 20200206039 | Mclain | Jul 2020 | A1 |
| 20200214910 | Varona et al. | Jul 2020 | A1 |
| 20200216898 | Hubbell | Jul 2020 | A1 |
| 20200216989 | Kinugasa et al. | Jul 2020 | A1 |
| 20200229964 | Staali et al. | Jul 2020 | A1 |
| 20200231343 | Freedman et al. | Jul 2020 | A1 |
| 20200232841 | Satish et al. | Jul 2020 | A1 |
| 20200246172 | Ho | Aug 2020 | A1 |
| 20200246203 | Tulk et al. | Aug 2020 | A1 |
| 20200255189 | Liu | Aug 2020 | A1 |
| 20200261280 | Heyman | Aug 2020 | A1 |
| 20200276046 | Staali et al. | Sep 2020 | A1 |
| 20200306075 | Newton et al. | Oct 2020 | A1 |
| 20200315837 | Radl et al. | Oct 2020 | A1 |
| 20200315838 | Eckert | Oct 2020 | A1 |
| 20200315872 | Viens et al. | Oct 2020 | A1 |
| 20200315874 | Viens et al. | Oct 2020 | A1 |
| 20200331672 | Bertram et al. | Oct 2020 | A1 |
| 20200345332 | Duval | Nov 2020 | A1 |
| 20200353135 | Gregory et al. | Nov 2020 | A1 |
| 20200367677 | Silsby et al. | Nov 2020 | A1 |
| 20200369444 | Silsby et al. | Nov 2020 | A1 |
| 20200375781 | Staali et al. | Dec 2020 | A1 |
| 20200375810 | Carlin et al. | Dec 2020 | A1 |
| 20200385179 | Mccourt | Dec 2020 | A1 |
| 20200390591 | Glithero et al. | Dec 2020 | A1 |
| 20200390592 | Merrill | Dec 2020 | A1 |
| 20200405521 | Glasroe | Dec 2020 | A1 |
| 20210008771 | Huber et al. | Jan 2021 | A1 |
| 20210009323 | Markarian et al. | Jan 2021 | A1 |
| 20210020072 | Moehring et al. | Jan 2021 | A1 |
| 20210059853 | Davis | Mar 2021 | A1 |
| 20210061523 | Bytheway | Mar 2021 | A1 |
| 20210069005 | Sanchez | Mar 2021 | A1 |
| 20210069008 | Blabas et al. | Mar 2021 | A1 |
| 20210069009 | Im | Mar 2021 | A1 |
| 20210069030 | Nishikawa et al. | Mar 2021 | A1 |
| 20210077993 | Nazareth et al. | Mar 2021 | A1 |
| 20210113749 | Radl et al. | Apr 2021 | A1 |
| 20210121318 | Pinlac | Apr 2021 | A1 |
| 20210137724 | Ecklund et al. | May 2021 | A1 |
| 20210138190 | Erbey et al. | May 2021 | A1 |
| 20210154055 | Mllarreal | May 2021 | A1 |
| 20210170079 | Radl et al. | Jun 2021 | A1 |
| 20210178390 | Oueslati et al. | Jun 2021 | A1 |
| 20210186742 | Newton et al. | Jun 2021 | A1 |
| 20210212865 | Wallajapet et al. | Jul 2021 | A1 |
| 20210220162 | Jamison | Jul 2021 | A1 |
| 20210220163 | Mayrand | Jul 2021 | A1 |
| 20210228400 | Glithero | Jul 2021 | A1 |
| 20210228401 | Becker et al. | Jul 2021 | A1 |
| 20210228795 | Hughett et al. | Jul 2021 | A1 |
| 20210229877 | Ragias et al. | Jul 2021 | A1 |
| 20210236323 | Austermann | Aug 2021 | A1 |
| 20210236324 | Sweeney | Aug 2021 | A1 |
| 20210251814 | Jönegren et al. | Aug 2021 | A1 |
| 20210267787 | Nazemi | Sep 2021 | A1 |
| 20210275343 | Sanchez | Sep 2021 | A1 |
| 20210290454 | Yamada | Sep 2021 | A1 |
| 20210315727 | Jiang | Oct 2021 | A1 |
| 20210353450 | Sharma et al. | Nov 2021 | A1 |
| 20210361469 | Liu et al. | Nov 2021 | A1 |
| 20210369495 | Cheng | Dec 2021 | A1 |
| 20210386925 | Hartwell et al. | Dec 2021 | A1 |
| 20210393433 | Godinez et al. | Dec 2021 | A1 |
| 20220023091 | Ecklund et al. | Jan 2022 | A1 |
| 20220031523 | Pierpoint | Feb 2022 | A1 |
| 20220039995 | Johannes et al. | Feb 2022 | A1 |
| 20220047410 | Walthall | Feb 2022 | A1 |
| 20220062027 | Mitchell et al. | Mar 2022 | A1 |
| 20220062028 | Mitchell et al. | Mar 2022 | A1 |
| 20220062029 | Johannes | Mar 2022 | A1 |
| 20220066825 | Saraf et al. | Mar 2022 | A1 |
| 20220071811 | Cheng et al. | Mar 2022 | A1 |
| 20220071826 | Kulkarni et al. | Mar 2022 | A1 |
| 20220104965 | Vaninetti et al. | Apr 2022 | A1 |
| 20220104976 | Hoeger et al. | Apr 2022 | A1 |
| 20220104981 | Jones | Apr 2022 | A1 |
| 20220117773 | Davis et al. | Apr 2022 | A1 |
| 20220117774 | Meyer et al. | Apr 2022 | A1 |
| 20220117775 | Jones | Apr 2022 | A1 |
| 20220133524 | Davis | May 2022 | A1 |
| 20220151817 | Mann | May 2022 | A1 |
| 20220160949 | Simiele et al. | May 2022 | A1 |
| 20220168159 | Triado et al. | Jun 2022 | A1 |
| 20220193312 | Lee et al. | Jun 2022 | A1 |
| 20220211536 | Johannes et al. | Jul 2022 | A1 |
| 20220218510 | Metzger et al. | Jul 2022 | A1 |
| 20220229053 | Levin et al. | Jul 2022 | A1 |
| 20220241106 | Johannes et al. | Aug 2022 | A1 |
| 20220247407 | Yamamoto et al. | Aug 2022 | A1 |
| 20220248836 | Cagle et al. | Aug 2022 | A1 |
| 20220257407 | Johannes | Aug 2022 | A1 |
| 20220265460 | Coker | Aug 2022 | A1 |
| 20220265462 | Alder | Aug 2022 | A1 |
| 20220270711 | Feala et al. | Aug 2022 | A1 |
| 20220273482 | Johannes et al. | Sep 2022 | A1 |
| 20220280357 | Jagannathan | Sep 2022 | A1 |
| 20220287689 | Johannes | Sep 2022 | A1 |
| 20220296408 | Evans et al. | Sep 2022 | A1 |
| 20220305191 | Joseph et al. | Sep 2022 | A1 |
| 20220313222 | Austermann | Oct 2022 | A1 |
| 20220313474 | Kriscovich et al. | Oct 2022 | A1 |
| 20220331170 | Erdem et al. | Oct 2022 | A1 |
| 20220339024 | Johannes et al. | Oct 2022 | A1 |
| 20220354685 | Davis et al. | Nov 2022 | A1 |
| 20220362049 | Austermann et al. | Nov 2022 | A1 |
| 20220370231 | Wang et al. | Nov 2022 | A1 |
| 20220370234 | Hughett | Nov 2022 | A1 |
| 20220370235 | Johannes | Nov 2022 | A1 |
| 20220370237 | Parmar et al. | Nov 2022 | A1 |
| 20220387001 | Askenazi et al. | Dec 2022 | A1 |
| 20220395390 | Brooks | Dec 2022 | A1 |
| 20220395391 | Saunders | Dec 2022 | A1 |
| 20230018845 | Lee | Jan 2023 | A1 |
| 20230020563 | Sharma et al. | Jan 2023 | A1 |
| 20230031640 | Hughett et al. | Feb 2023 | A1 |
| 20230037159 | Brennan | Feb 2023 | A1 |
| 20230052238 | Oluwasogo | Feb 2023 | A1 |
| 20230062944 | Vollenberg et al. | Mar 2023 | A1 |
| 20230062994 | Ecklund et al. | Mar 2023 | A1 |
| 20230070347 | Watson et al. | Mar 2023 | A1 |
| 20230073708 | Xu et al. | Mar 2023 | A1 |
| 20230089032 | Hughett | Mar 2023 | A1 |
| 20230099821 | Radl et al. | Mar 2023 | A1 |
| 20230099991 | Bianchi et al. | Mar 2023 | A1 |
| 20230105001 | Whittome | Apr 2023 | A1 |
| 20230110577 | Choi | Apr 2023 | A1 |
| 20230138269 | Abdelal | May 2023 | A1 |
| 20230145365 | Martin et al. | May 2023 | A1 |
| 20230155253 | Yin et al. | May 2023 | A1 |
| 20230210504 | Kuroda et al. | Jul 2023 | A1 |
| 20230218426 | Hughett | Jul 2023 | A1 |
| 20230240884 | Davis et al. | Aug 2023 | A1 |
| 20230248562 | Sanchez et al. | Aug 2023 | A1 |
| 20230248564 | Mann et al. | Aug 2023 | A1 |
| 20230255812 | Sanchez et al. | Aug 2023 | A1 |
| 20230255813 | Sanchez et al. | Aug 2023 | A1 |
| 20230255815 | Newton | Aug 2023 | A1 |
| 20230263650 | Sanchez et al. | Aug 2023 | A1 |
| 20230263655 | Johannes et al. | Aug 2023 | A1 |
| 20230277362 | Davis | Sep 2023 | A1 |
| 20230285178 | Sanchez et al. | Sep 2023 | A1 |
| 20230293339 | James | Sep 2023 | A1 |
| 20230301846 | Greenwood | Sep 2023 | A1 |
| 20230355423 | Stevenson et al. | Nov 2023 | A1 |
| 20230404791 | Ecklund et al. | Dec 2023 | A1 |
| 20240008444 | Su et al. | Jan 2024 | A1 |
| 20240009023 | Johannes et al. | Jan 2024 | A1 |
| 20240024170 | Scott | Jan 2024 | A1 |
| 20240041638 | Johannes et al. | Feb 2024 | A1 |
| 20240058161 | Ulreich et al. | Feb 2024 | A1 |
| 20240065881 | Kuroda et al. | Feb 2024 | A1 |
| 20240099874 | Sanchez et al. | Mar 2024 | A1 |
| 20240110318 | Bendt et al. | Apr 2024 | A1 |
| 20240123134 | Kharkar et al. | Apr 2024 | A1 |
| Number | Date | Country |
|---|---|---|
| 2018216821 | Aug 2019 | AU |
| 2021299304 | Feb 2023 | AU |
| 2165286 | Sep 1999 | CA |
| 2354132 | Jun 2000 | CA |
| 2359091 | Sep 2003 | CA |
| 2488867 | Aug 2007 | CA |
| 3050918 | Aug 2018 | CA |
| 3098571 | Nov 2019 | CA |
| 2269203 | Dec 1997 | CN |
| 1332620 | Jan 2002 | CN |
| 1434693 | Aug 2003 | CN |
| 1533755 | Oct 2004 | CN |
| 1602825 | Apr 2005 | CN |
| 1720888 | Jan 2006 | CN |
| 2936204 | Aug 2007 | CN |
| 101262836 | Sep 2008 | CN |
| 101522148 | Sep 2009 | CN |
| 102159159 | Aug 2011 | CN |
| 202184840 | Apr 2012 | CN |
| 102481441 | May 2012 | CN |
| 202463712 | Oct 2012 | CN |
| 103533968 | Jan 2014 | CN |
| 103717180 | Apr 2014 | CN |
| 204562697 | Aug 2015 | CN |
| 105411783 | Mar 2016 | CN |
| 105451693 | Mar 2016 | CN |
| 105534632 | May 2016 | CN |
| 205849719 | Jan 2017 | CN |
| 106726089 | May 2017 | CN |
| 107847384 | Mar 2018 | CN |
| 107920912 | Apr 2018 | CN |
| 209285902 | Aug 2019 | CN |
| 110381883 | Oct 2019 | CN |
| 211198839 | Aug 2020 | CN |
| 112566550 | Mar 2021 | CN |
| 112603184 | Apr 2021 | CN |
| 114007493 | Feb 2022 | CN |
| 114375187 | Apr 2022 | CN |
| 116096332 | May 2023 | CN |
| 79818 | Oct 1893 | DE |
| 1516466 | Jun 1969 | DE |
| 2721330 | Nov 1977 | DE |
| 2742298 | Mar 1978 | DE |
| 9407554.9 | May 1995 | DE |
| 4443710 | Jun 1995 | DE |
| 4416094 | Nov 1995 | DE |
| 4236097 | Oct 1996 | DE |
| 19619597 | Nov 1997 | DE |
| 102005037762 | Sep 2006 | DE |
| 102011103783 | Dec 2012 | DE |
| 202015104597 | Jul 2016 | DE |
| 9600118 | Nov 1996 | DK |
| 0032138 | Jul 1981 | EP |
| 0066070 | Dec 1982 | EP |
| 0068712 | Jan 1983 | EP |
| 0140470 | May 1985 | EP |
| 0140471 | May 1988 | EP |
| 0274753 | Jul 1988 | EP |
| 0119143 | Nov 1988 | EP |
| 0483592 | May 1992 | EP |
| 0610638 | Aug 1994 | EP |
| 0613355 | Sep 1994 | EP |
| 0613355 | Jan 1997 | EP |
| 0787472 | Aug 1997 | EP |
| 0966936 | Dec 1999 | EP |
| 0987293 | Mar 2000 | EP |
| 1063953 | Jan 2001 | EP |
| 0653928 | Oct 2002 | EP |
| 1332738 | Aug 2003 | EP |
| 1382318 | Jan 2004 | EP |
| 1089684 | Oct 2004 | EP |
| 1616542 | Jan 2006 | EP |
| 1382318 | May 2006 | EP |
| 1063953 | Jan 2007 | EP |
| 1872752 | Jan 2008 | EP |
| 2180907 | May 2010 | EP |
| 2380532 | Oct 2011 | EP |
| 2389908 | Nov 2011 | EP |
| 2601916 | Jun 2013 | EP |
| 2676643 | Dec 2013 | EP |
| 2997950 | Mar 2016 | EP |
| 2879534 | Mar 2017 | EP |
| 3424471 | Jan 2019 | EP |
| 3169292 | Nov 2019 | EP |
| 3753492 | Dec 2020 | EP |
| 3788992 | Mar 2021 | EP |
| 3576689 | Mar 2022 | EP |
| 3752110 | Mar 2022 | EP |
| 3787570 | Mar 2022 | EP |
| 4025163 | Jul 2022 | EP |
| 3463180 | Mar 2023 | EP |
| 1011517 | Dec 1965 | GB |
| 1467144 | Mar 1977 | GB |
| 2106395 | Apr 1983 | GB |
| 2106784 | Apr 1983 | GB |
| 2148126 | May 1985 | GB |
| 2171315 | Aug 1986 | GB |
| 2181953 | May 1987 | GB |
| 2148126 | Jul 1987 | GB |
| 2191095 | Dec 1987 | GB |
| 2199750 | Jul 1988 | GB |
| 2260907 | May 1993 | GB |
| 2462267 | Feb 2010 | GB |
| 2469496 | Oct 2010 | GB |
| 2490327 | Oct 2012 | GB |
| 2507318 | Apr 2014 | GB |
| 2612752 | May 2023 | GB |
| 201800009129 | Apr 2020 | IT |
| S498638 | Jan 1974 | JP |
| S5410596 | Jan 1979 | JP |
| S5410596 | May 1979 | JP |
| S55155618 | Dec 1980 | JP |
| S5888596 | Jun 1983 | JP |
| S63107780 | Jul 1988 | JP |
| H0267530 | Mar 1990 | JP |
| H02103871 | Apr 1990 | JP |
| H02131422 | May 1990 | JP |
| H02131422 | Nov 1990 | JP |
| H0460220 | Feb 1992 | JP |
| H05123349 | May 1993 | JP |
| H05123350 | May 1993 | JP |
| 3087938 | Oct 1995 | JP |
| H085630 | Jan 1996 | JP |
| H1040141 | Feb 1998 | JP |
| H10225430 | Aug 1998 | JP |
| H11113946 | Apr 1999 | JP |
| H11290365 | Oct 1999 | JP |
| 2000116690 | Apr 2000 | JP |
| 2000185068 | Jul 2000 | JP |
| 2001054531 | Feb 2001 | JP |
| 2001070331 | Mar 2001 | JP |
| 2001224616 | Aug 2001 | JP |
| 2001276107 | Oct 2001 | JP |
| 2001276108 | Oct 2001 | JP |
| 2002028173 | Jan 2002 | JP |
| 2003505152 | Feb 2003 | JP |
| 2003180722 | Jul 2003 | JP |
| 2004130056 | Apr 2004 | JP |
| 2004267530 | Sep 2004 | JP |
| 2005066011 | Mar 2005 | JP |
| 2005066325 | Mar 2005 | JP |
| 2005518237 | Jun 2005 | JP |
| 3749097 | Dec 2005 | JP |
| 2006026108 | Feb 2006 | JP |
| 3123547 | Jun 2006 | JP |
| 2006136492 | Jun 2006 | JP |
| 2006204868 | Aug 2006 | JP |
| 2007044494 | Feb 2007 | JP |
| 3132659 | May 2007 | JP |
| 4039641 | Nov 2007 | JP |
| 2009509570 | Mar 2009 | JP |
| 2010081981 | Apr 2010 | JP |
| 4640772 | Dec 2010 | JP |
| 2010536439 | Dec 2010 | JP |
| 4747166 | May 2011 | JP |
| 2011087823 | May 2011 | JP |
| 4801218 | Aug 2011 | JP |
| 2011218130 | Nov 2011 | JP |
| 2011224070 | Nov 2011 | JP |
| 2012523869 | Oct 2012 | JP |
| 2013238608 | Nov 2013 | JP |
| 2014521960 | Aug 2014 | JP |
| 2015092945 | May 2015 | JP |
| 3198994 | Jul 2015 | JP |
| 2019525811 | Sep 2019 | JP |
| 2021120686 | Aug 2021 | JP |
| 2021522009 | Aug 2021 | JP |
| 7129493 | Aug 2022 | JP |
| 2023532132 | Jul 2023 | JP |
| 200290061 | Sep 2002 | KR |
| 20030047451 | Jun 2003 | KR |
| 20140039485 | Apr 2014 | KR |
| 101432639 | Aug 2014 | KR |
| 20180106659 | Oct 2018 | KR |
| 20180108774 | Oct 2018 | KR |
| 2068717 | Jun 2013 | PT |
| 8101957 | Jul 1981 | WO |
| 8804558 | Jun 1988 | WO |
| 9104714 | Apr 1991 | WO |
| 9104714 | Jun 1991 | WO |
| 9220299 | Feb 1993 | WO |
| 9307839 | Apr 1993 | WO |
| 9309736 | May 1993 | WO |
| 9309736 | Jun 1993 | WO |
| 9514448 | Jun 1995 | WO |
| 9600096 | Jan 1996 | WO |
| 9634636 | Nov 1996 | WO |
| 9817211 | Apr 1998 | WO |
| 9830336 | Jul 1998 | WO |
| 0000112 | Jan 2000 | WO |
| 0000113 | Jan 2000 | WO |
| 0025651 | May 2000 | WO |
| 0033773 | Jun 2000 | WO |
| 0057784 | Oct 2000 | WO |
| 0069377 | Nov 2000 | WO |
| 0079497 | Dec 2000 | WO |
| 0145618 | Jun 2001 | WO |
| 0145621 | Jun 2001 | WO |
| 02094160 | Nov 2002 | WO |
| 03013967 | Feb 2003 | WO |
| 03024824 | Mar 2003 | WO |
| 03055423 | Jul 2003 | WO |
| 03071931 | Sep 2003 | WO |
| 03079942 | Oct 2003 | WO |
| 03071931 | Feb 2004 | WO |
| 2004019836 | Mar 2004 | WO |
| 2004024046 | Mar 2004 | WO |
| 2005051252 | Jun 2005 | WO |
| 2005074571 | Sep 2005 | WO |
| 2005089687 | Sep 2005 | WO |
| 2005107661 | Nov 2005 | WO |
| 2006021220 | Mar 2006 | WO |
| 2006037140 | Apr 2006 | WO |
| 2007005851 | Jan 2007 | WO |
| 2007007845 | Jan 2007 | WO |
| 2007042823 | Apr 2007 | WO |
| 2007055651 | May 2007 | WO |
| 2006098950 | Nov 2007 | WO |
| 2007134608 | Nov 2007 | WO |
| 2007128156 | Feb 2008 | WO |
| 2008026106 | Mar 2008 | WO |
| 2008078117 | Jul 2008 | WO |
| 2008104019 | Sep 2008 | WO |
| 2008141471 | Nov 2008 | WO |
| 2009004368 | Jan 2009 | WO |
| 2009004369 | Jan 2009 | WO |
| 2009052496 | Apr 2009 | WO |
| 2009052502 | Apr 2009 | WO |
| 2009007702 | Jul 2009 | WO |
| 2009101738 | Aug 2009 | WO |
| 2010058192 | May 2010 | WO |
| 2010030122 | Jul 2010 | WO |
| 2010101915 | Jan 2011 | WO |
| 2011018132 | Feb 2011 | WO |
| 2011018133 | Feb 2011 | WO |
| 2011024864 | Mar 2011 | WO |
| 2011054118 | May 2011 | WO |
| 2011079132 | Jun 2011 | WO |
| 2011107972 | Sep 2011 | WO |
| 2011108972 | Sep 2011 | WO |
| 2011117292 | Sep 2011 | WO |
| 2011123219 | Oct 2011 | WO |
| 2011132043 | Oct 2011 | WO |
| 2012012908 | Feb 2012 | WO |
| 2012065274 | May 2012 | WO |
| 2012097462 | Jul 2012 | WO |
| 2012098796 | Jul 2012 | WO |
| 2012101288 | Aug 2012 | WO |
| 2012175916 | Dec 2012 | WO |
| 2013018435 | Feb 2013 | WO |
| 2013033429 | Mar 2013 | WO |
| 2013055434 | Apr 2013 | WO |
| 2013082397 | Jun 2013 | WO |
| 2013103291 | Jul 2013 | WO |
| 2013131109 | Sep 2013 | WO |
| 2013167478 | Nov 2013 | WO |
| 2013177716 | Dec 2013 | WO |
| 2014041534 | Mar 2014 | WO |
| 2014046420 | Mar 2014 | WO |
| 2014118518 | Aug 2014 | WO |
| 2014160852 | Oct 2014 | WO |
| 2015023599 | Feb 2015 | WO |
| 2015052348 | Apr 2015 | WO |
| 2015068384 | May 2015 | WO |
| 2015169403 | Nov 2015 | WO |
| 2015170307 | Nov 2015 | WO |
| 2015197462 | Dec 2015 | WO |
| 2016051385 | Apr 2016 | WO |
| 2016055989 | Apr 2016 | WO |
| 2016071894 | May 2016 | WO |
| 2016103242 | Jun 2016 | WO |
| 2016116915 | Jul 2016 | WO |
| 2016124203 | Aug 2016 | WO |
| 2016139448 | Sep 2016 | WO |
| 2016166562 | Oct 2016 | WO |
| 2016167535 | Oct 2016 | WO |
| 2016191574 | Dec 2016 | WO |
| 2016200088 | Dec 2016 | WO |
| 2016200361 | Dec 2016 | WO |
| 2016204731 | Dec 2016 | WO |
| 2017001532 | Jan 2017 | WO |
| 2017001846 | Jan 2017 | WO |
| 2017075226 | May 2017 | WO |
| 2017152198 | Sep 2017 | WO |
| 2017153357 | Sep 2017 | WO |
| 2017162559 | Sep 2017 | WO |
| 2017205446 | Nov 2017 | WO |
| 2017209779 | Dec 2017 | WO |
| 2017210524 | Dec 2017 | WO |
| 2018022414 | Feb 2018 | WO |
| 2018044781 | Mar 2018 | WO |
| 2018056953 | Mar 2018 | WO |
| 2018090550 | May 2018 | WO |
| 2018138513 | Aug 2018 | WO |
| 2018144318 | Aug 2018 | WO |
| 2018144463 | Aug 2018 | WO |
| 2018150263 | Aug 2018 | WO |
| 2018150268 | Aug 2018 | WO |
| 2018152156 | Aug 2018 | WO |
| 2018183791 | Oct 2018 | WO |
| 2018150267 | Nov 2018 | WO |
| 2018235026 | Dec 2018 | WO |
| 2018235065 | Dec 2018 | WO |
| 2019004404 | Jan 2019 | WO |
| 2019041005 | Mar 2019 | WO |
| 2019044217 | Mar 2019 | WO |
| 2019044218 | Mar 2019 | WO |
| 2019044219 | Mar 2019 | WO |
| 2019065541 | Apr 2019 | WO |
| 2019096845 | May 2019 | WO |
| 2019150385 | Aug 2019 | WO |
| 2019161094 | Aug 2019 | WO |
| 2019188566 | Oct 2019 | WO |
| 2019190593 | Oct 2019 | WO |
| 2019212949 | Nov 2019 | WO |
| 2019212950 | Nov 2019 | WO |
| 2019212951 | Nov 2019 | WO |
| 2019212952 | Nov 2019 | WO |
| 2019212954 | Nov 2019 | WO |
| 2019212955 | Nov 2019 | WO |
| 2019212956 | Nov 2019 | WO |
| 2019214787 | Nov 2019 | WO |
| 2019214788 | Nov 2019 | WO |
| 2019226826 | Nov 2019 | WO |
| 2019239433 | Dec 2019 | WO |
| 2020000994 | Jan 2020 | WO |
| 2020020618 | Jan 2020 | WO |
| 2020038822 | Feb 2020 | WO |
| 2020088409 | May 2020 | WO |
| 2020049394 | Jun 2020 | WO |
| 2020120657 | Jun 2020 | WO |
| 2020152575 | Jul 2020 | WO |
| 2020182923 | Sep 2020 | WO |
| 2020204967 | Oct 2020 | WO |
| 2020205939 | Oct 2020 | WO |
| 2020209898 | Oct 2020 | WO |
| 2020242790 | Dec 2020 | WO |
| 2020251893 | Dec 2020 | WO |
| 2020256865 | Dec 2020 | WO |
| 2021007144 | Jan 2021 | WO |
| 2021007345 | Jan 2021 | WO |
| 2021010844 | Jan 2021 | WO |
| 2021016026 | Jan 2021 | WO |
| 2021016300 | Jan 2021 | WO |
| 2021025919 | Feb 2021 | WO |
| 2021034886 | Feb 2021 | WO |
| 2021041123 | Mar 2021 | WO |
| 2021046501 | Mar 2021 | WO |
| 2021086868 | May 2021 | WO |
| 2021094352 | May 2021 | WO |
| 2021094639 | May 2021 | WO |
| 2021097067 | May 2021 | WO |
| 2021102296 | May 2021 | WO |
| 2021107025 | Jun 2021 | WO |
| 2021138411 | Jul 2021 | WO |
| 2021138414 | Jul 2021 | WO |
| 2021154686 | Aug 2021 | WO |
| 2021155206 | Aug 2021 | WO |
| 2021170075 | Sep 2021 | WO |
| 2021173436 | Sep 2021 | WO |
| 2021188817 | Sep 2021 | WO |
| 2021195384 | Sep 2021 | WO |
| 2021205995 | Oct 2021 | WO |
| 2021207621 | Oct 2021 | WO |
| 2021211568 | Oct 2021 | WO |
| 2021211801 | Oct 2021 | WO |
| 2021211914 | Oct 2021 | WO |
| 2021216419 | Oct 2021 | WO |
| 2021216422 | Oct 2021 | WO |
| 2021231532 | Nov 2021 | WO |
| 2021247523 | Dec 2021 | WO |
| 2021257202 | Dec 2021 | WO |
| 2022006256 | Jan 2022 | WO |
| 2022031943 | Feb 2022 | WO |
| 2022035745 | Feb 2022 | WO |
| 2022051360 | Mar 2022 | WO |
| 2022054613 | Mar 2022 | WO |
| 2022066704 | Mar 2022 | WO |
| 2022067392 | Apr 2022 | WO |
| 2022069950 | Apr 2022 | WO |
| 2022071429 | Apr 2022 | WO |
| 2022076322 | Apr 2022 | WO |
| 2022076427 | Apr 2022 | WO |
| 2022086898 | Apr 2022 | WO |
| 2022090199 | May 2022 | WO |
| 2022098536 | May 2022 | WO |
| 2022099087 | May 2022 | WO |
| 2022101999 | May 2022 | WO |
| 2022115692 | Jun 2022 | WO |
| 2022125685 | Jun 2022 | WO |
| 2022140545 | Jun 2022 | WO |
| 2022145231 | Jul 2022 | WO |
| 2022150360 | Jul 2022 | WO |
| 2022150463 | Jul 2022 | WO |
| 2022159392 | Jul 2022 | WO |
| 2022170182 | Aug 2022 | WO |
| 2022182385 | Sep 2022 | WO |
| 2022187152 | Sep 2022 | WO |
| 2022192188 | Sep 2022 | WO |
| 2022192347 | Sep 2022 | WO |
| 2022216507 | Oct 2022 | WO |
| 2022222030 | Oct 2022 | WO |
| 2023286058 | Jan 2023 | WO |
| 2023014639 | Feb 2023 | WO |
| 2023014641 | Feb 2023 | WO |
| 2023018475 | Feb 2023 | WO |
| 2023023777 | Mar 2023 | WO |
| 2023034453 | Mar 2023 | WO |
| 2023038945 | Mar 2023 | WO |
| 2023038950 | Mar 2023 | WO |
| 2023049109 | Mar 2023 | WO |
| 2023049175 | Mar 2023 | WO |
| 2023086394 | May 2023 | WO |
| 2023149884 | Aug 2023 | WO |
| 2023149902 | Aug 2023 | WO |
| 2023149903 | Aug 2023 | WO |
| 2023154390 | Aug 2023 | WO |
| 2023191764 | Oct 2023 | WO |
| 2023244238 | Dec 2023 | WO |
| 2024058788 | Mar 2024 | WO |
| Entry |
|---|
| US 9,908,683 B2, 03/2018, Sandhausen et al. (withdrawn) |
| Advisory Action for U.S. Appl. No. 14/722,613 dated Mar. 4, 2019. |
| Advisory Action for U.S. Appl. No. 14/952,591 dated Jun. 1, 2018. |
| Advisory Action for U.S. Appl. No. 15/238,427 dated Apr. 10, 2019. |
| Advisory Action for U.S. Appl. No. 16/899,956 dated Jul. 9, 2021. |
| Advisory Action for U.S. Appl. No. 16/904,868 dated Jul. 2, 2021. |
| Advisory Action for U.S. Appl. No. 16/905,400 dated Feb. 16, 2022. |
| Advisory Action for U.S. Appl. No. 16/905,400 dated Jun. 9, 2021. |
| Corrected International Search Report and Written Opinion for International Application No. PCT/US2017/043025 dated Jan. 11, 2018. |
| Corrected Notice of Allowability for U.S. Appl. No. 15/221,106 dated Jul. 2, 2019. |
| Corrected Notice of Allowability for U.S. Appl. No. 15/612,325 dated Mar. 17, 2021. |
| Corrected Notice of Allowability for U.S. Appl. No. 17/330,657 dated Dec. 9, 2021. |
| Final Office Action for U.S. Appl. No. 14/722,613 dated Nov. 29, 2018. |
| Final Office Action for U.S. Appl. No. 14/947,759 dated Apr. 8, 2016. |
| Final Office Action for U.S. Appl. No. 14/952,591 dated Feb. 23, 2018. |
| Final Office Action for U.S. Appl. No. 14/952,591 dated Nov. 1, 2019. |
| Final Office Action for U.S. Appl. No. 14/952,591 dated Nov. 27, 2020. |
| Final Office Action for U.S. Appl. No. 15/171,968 dated Feb. 14, 2020. |
| Final Office Action for U.S. Appl. No. 15/171,968 dated Mar. 19, 2019. |
| Final Office Action for U.S. Appl. No. 15/221,106 dated Jan. 23, 2019. |
| Final Office Action for U.S. Appl. No. 15/238,427 dated Jan. 2, 2019. |
| Final Office Action for U.S. Appl. No. 15/260,103 dated Feb. 14, 2019. |
| Final Office Action for U.S. Appl. No. 15/612,325 dated Sep. 17, 2020. |
| Final Office Action for U.S. Appl. No. 16/452,145 dated Mar. 25, 2022. |
| Final Office Action for U.S. Appl. No. 16/899,956 dated Apr. 19, 2021. |
| Final Office Action for U.S. Appl. No. 16/904,868 dated Mar. 10, 2022. |
| Final Office Action for U.S. Appl. No. 16/904,868 dated Mar. 26, 2021. |
| Final Office Action for U.S. Appl. No. 16/905,400 dated Apr. 6, 2021. |
| Final Office Action for U.S. Appl. No. 16/905,400 dated Dec. 9, 2021. |
| Final Office Action for U.S. Appl. No. 17/088,272 dated May 25, 2021. |
| Final Office Action for U.S. Appl. No. 29/624,661 dated Feb. 18, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2016/049274 dated Dec. 1, 2016. |
| International Search Report and Written Opinion from International Application No. PCT/US2017/035625 dated Aug. 15, 2017. |
| International Search Report and Written Opinion from International Application No. PCT/US2017/043025 dated Oct. 18, 2017. |
| International Search Report and Written Opinion from International Application No. PCT/US2018/015968 dated Apr. 6, 2018. |
| International Search Report and Written Opinion from International Application No. PCT/US2019/029608 dated Sep. 3, 2019. |
| International Search Report and Written Opinion from International Application No. PCT/US2019/029609 dated Sep. 3, 2019. |
| International Search Report and Written Opinion from International Application No. PCT/US2019/029610 dated Sep. 3, 2019. |
| International Search Report and Written Opinion from International Application No. PCT/US2019/029611 dated Jul. 3, 2019. |
| International Search Report and Written Opinion from International Application No. PCT/US2019/029613 dated Jul. 3, 2019. |
| International Search Report and Written Opinion from International Application No. PCT/US2019/029614 dated Sep. 26, 2019. |
| International Search Report and Written Opinion from International Application No. PCT/US2019/029616 dated Aug. 30, 2019. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/023572 dated Jul. 6, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/033064 dated Aug. 31, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/033122 dated Aug. 31, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/040860 dated Oct. 2, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/041242 dated Nov. 17, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/041249 dated Oct. 2, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/042262 dated Oct. 14, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/043059 dated Oct. 6, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/044024 dated Nov. 12, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/046914 dated Dec. 1, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/055680 dated Dec. 15, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/057562 dated Jan. 27, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/061563 dated Feb. 19, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/065234 dated Apr. 12, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/067451 dated Mar. 25, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/067454 dated Mar. 29, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/067455 dated Mar. 26, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/015024 dated May 18, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/015787 dated May 27, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/023001 dated Jun. 21, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/024162 dated Jul. 8, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/026607 dated Jul. 29, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/027061 dated Jul. 19, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/027104 dated Jul. 6, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/027314 dated Jul. 6, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/027422 dated Aug. 12, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/027425 dated Aug. 11, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/027913 dated Jul. 12, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/027917 dated Aug. 19, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/035181 dated Sep. 16, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/043893 dated Nov. 22, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/044699 dated Nov. 22, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/045188 dated Jan. 26, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/047536 dated Dec. 23, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/048211 dated Dec. 22, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/048661 dated Feb. 14, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/049404 dated Jan. 18, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/053593 dated Apr. 11, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/056566 dated Feb. 11, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/060993 dated Mar. 18, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/062440 dated Mar. 28, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/011108 dated Apr. 22, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/011281 dated Apr. 25, 2022. |
| Issue Notification for U.S. Appl. No. 14/952,591 dated Jul. 28, 2021. |
| Issue Notification for U.S. Appl. No. 15/171,968 dated Mar. 3, 2021. |
| Issue Notification for U.S. Appl. No. 15/221,106 dated Jul. 24, 2019. |
| Issue Notification for U.S. Appl. No. 15/238,427 dated Jul. 24, 2019. |
| Issue Notification for U.S. Appl. No. 15/260,103 dated Aug. 7, 2019. |
| Issue Notification for U.S. Appl. No. 15/611,587 dated Feb. 20, 2019. |
| Issue Notification for U.S. Appl. No. 15/612,325 dated Mar. 24, 2021. |
| Issue Notification for U.S. Appl. No. 29/624,661 dated Aug. 4, 2021. |
| Non-Final Office Action for U.S. Appl. No. 14/592,591 dated Mar. 20, 2020. |
| Non-Final Office Action for U.S. Appl. No. 14/722,613 dated Jun. 13, 2019. |
| Non-Final Office Action for U.S. Appl. No. 14/947,759 dated Mar. 17, 2016. |
| Non-Final Office Action for U.S. Appl. No. 14/952,591 dated Aug. 1, 2017. |
| Non-Final Office Action for U.S. Appl. No. 14/952,591 dated Mar. 20, 2020. |
| Non-Final Office Action for U.S. Appl. No. 14/952,591 dated Mar. 21, 2019. |
| Non-Final Office Action for U.S. Appl. No. 14/952,591 dated Sep. 28, 2018. |
| Non-Final Office Action for U.S. Appl. No. 15/171,968 dated May 11, 2020. |
| Non-Final Office Action for U.S. Appl. No. 15/171,968 dated Aug. 20, 2019. |
| Non-Final Office Action for U.S. Appl. No. 15/171,968 dated Jun. 12, 2018. |
| Non-Final Office Action for U.S. Appl. No. 15/221,106 dated Jun. 5, 2018. |
| Non-Final Office Action for U.S. Appl. No. 15/238,427 dated Aug. 8, 2018. |
| Non-Final Office Action for U.S. Appl. No. 15/260,103 dated Sep. 26, 2018. |
| Non-Final Office Action for U.S. Appl. No. 15/611,587 dated Dec. 29, 2017. |
| Non-Final Office Action for U.S. Appl. No. 15/611,587 dated Jul. 13, 2018. |
| Non-Final Office Action for U.S. Appl. No. 15/612,325 dated Mar. 19, 2020. |
| Non-Final Office Action for U.S. Appl. No. 16/245,726 dated Jan. 21, 2022. |
| Non-Final Office Action for U.S. Appl. No. 16/369,676 dated Mar. 31, 2022. |
| Non-Final Office Action for U.S. Appl. No. 16/433,773 dated Apr. 21, 2022. |
| Non-Final Office Action for U.S. Appl. No. 16/449,039 dated Dec. 8, 2021. |
| Non-Final Office Action for U.S. Appl. No. 16/452,145 dated Sep. 28, 2021. |
| Non-Final Office Action for U.S. Appl. No. 16/452,258 dated Sep. 28, 2021. |
| Non-Final Office Action for U.S. Appl. No. 16/478,180 dated Oct. 22, 2021. |
| Non-Final Office Action for U.S. Appl. No. 16/899,956 dated Oct. 16, 2020. |
| Non-Final Office Action for U.S. Appl. No. 16/899,956 dated Sep. 2, 2021. |
| Non-Final Office Action for U.S. Appl. No. 16/904,868 dated Nov. 25, 2020. |
| Non-Final Office Action for U.S. Appl. No. 16/904,868 dated Oct. 5, 2021. |
| Non-Final Office Action for U.S. Appl. No. 16/905,400 dated Apr. 27, 2022. |
| Non-Final Office Action for U.S. Appl. No. 16/905,400 dated Dec. 2, 2020. |
| Non-Final Office Action for U.S. Appl. No. 16/905,400 dated Jul. 22, 2021. |
| Non-Final Office Action for U.S. Appl. No. 17/088,272 dated Jan. 25, 2021. |
| Non-Final Office Action for U.S. Appl. No. 17/330,657 dated Aug. 11, 2021. |
| Non-Final Office Action for U.S. Appl. No. 29/624,661 dated Jul. 18, 2019. |
| Non-Final Office Action for U.S. Appl. No. 29/694,002 dated Jun. 24, 2020. |
| Non-Final Office Action for U.S. Appl. No. 29/741,751 dated Jan. 18, 2022. |
| Notice of Allowance for U.S. Appl. No. 14/952,591 dated Apr. 5, 2021. |
| Notice of Allowance for U.S. Appl. No. 14/952,591 dated Jul. 8, 2021. |
| Notice of Allowance for U.S. Appl. No. 15/171,968 dated Feb. 16, 2021. |
| Notice of Allowance for U.S. Appl. No. 15/171,968 dated Nov. 6, 2020. |
| Notice of Allowance for U.S. Appl. No. 15/221,106 dated May 1, 2019. |
| Notice of Allowance for U.S. Appl. No. 15/238,427 dated May 23, 2019. |
| Notice of Allowance for U.S. Appl. No. 15/260,103 dated Jun. 7, 2019. |
| Notice of Allowance for U.S. Appl. No. 15/611,587 dated Dec. 21, 2018. |
| Notice of Allowance for U.S. Appl. No. 15/612,325 dated Feb. 19, 2021. |
| Notice of Allowance for U.S. Appl. No. 15/612,325 dated Jan. 21, 2021. |
| Notice of Allowance for U.S. Appl. No. 16/899,956 dated Apr. 19, 2022. |
| Notice of Allowance for U.S. Appl. No. 16/899,956 dated Dec. 29, 2021. |
| Notice of Allowance for U.S. Appl. No. 17/088,272 dated Aug. 5, 2021. |
| Notice of Allowance for U.S. Appl. No. 17/088,272 dated Mar. 4, 2022. |
| Notice of Allowance for U.S. Appl. No. 17/088,272 dated Nov. 24, 2021. |
| Notice of Allowance for U.S. Appl. No. 17/330,657 dated Mar. 16, 2022. |
| Notice of Allowance for U.S. Appl. No. 17/330,657 dated Nov. 26, 2021. |
| Notice of Allowance for U.S. Appl. No. 29/624,661 datedd Apr. 28, 2021. |
| Notice of Allowance for U.S. Appl. No. 29/624,661 dated Jul. 10, 2020. |
| Notice of Allowance for U.S. Appl. No. 29/624,661 dated May 14, 2020. |
| Notice of Allowance for U.S. Appl. No. 29/624,661 dated Sep. 29, 2020. |
| Notice of Allowance for U.S. Appl. No. 29/694,002 dated Apr. 29, 2021. |
| Notice of Allowance for U.S. Appl. No. 29/694,002 dated Jan. 29, 2021. |
| Notice of Allowance for U.S. Appl. No. 29/694,002 dated Oct. 16, 2020. |
| Notice to File Missing Parts for U.S. Appl. No. 17/179,116 mailed Mar. 3, 2021. |
| Restriction Requirement for U.S. Appl. No. 16/433,773 dated Dec. 7, 2021. |
| Restriction Requirement for U.S. Appl. No. 16/478,180 dated May 25, 2021. |
| U.S. Appl. No. 14/625,469, filed Feb. 28, 2015. |
| U.S. Appl. No. 14/947,759, filed Nov. 20, 2015. |
| U.S. Appl. No. 14/952,591, filed Nov. 25, 2015. |
| U.S. Appl. No. 15/171,968, filed Jun. 2, 2016. |
| U.S. Appl. No. 15/221,106, filed Jul. 27, 2016. |
| U.S. Appl. No. 15/260,103, filed Sep. 8, 2016. |
| U.S. Appl. No. 15/384,196, filed Dec. 19, 2016. |
| U.S. Appl. No. 15/611,587, filed Jun. 1, 2017. |
| U.S. Appl. No. 15/612,325, filed Jun. 2, 2017. |
| U.S. Appl. No. 16/245,726, filed Jan. 11, 2019. |
| U.S. Appl. No. 16/369,676, filed Mar. 29, 2019. |
| U.S. Appl. No. 16/433,773, filed Jun. 6, 2019. |
| U.S. Appl. No. 16/449,039, filed Jun. 21, 2019. |
| U.S. Appl. No. 16/452,145, filed Jun. 25, 2019. |
| U.S. Appl. No. 16/452,258, filed Jun. 25, 2019. |
| U.S. Appl. No. 16/478,180, filed Jul. 16, 2019. |
| U.S. Appl. No. 16/904,868, filed Jun. 18, 2020. |
| U.S. Appl. No. 16/905,400, filed Jun. 18, 2020. |
| U.S. Appl. No. 17/051,550, filed Oct. 29, 2020. |
| U.S. Appl. No. 17/051,554, filed Oct. 29, 2020. |
| U.S. Appl. No. 17/051,585, filed Oct. 29, 2020. |
| U.S. Appl. No. 17/051,600, filed Oct. 29, 2020. |
| U.S. Appl. No. 17/088,272, filed Nov. 3, 2020. |
| U.S. Appl. No. 17/179,116, filed Feb. 18, 2021. |
| U.S. Appl. No. 17/330,657, filed May 26, 2021. |
| U.S. Appl. No. 17/378,015, filed Jul. 16, 2021. |
| U.S. Appl. No. 17/394,055, filed Aug. 4, 2021. |
| U.S. Appl. No. 17/412,864, filed Aug. 26, 2021. |
| U.S. Appl. No. 17/444,825, filed Aug. 10, 2021. |
| U.S. Appl. No. 17/446,256, filed Aug. 27, 2021. |
| U.S. Appl. No. 17/446,654, filed Sep. 1, 2021. |
| U.S. Appl. No. 17/447,123, filed Sep. 8, 2021. |
| U.S. Appl. No. 17/450,864, filed Oct. 14, 2021. |
| U.S. Appl. No. 17/451,345, filed Oct. 19, 2021. |
| U.S. Appl. No. 17/451,354, filed Oct. 19, 2021. |
| U.S. Appl. No. 17/453,260, filed Nov. 2, 2021. |
| U.S. Appl. No. 17/453,560, filed Nov. 4, 2021. |
| U.S. Appl. No. 17/461,036 mailed Aug. 30, 2021. |
| U.S. Appl. No. 17/494,578, filed Oct. 5, 2021. |
| U.S. Appl. No. 17/501,591, filed Oct. 14, 2021. |
| U.S. Appl. No. 17/595,747, filed Nov. 23, 2021. |
| U.S. Appl. No. 17/597,408, filed Jan. 5, 2022. |
| U.S. Appl. No. 17/597,673, filed Jan. 18, 2022. |
| U.S. Appl. No. 17/614,173, filed Nov. 24, 2021. |
| U.S. Appl. No. 17/631,619, filed Jan. 31, 2022. |
| U.S. Appl. No. 17/645,821, filed Dec. 23, 2021. |
| U.S. Appl. No. 17/646,771, filed Jan. 3, 2022. |
| U.S. Appl. No. 17/653,314, filed Mar. 3, 2022. |
| U.S. Appl. No. 17/653,920, filed Mar. 8, 2022. |
| U.S. Appl. No. 17/654,156, filed Mar. 9, 2022. |
| U.S. Appl. No. 17/655,464, filed Mar. 18, 2022. |
| U.S. Appl. No. 17/657,474, filed Mar. 31, 2022. |
| U.S. Appl. No. 17/661,090, filed Apr. 28, 2022. |
| U.S. Appl. No. 17/754,736, filed Apr. 11, 2022. |
| U.S. Appl. No. 29/741,751, filed Jul. 15, 2020. |
| U.S. Appl. No. 61/955,537, filed Mar. 19, 2014. |
| U.S. Appl. No. 62/082,279, filed Nov. 20, 2014. |
| U.S. Appl. No. 62/084,078, filed Nov. 25, 2014. |
| U.S. Appl. No. 62/414,963, filed Oct. 31, 2016. |
| U.S. Appl. No. 62/452,437, filed Jan. 31, 2017. |
| U.S. Appl. No. 62/485,578, filed Apr. 14, 2017. |
| U.S. Appl. No. 62/665,297, filed May 1, 2018. |
| U.S. Appl. No. 62/665,302, filed May 1, 2018. |
| U.S. Appl. No. 62/665,317, filed May 1, 2018. |
| U.S. Appl. No. 62/665,321, filed May 1, 2018. |
| U.S. Appl. No. 62/665,331, filed May 1, 2018. |
| U.S. Appl. No. 62/665,335, filed May 1, 2018. |
| U.S. Appl. No. 62/853,279, filed May 28, 2019. |
| U.S. Appl. No. 62/853,889, filed May 29, 2019. |
| U.S. Appl. No. 62/864,656, filed Jun. 21, 2019. |
| U.S. Appl. No. 62/873,045, filed Jul. 11, 2019. |
| U.S. Appl. No. 62/873,048, filed Jul. 11, 2019. |
| U.S. Appl. No. 62/876,500, filed Jul. 19, 2019. |
| U.S. Appl. No. 62/877,558, filed Jul. 23, 2019. |
| U.S. Appl. No. 62/883,172, filed Aug. 6, 2019. |
| U.S. Appl. No. 62/889,149, filed Aug. 20, 2019. |
| U.S. Appl. No. 62/923,279, filed Oct. 18, 2019. |
| U.S. Appl. No. 62/926,767, filed Oct. 28, 2019. |
| U.S. Appl. No. 62/935,337, filed Nov. 14, 2019. |
| U.S. Appl. No. 62/938,447, filed Nov. 21, 2019. |
| U.S. Appl. No. 62/949,187, filed Dec. 17, 2019. |
| U.S. Appl. No. 62/956,756, filed Jan. 3, 2020. |
| U.S. Appl. No. 62/956,767, filed Jan. 3, 2020. |
| U.S. Appl. No. 62/956,770, filed Jan. 3, 2020. |
| U.S. Appl. No. 62/967,977, filed Jan. 30, 2020. |
| U.S. Appl. No. 62/994,912, filed Mar. 26, 2020. |
| U.S. Appl. No. 63/008,112, filed Apr. 10, 2020. |
| U.S. Appl. No. 63/011,445, filed Apr. 17, 2020. |
| U.S. Appl. No. 63/011,487, filed Apr. 17, 2020. |
| U.S. Appl. No. 63/011,571, filed Apr. 17, 2020. |
| U.S. Appl. No. 63/011,657, filed Apr. 17, 2020. |
| U.S. Appl. No. 63/011,760, filed Apr. 17, 2020. |
| U.S. Appl. No. 63/012,347, filed Apr. 20, 2020. |
| U.S. Appl. No. 63/012,384, filed Apr. 20, 2020. |
| U.S. Appl. No. 63/030,685, filed May 27, 2020. |
| U.S. Appl. No. 63/033,310, filed Jun. 2, 2020. |
| U.S. Appl. No. 63/047,374, filed Jul. 2, 2020. |
| U.S. Appl. No. 63/061,241, filed Aug. 5, 2020. |
| U.S. Appl. No. 63/061,244, filed Aug. 5, 2020. |
| U.S. Appl. No. 63/061,834, filed Aug. 6, 2020. |
| U.S. Appl. No. 63/064,017, filed Aug. 11, 2020. |
| U.S. Appl. No. 63/064,126, filed Aug. 11, 2020. |
| U.S. Appl. No. 63/067,542, filed Aug. 19, 2020. |
| U.S. Appl. No. 63/071,438, filed Aug. 28, 2020. |
| U.S. Appl. No. 63/071,821, filed Aug. 28, 2020. |
| U.S. Appl. No. 63/073,545, filed Sep. 2, 2020. |
| U.S. Appl. No. 63/073,553, filed Sep. 2, 2020. |
| U.S. Appl. No. 63/074,051, filed Sep. 3, 2020. |
| U.S. Appl. No. 63/074,066, filed Sep. 3, 2020. |
| U.S. Appl. No. 63/076,032, filed Sep. 9, 2020. |
| U.S. Appl. No. 63/076,474, filed Sep. 10, 2020. |
| U.S. Appl. No. 63/076,477, filed Sep. 10, 2020. |
| U.S. Appl. No. 63/082,261, filed Sep. 23, 2020. |
| U.S. Appl. No. 63/088,506, filed Oct. 7, 2020. |
| U.S. Appl. No. 63/088,511, filed Oct. 7, 2020. |
| U.S. Appl. No. 63/088,539, filed Oct. 7, 2020. |
| U.S. Appl. No. 63/094,464, filed Oct. 21, 2020. |
| U.S. Appl. No. 63/094,498, filed Oct. 21, 2020. |
| U.S. Appl. No. 63/094,594, filed Oct. 21, 2020. |
| U.S. Appl. No. 63/094,608, filed Oct. 21, 2020. |
| U.S. Appl. No. 63/094,626, filed Oct. 21, 2020. |
| U.S. Appl. No. 63/094,646, filed Oct. 21, 2020. |
| U.S. Appl. No. 63/109,066, filed Nov. 3, 2020. |
| U.S. Appl. No. 63/109,084, filed Nov. 3, 2020. |
| U.S. Appl. No. 63/112,417, filed Nov. 11, 2020. |
| U.S. Appl. No. 63/119,161, filed Nov. 30, 2020. |
| U.S. Appl. No. 63/124,271, filed Dec. 11, 2020. |
| U.S. Appl. No. 63/133,892, filed Jan. 5, 2021. |
| U.S. Appl. No. 63/134,287, filed Jan. 6, 2021. |
| U.S. Appl. No. 63/134,450, filed Jan. 6, 2021. |
| U.S. Appl. No. 63/134,631, filed Jan. 7, 2021. |
| U.S. Appl. No. 63/134,632, filed Jan. 7, 2021. |
| U.S. Appl. No. 63/134,754, filed Jan. 7, 2021. |
| U.S. Appl. No. 63/138,878, filed Jan. 19, 2021. |
| U.S. Appl. No. 63/146,946, filed Feb. 8, 2021. |
| U.S. Appl. No. 63/147,013, filed Feb. 8, 2021. |
| U.S. Appl. No. 63/147,299, filed Feb. 9, 2021. |
| U.S. Appl. No. 63/148,723, filed Feb. 12, 2021. |
| U.S. Appl. No. 63/154,248, filed Feb. 26, 2021. |
| U.S. Appl. No. 63/155,395, filed Mar. 2, 2021. |
| U.S. Appl. No. 63/157,007, filed Mar. 5, 2021. |
| U.S. Appl. No. 63/157,014, filed Mar. 5, 2021. |
| U.S. Appl. No. 63/159,142, filed Mar. 10, 2021. |
| U.S. Appl. No. 63/159,186, filed Mar. 10, 2021. |
| U.S. Appl. No. 63/159,210, filed Mar. 10, 2021. |
| U.S. Appl. No. 63/159,280, filed Mar. 10, 2021. |
| U.S. Appl. No. 63/165,273 filed Mar. 24, 2021. |
| U.S. Appl. No. 63/165,384, filed Mar. 24, 2021. |
| U.S. Appl. No. 63/171,165, filed Apr. 6, 2021. |
| U.S. Appl. No. 63/172,975, filed Apr. 9, 2021. |
| U.S. Appl. No. 63/181,695, filed Apr. 29, 2021. |
| U.S. Appl. No. 63/192,274, filed May 24, 2021. |
| U.S. Appl. No. 63/192,289, filed May 24, 2021. |
| U.S. Appl. No. 63/193,235, filed May 26, 2021. |
| U.S. Appl. No. 63/193,406, filed May 26, 2021. |
| U.S. Appl. No. 63/193,891, filed May 27, 2021. |
| U.S. Appl. No. 63/208,262, filed Jun. 8, 2021. |
| U.S. Appl. No. 63/214,551, filed Jun. 24, 2021. |
| U.S. Appl. No. 63/214,570, filed Jun. 24, 2021. |
| U.S. Appl. No. 63/215,017, filed Jun. 25, 2021. |
| U.S. Appl. No. 63/228,244, filed Aug. 2, 2021. |
| U.S. Appl. No. 63/228,252, filed Aug. 2, 2021. |
| U.S. Appl. No. 63/228,258, filed Aug. 2, 2021. |
| U.S. Appl. No. 63/230,894, filed Aug. 9, 2021. |
| U.S. Appl. No. 63/230,897, filed Aug. 9, 2021. |
| U.S. Appl. No. 63/238,457, filed Aug. 30, 2021. |
| U.S. Appl. No. 63/238,477, filed Aug. 30, 2021. |
| U.S. Appl. No. 63/241,562, filed Sep. 8, 2021. |
| U.S. Appl. No. 63/241,564, filed Sep. 8, 2021. |
| U.S. Appl. No. 63/241,575, filed Sep. 8, 2021. |
| U.S. Appl. No. 63/246,972, filed Sep. 22, 2021. |
| U.S. Appl. No. 63/247,375, filed Sep. 23, 2021. |
| U.S. Appl. No. 63/247,478, filed Sep. 23, 2021. |
| U.S. Appl. No. 63/247,491, filed Sep. 23, 2021. |
| U.S. Appl. No. 63/299,208, filed Jan. 13, 2022. |
| Sage's Second Supplemental Invalidity Contentions Regarding U.S. Pat. Nos. 8,287,508, 10,226,375, 10,390,989, and 10,376,407, 292 pages. |
| Plaintiff's Identification of Claim Terms and Proposed Constructions, 3 pages. |
| Sage's Preliminary Identification of Claim Elements and Proposed Constructions for U.S. Pat. Nos. 8,287,508, 10,226,376, 10,390,989 and 10,376,407, 7 pages. |
| Corrected Certificate of Service, 2020, 2 pages. |
| Excerpts from the 508 (U.S. Pat. No. 8,278,508) Patent's Prosecution History, 2020, 99 pages. |
| Declaration of Diane K. Newman Curriculum Vitae, 2020, pp. 1-199. |
| Sage's Supplemental and Initial Invalidity Contentions Regarding U.S. Pat. Nos. 8,287,508; 10,226,375; 10,390,989 and Initial Invalidity Contentions Regarding U.S. Pat. No. 10,376,407, Aug. 21, 2020, 277 pages. |
| Decision Granting Institution of Inter Partes Review for U.S. Pat. No. 8,287,508, Feb. 17, 2021, 39 pages. |
| Memorandum Order, Feb. 2021, 14 pgs. |
| Boehringer CareDry System—Second Generation for Non-Invasive Urinary Management for Females, Mar. 2021, 3 pgs. |
| PureWick's Response to Interrogatory No. 9 in PureWick, LLC v. Sage Products, LLC, Mar. 23, 2020, 6 pages. |
| Sage's Initial Invalidity Contentions Regarding U.S. Pat. Nos. 8,287,508; 10,226,375; and 10,390,989, May 29, 2020, 193 pages. |
| Defendant and Counterclaim Plaintiff Sage Products, LLC's Answer, Defenses, and Counterclaims to Plaintiff's Amended Complaint, Nov. 1, 2019. |
| Plaintiff's Opening Claim Construction Brief, Oct. 16, 2020, 26 pages. |
| “3 Devices Take Top Honors in Dare-To-Dream Medtech Design Contest”, R+D Digest, Nov. 2013, 1 page. |
| “Advanced Mission Extender Device (AMDX) Products”, Omni Medical Systems, Inc., 15 pages. |
| “AMXD Control Starter Kit Brochure”, https://www.omnimedicalsys.com/index.php?page=products, 8 pages. |
| “AMXDmax In-Flight Bladder Relief”, Omni Medical; Omni Medical Systems, Inc., 2015. |
| “AMXDX—Advanced Mission Extender Device Brochure”, Omni Medical, 2 pages. |
| “External Urine Management for Female Anatomy”, https://www.stryker.com/us/en/sage/products/sage-primafit.html, Jul. 2020, 4 pages. |
| “High Absorbancy Cellulose Acetate Electrospun Nanofibers for Feminine Hygiene Application”, https://www.sciencedirect.com/science/article/abs/pii/S2352940716300701?via%3Dihub, Jul. 2016, 3 pages. |
| “How Period Panties Work”, www.shethinx.com/pages/thinx-itworks, 2020, 10 pages. |
| “Hydrogel properties of electrospun polyvinylpyrrolidone and polyvinylpyrrolidone/poly(acrylic acid) blend nanofibers”, https://pubs.rsc.org/en/content/articlelanding/2015/ra/c5ra07514a#!divAbstract, 2015, 5 pages. |
| “In Flight Bladder Relief”, Omni Medical, 14 pages. |
| “Making Women's Sanitary Products Safer and Cheaper”, https://www.elsevier.com/connect/making-womens-sanitary-products-safer-and-cheaper, Sep. 2016, 10 pages. |
| “Novel Nanofibers Make Safe and Effective Absorbent for Sanitary Products”, https://www.materialstoday.com/nanomaterials/news/nanofibers-make-safe-and-effective-absorbent/, Oct. 2016, 3 pages. |
| “Research and Development Work Relating to Assistive Technology 2005-06”, British Department of Health, Nov. 2006, 40 pages. |
| “Rising Warrior Insulated Gallon Jug Cover”, https://www.amazon.com/Rising-Warrior-Insulated-Sleeve, 2021, 2 pages. |
| “Step by Step How Ur24 WorksHome”, http://medicalpatentur24.com, Aug 30, 2017, 4 pages. |
| “Underwear that absorbs your period”, Thinx!, 7 pages. |
| “Urine Bag Cover-Catheter Bag Cover 2000 ml Volume-Medline Style-Multiple Sclerosis-Spine Injury-Suprapublic Catheter-Bladder Incontinence”, https://www.etsy.com/listing/1142934658/urine-bag-cover-caatheter-bag-cover-2000, 2022, 1 page. |
| “User & Maintenance Guide”, Omni Medical, 2007, 16 pages. |
| “Vinyl Dust Cover, Janome #741811000, Janome, Sewing Parts Online”, https://www.sewingpartsonline.com/vinyl-dust-cover-janome-74181000, 2020, 2 pages. |
| “Winners Announced for Dare-to-Dream Medtech Design Challenge”, https://www.mddionline.com/design-engineering/winners-announced-dare-dream-medtech-design-challenge, 2014, 4 pages. |
| Ali , “Sustainability Assessment: Seventh Generation Diapers versus gDiapers”, The University of Vermont, Dec. 6, 2011, pp. 1-31. |
| Autumn , et al., “Frictional adhesion: a new angle on gecko attachment”, The Journal of Experimental Biology, 2006, pp. 3569-3579. |
| Cañas , et al., “Effect of nano- and micro-roughness on adhesion of bioinspired micropatterned surfaces”, Acta Biomaterialia 8, 2012, pp. 282-288. |
| Chaudhary , et al., “Bioinspired dry adhesive: Poly(dimethylsiloxane) grafted with poly(2-ethylhexyl acrylate) brushes”, European Polymer Journal, 2015, pp. 432-440. |
| Dai , et al., “Non-sticky and Non-slippery Biomimetic Patterned Surfaces”, Journal of Bionic Engineering, Mar. 2020, pp. 326-334. |
| Espinoza-Ramirez , “Nanobiodiversity and Biomimetic Adhesives Development: From Nature to Production and Application”, Journal of Biomaterials and Nanobiotechnology, pp. 78-101, 2019. |
| Hollister , “Female Urinary and Pouch and Male Urinary Pouch Brochure”, 2011, 1 page. |
| Hollister , “Male Urinary Pouch External Collection Device”, http://www.hollister.com/en/products/Continence-Care-Products/Urine-Collectors/Urine-Collection-Accessories/Male-Urinary-Pouch-External-Collection-Device. |
| Hollister , “Retracted Penis Pouch by Hollister”, Vitality Medical.com, 6 pages. |
| Hwang , et al., “Multifunctional Smart Skin Adhesive Patches for Advanced Health Care”, Adv. Healthcare Mater, 2018, pp. 1-20. |
| Jagota , et al., “Adhesion, friction, and compliance of bio-mimetic and bio-inspired structured interfaces”, Materials Science and Engineering, 2011, pp. 253-292. |
| Jeong , et al., “A nontransferring dry adhesive with hierarchical polymer nanohairs”, PNAS, Apr. 7, 2009, pp. 5639-5644. |
| Jeong , et al., “Nanohairs and nanotubes: Efficient structural elements for gecko-inspired artificial dry adhesives”, Science Direct, 2009, pp. 335-346. |
| Karp , et al., “Dry solution to a sticky problem”, Nature., 2011, pp. 42-43. |
| Lee , et al., “Continuous Fabrication of Wide-Tip Microstructures for Bio-Inspired Dry Adhesives via Tip Inking Process”, Journal of Chemistry, Jan. 2, 2019, pp. 1-5. |
| Macaulay , et al., “A Noninvasive Continence Management System: Development and Evaluation of a Novel Toileting Device for Women”, The Wound, Ostomy and Continence Nurses Society, 2007, pp. 641-648. |
| Newman , et al., “The Urinary Incontinence Sourcebook”, Petition for Interparties Review, 1997, 23 pages. |
| Newton , et al., “Measuring Safety, Effectiveness and Ease of Use of PureWick in the Management of Urinary Incontinence in Bedbound Women: Case Studies”, Jan. 8, 2016, 11 pages. |
| Parmar , “10 Finalists Chosen for Dare-to-Dream Medtech Design Challenge (PureWick)”, Design Services, Nov. 10, 2014, 3 pages. |
| Parness , et al. “A microfabricated wedge-shaped adhesive array displaying gecko-like dynamic adhesion, directionality”, J.R. Soc. Interface, 2009, pp. 1223-1232. |
| Purewick , “Incontinence Relief for Women”, Presentation, Sep. 23, 2015, 7 pages. |
| Pytlik , “Super Absorbent Polymers”, University of Buffalo. |
| Sachtman , “New Relief for Pilots? It Depends”, Wired, 2008, 2 pages. |
| Tsipenyuk , et al., “Use of biomimetic hexagonal surface texture in friction against lubricated skin”, Journal of the Royal Society—Interface, 2014, pp. 1-6. |
| Advisory Action for U.S. Appl. No. 16/904,868 dated Jun. 15, 2022. |
| Final Office Action for U.S. Appl. No. 16/449,039 dated Aug. 1, 2022. |
| Final Office Action for U.S. Appl. No. 16/452,258 dated Jun. 14, 2022. |
| Final Office Action for U.S. Appl. No. 16/478,180 dated Jun. 22, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/039866 dated Oct. 7, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/051456 dated Jan. 19, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/055515 dated Jan. 28, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/011419 dated Jun. 7, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/011421 dated Jun. 13, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/012794 dated May 3, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/015471 dated May 16, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/015492 dated Apr. 26, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/016942 dated Jun. 3, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/018170 dated May 31, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/019254 dated Jun. 7, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/019480 dated Jun. 13, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/021103 dated Jun. 23, 2022. |
| Issue Notification for U.S. Appl. No. 17/088,272 dated Jun. 15, 2022. |
| Issue Notification for U.S. Appl. No. 17/330,657 dated Jun. 22, 2022. |
| Notice of Allowance for U.S. Appl. No. 16/899,956 dated Aug. 10, 2022. |
| Notice of Allowance for U.S. Appl. No. 16/905,400 dated Aug. 17, 2022. |
| Notice of Allowance for U.S. Appl. No. 29/741,751 dated Jun. 9, 2022. |
| U.S. Appl. No. 17/663,046, filed May 12, 2022. |
| U.S. Appl. No. 17/664,914, filed May 25, 2022. |
| U.S. Appl. No. 17/749,340, filed May 20, 2022. |
| U.S. Appl. No. 17/756,201, filed May 19, 2022. |
| U.S. Appl. No. 17/758,152, filed Jun. 29, 2022. |
| U.S. Appl. No. 17/758,316, filed Jul. 1, 2022. |
| U.S. Appl. No. 17/759,697, filed Jul. 28, 2022. |
| U.S. Appl. No. 17/878,268, filed Aug. 1, 2022. |
| U.S. Appl. No. 17/929,887, filed Sep. 6, 2022. |
| U.S. Appl. No. 17/930,238, filed Sep. 7, 2022. |
| U.S. Appl. No. 62/967,158, filed Jan. 26, 2020. |
| U.S. Appl. No. 63/191,558, filed May 21, 2021. |
| U.S. Appl. No. 63/241,328, filed Sep. 7, 2021. |
| Advisory Action for U.S. Appl. No. 16/433,773 dated Feb. 15, 2023. |
| Advisory Action for U.S. Appl. No. 16/452,258 dated Oct. 26, 2022. |
| Advisory Action for U.S. Appl. No. 16/478,180 dated Sep. 21, 2022. |
| Final Office Action for U.S. Appl. No. 16/245,726 dated Nov. 25, 2022. |
| Final Office Action for U.S. Appl. No. 16/369,676 dated Dec. 5, 2022. |
| Final Office Action for U.S. Appl. No. 16/433,773 dated Oct. 25, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/IB2021/057173 dated Nov. 5, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/014285 dated Sep. 28, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/014749 dated Sep. 28, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/015026 dated Oct. 31, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/015045 dated Sep. 9, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/015073 dated Sep. 8, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/015418 dated Nov. 11, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/015420 dated Nov. 18, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/015781 dated May 6, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/018159 dated Dec. 12, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/022111 dated Oct. 26, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/023594 dated Jul. 12, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/026667 dated Aug. 22, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/030685 dated Oct. 31, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/031032 dated Sep. 9, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/032424 dated Oct. 11, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/034457 dated Oct. 12, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/034744 dated Dec. 9, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/039022 dated Jan. 10, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/039711 dated Jan. 12, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/039714 dated Nov. 22, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/042719 dated Dec. 5, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/042725 dated Dec. 19, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/044107 dated Dec. 23, 2022. |
| Issue Notification for U.S. Appl. No. 16,905,400 dated Nov. 30, 2022. |
| Non-Final Office Action for U.S. Appl. No. 16/478,180 dated Dec. 20, 2022. |
| Non-Final Office Action for U.S. Appl. No. 17/051,550 dated Dec. 15, 2022. |
| Non-Final Office Action for U.S. Appl. No. 17/451,345 dated Dec. 7, 2022. |
| Notice of Allowance for U.S. Appl. No. 16/449,039 dated Dec. 15, 2022. |
| Notice of Allowance for U.S. Appl. No. 16/899,956 dated Dec. 1, 2022. |
| Notice of Allowance for U.S. Appl. No. 17/461,036 dated Feb. 22, 2023. |
| Notice of Allowance for U.S. Appl. No. 17/461,036 dated Oct. 6, 2022. |
| Notice of Allowance for U.S. Appl. No. 17/663,046 dated Jan. 30, 2023. |
| U.S. Appl. No. 17/907,125, filed Sep. 23, 2022. |
| U.S. Appl. No. 17/912,147, filed Sep. 16, 2022. |
| U.S. Appl. No. 17/933,590, filed Sep. 20, 2022. |
| U.S. Appl. No. 17/996,064, filed Oct. 12, 2022. |
| U.S. Appl. No. 17/996,155, filed Oct. 13, 2022. |
| U.S. Appl. No. 17/996,253, filed Oct. 14, 2022. |
| U.S. Appl. No. 17/996,468, filed Oct. 18, 2022. |
| U.S. Appl. No. 17/996,556, filed Oct. 19, 2022. |
| U.S. Appl. No. 18/003,029, filed Dec. 22, 2022. |
| U.S. Appl. No. 18/006,807, filed Jan. 25, 2023. |
| U.S. Appl. No. 18/007,105, filed Jan. 27, 2023. |
| U.S. Appl. No. 18/041,109, filed Feb. 9, 2023. |
| U.S. Appl. No. 18/042,842, filed Feb. 24, 2023. |
| U.S. Appl. No. 18/164,800, filed Feb. 6, 2023. |
| U.S. Appl. No. 62/991,754, filed Mar. 19, 2020. |
| Advisory Action for U.S. Appl. No. 16/245,726 mailed Apr. 19, 2023. |
| Advisory Action for U.S. Appl. No. 16/369,676 mailed Mar. 24, 2023. |
| Final Office Action for U.S. Appl. No. 16/478,180 mailed May 31, 2023. |
| Final Office Action for U.S. Appl. No. 17/051,399 mailed Mar. 9, 2023. |
| Final Office Action for U.S. Appl. No. 17/051,550 mailed May 23, 2023. |
| Final Office Action for U.S. Appl. No. 17/451,345 mailed May 3, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/039018 mailed Jan. 10, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/041085 mailed Mar. 16, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/041688 mailed Nov. 21, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/043818 mailed Mar. 24, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/044208 mailed May 8, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/044212 mailed Jan. 20, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/044243 mailed Feb. 24, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/049300 mailed Jun. 6, 2023. |
| Issue Notification for U.S. Appl. No. 16/899,956 mailed Mar. 29, 2023. |
| Non-Final Office Action for U.S. Appl. No. 16/433,773 mailed Apr. 11, 2023. |
| Non-Final Office Action for U.S. Appl. No. 16/449,039 mailed Apr. 27, 2023. |
| Non-Final Office Action for U.S. Appl. No. 16/452,145 mailed Mar. 28, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/653,137 mailed Apr. 7, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/655,464 mailed Mar. 14, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/664,487 mailed Jun. 8, 2023. |
| Restriction Requirement for U.S. Appl. No. 17/326,980 mailed Mar. 20, 2023. |
| Restriction Requirement for U.S. Appl. No. 17/446,256 mailed Jan. 23, 2023. |
| Restriction Requirement for U.S. Appl. No. 17/646,771 mailed Apr. 6, 2023. |
| Text Messages to Lorena Eckert Re Prototype PureWick Holder dated Apr. 16, 2022. |
| U.S. Appl. No. 17/664,487, filed May 23, 2022. |
| U.S. Appl. No. 18/043,618, filed Mar. 1, 2023. |
| U.S. Appl. No. 18/115,444, filed Feb. 28, 2023. |
| U.S. Appl. No. 18/134,857, filed Apr. 14, 2023. |
| Non-Final Office Action for U.S. Appl. No. 16/452,258 mailed Apr. 26, 2023. |
| Non-Final Office Action for U.S. Appl. No. 16/904,868 mailed Mar. 15, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/051,585 mailed Mar. 29, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/179,116 mailed Mar. 24, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/444,792 mailed Feb. 10, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/446,256 mailed Apr. 13, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/448,811 mailed Mar. 1, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/450,864 mailed May 10, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/451,354 mailed May 3, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/453,260 mailed Mar. 14, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/501,591 mailed Apr. 25, 2023. |
| U.S. Appl. No. 18/140,163, filed Apr. 27, 2023. |
| U.S. Appl. No. 18/140,751, filed Apr. 28, 2023. |
| U.S. Appl. No. 18/198,464, filed May 17, 2023. |
| U.S. Appl. No. 18/246,121, filed Mar. 21, 2023. |
| U.S. Appl. No. 18/247,986, filed Apr. 5, 2023. |
| U.S. Appl. No. 18/265,736, filed Jun. 7, 2023. |
| U.S. Appl. No. 18/299,788, filed Apr. 13, 2023. |
| U.S. Appl. No. 18/335,579, filed Jun. 15, 2023. |
| U.S. Appl. No. 63/308,190, filed Feb. 9, 2022. |
| PureWick Corporation v. Sage Products, LLC Transcripts vol. 5, Apr. 1, 2022, 72 pages. |
| PureWick Corporation v. Sage Products, LLC Transcripts vol. 1, Mar. 28, 2022, 99 pages. |
| PureWick Corporation v. Sage Products, LLC Transcripts vol. 2, Mar. 29, 2022, 106 pages. |
| PureWick Corporation v. Sage Products, LLC Transcripts vol. 3, Mar. 30, 2022, 115 pages. |
| PureWick Corporation v. Sage Products, LLC Transcripts vol. 4, Mar. 31, 2022, 117 pages. |
| “AMXD Control Starter Kit”, Omni Medical Systems, Inc., 1 page. |
| “AMXDmax Advanced Mission Extender Device User & Maintenance Guide”, Omni Medical, Jan. 11, 2010, 10 pages. |
| “AMXDmax Development History 2002-2014”, Omni Medical Systems, Inc., 2 pages. |
| “Combat Force Multiplier in Flight Bladder Relief Cockpit Essential Equipment Brochure”, Omni Medical, 20 pages. |
| “GSA Price List”, Omni Medical, Apr. 2011, 2 pages. |
| “How is Polypropylene Fiber Made”, https:www.yarnsandfibers.com/textile-resources/synthetic-fibers/polypropylene-fiber/polypropylene-fiber-production-raw-materials/how-is-polypropylene-fiber-made/ last accessed 2020, Oct. 7, 2020, 3 pages. |
| “Letter to Mark Harvie of Omni Measurement Systems”, Department of Veterans Affairs, Nov. 1, 2007, 11 pages. |
| “Revised AMXDmax Advanced Mission Extender Device User & Maintenance Guide”, Omni Medical Systems, Oct. 8, 2019, 52 pages. |
| Pieper , et al., “An external urine-collection device for women: A clinical trial”, Journal of ER Nursing, vol. 20, No. 2, Mar./Apr. 1993, pp. 51-55. |
| VINAS , “A Solution For An Awkward—But Serious—Subject”, http://www.aero-news.net/index.cfm?do=main.textpost&id=69ae2bb1-838b-4098-a7b5-7flbb2505688 last accessed Feb. 8, 2021, 3 pages. |
| Advisory Action for U.S. Appl. No. 16/478,180 mailed Sep. 7, 2023. |
| Advisory Action for U.S. Appl. No. 17/051,550 mailed Sep. 8, 2023. |
| Advisory Action for U.S. Appl. No. 17/051,585 mailed Oct. 17, 2023. |
| Advisory Action for U.S. Appl. No. 17/444,792 mailed Aug. 25, 2023. |
| Advisory Action for U.S. Appl. No. 17/451,345 mailed Oct. 20, 2023. |
| Final Office Action for U.S. Appl. No. 16/369,676 mailed Aug. 31, 2023. |
| Final Office Action for U.S. Appl. No. 16/433,773 mailed Oct. 10, 2023. |
| Final Office Action for U.S. Appl. No. 17/051,585 mailed Jul. 27, 2023. |
| Final Office Action for U.S. Appl. No. 17/444,792 mailed Jun. 15, 2023. |
| Final Office Action for U.S. Appl. No. 17/446,256 mailed Sep. 19, 2023. |
| Final Office Action for U.S. Appl. No. 17/448,811 mailed Aug. 3, 2023. |
| Final Office Action for U.S. Appl. No. 17/453,260 mailed Oct. 5, 2023. |
| Final Office Action for U.S. Appl. No. 17/653,137 mailed Sep. 21, 2023. |
| Final Office Action for U.S. Appl. No. 17/655,464 mailed Sep. 1, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/050909 mailed Jul. 24, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/012696 mailed Jul. 6, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/018474 mailed Sep. 11, 2023. |
| Issue Notification for U.S. Appl. No. 16/245,726 mailed Oct. 18, 2023. |
| Issue Notification for U.S. Appl. No. 17/461,036 mailed Oct. 11, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/051,399 mailed Aug. 18, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/326,980 mailed Jul. 11, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/446,654 mailed Sep. 8, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/453,560 mailed Oct. 16, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/646,771 mailed Jul. 5, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/657,474 mailed Sep. 12, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/661,090 mailed Jul. 6, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/663,330 mailed Jun. 29, 2023. |
| Non-Final Office Action for U.S. Appl. No. 18/139,523 mailed Aug. 17, 2023. |
| Non-Final Office Action for U.S. Appl. No. 18/140,751 mailed Sep. 14, 2023. |
| Notice of Allowance for U.S. Appl. No. 16/245,726 mailed Jul. 6, 2023. |
| Notice of Allowance for U.S. Appl. No. 17/051,554 mailed Jul. 6, 2023. |
| Notice of Allowance for U.S. Appl. No. 17/051,554 mailed Oct. 18, 2023. |
| Notice of Allowance for U.S. Appl. No. 17/461,036 mailed Jun. 30, 2023. |
| Notice of Allowance for U.S. Appl. No. 18/299,788 mailed Jul. 24, 2023. |
| Restriction Requirement for U.S. Appl. No. 17/051,600 mailed Sep. 21, 2023. |
| Restriction Requirement for U.S. Appl. No. 17/645,821 mailed Jul. 12, 2023. |
| Restriction Requirement for U.S. Appl. No. 17/657,474 mailed Jun. 30, 2023. |
| U.S. Appl. No. 18/259,626, filed Jun. 28, 2023. |
| U.S. Appl. No. 18/260,122, filed Jun. 30, 2023. |
| U.S. Appl. No. 18/260,391, filed Jul. 5, 2023. |
| U.S. Appl. No. 18/260,394, filed Jul. 5, 2023. |
| U.S. Appl. No. 18/263,800, filed Aug. 1, 2023. |
| U.S. Appl. No. 18/264,004, filed Aug. 2, 2023. |
| U.S. Appl. No. 18/373,424, filed Sep. 27, 2023. |
| U.S. Appl. No. 18/376,274, filed Oct. 3, 2023. |
| U.S. Appl. No. 18/548,152, filed Aug. 28, 2023. |
| U.S. Appl. No. 18/549,387, filed Sep. 7, 2023. |
| U.S. Appl. No. 18/549,658, filed Sep. 8, 2023. |
| U.S. Appl. No. 18/553,625, filed Oct. 2, 2023. |
| U.S. Appl. No. 63/150,640, filed Feb. 18, 2021. |
| Merriam-Webster Dictionary, “Embed Definition & Meaning”, https://www.merriam-webster.com/dictionary/embed last accessed Aug. 3, 2023, 2003. |
| Advisory Action for U.S. Appl. No. 16/433,773 mailed Dec. 29, 2023. |
| Advisory Action for U.S. Appl. No. 16/449,039 mailed Jan. 25, 2024. |
| Advisory Action for U.S. Appl. No. 16/904,868 mailed Jan. 2, 2024. |
| Advisory Action for U.S. Appl. No. 17/179,116 mailed Jan. 8, 2024. |
| Advisory Action for U.S. Appl. No. 17/446,256 mailed Dec. 8, 2023. |
| Advisory Action for U.S. Appl. No. 17/448,811 mailed Nov. 15, 2023. |
| Advisory Action for U.S. Appl. No. 17/451,354 mailed Jan. 30, 2024. |
| Advisory Action for U.S. Appl. No. 17/453,260 mailed Dec. 22, 2023. |
| Advisory Action for U.S. Appl. No. 17/653,137 mailed Dec. 1, 2023. |
| Advisory Action for U.S. Appl. No. 17/655,464 mailed Dec. 13, 2023. |
| Advisory Action for U.S. Appl. No. 18/164,800 mailed Feb. 12, 2024. |
| Communication of Notice of Opposition of European Application No. 17807547.9 mailed Jan. 5, 2024. |
| Corrected Notice of Allowability for U.S. Appl. No. 16/369,676 mailed Dec. 7, 2023. |
| Corrected Notice of Allowability for U.S. Appl. No. 17/326,980 mailed Feb. 8, 2024. |
| Final Office Action for U.S. Appl. No. 16/449,039 mailed Nov. 21, 2023. |
| Final Office Action for U.S. Appl. No. 16/452,258 mailed Dec. 21, 2023. |
| Final Office Action for U.S. Appl. No. 16/904,868 mailed Nov. 2, 2023. |
| Final Office Action for U.S. Appl. No. 17/051,399 mailed Jan. 8, 2024. |
| Final Office Action for U.S. Appl. No. 17/179,116 mailed Oct. 31, 2023. |
| Final Office Action for U.S. Appl. No. 17/446,654 mailed Jan. 31, 2024. |
| Final Office Action for U.S. Appl. No. 17/450,864 mailed Dec. 28, 2023. |
| Final Office Action for U.S. Appl. No. 17/451,354 mailed Oct. 30, 2023. |
| Final Office Action for U.S. Appl. No. 17/501,591 mailed Nov. 14, 2023. |
| Final Office Action for U.S. Appl. No. 17/646,771 mailed Dec. 21, 2023. |
| Final Office Action for U.S. Appl. No. 17/661,090 mailed Dec. 11, 2023. |
| Final Office Action for U.S. Appl. No. 17/663,330 mailed Dec. 12, 2023. |
| Final Office Action for U.S. Appl. No. 17/664,487 mailed Jan. 4, 2024. |
| Final Office Action for U.S. Appl. No. 18/139,523 mailed Dec. 22, 2023. |
| Final Office Action for U.S. Appl. No. 18/140,751 mailed Jan. 17, 2024. |
| Final Office Action for U.S. Appl. No. 18/164,800 mailed Dec. 6, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/024805 mailed Dec. 14, 2023. |
| Issue Notification for U.S. Appl. No. 17/663,046 mailed Dec. 20, 2023. |
| Non-Final Office Action for U.S. Appl. No. 16/452,145 mailed Nov. 2, 2023. |
| Non-Final Office Action for U.S. Appl. No. 16/478,180 mailed Nov. 7, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/051,550 mailed Oct. 24, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/051,585 mailed Jan. 8, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/051,600 mailed Jan. 17, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/444,792 mailed Nov. 17, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/446,256 mailed Feb. 13, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/447,123 mailed Jan. 24, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/448,811 mailed Jan. 17, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/451,345 mailed Jan. 17, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/645,821 mailed Oct. 25, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/653,137 mailed Jan. 18, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/664,914 mailed Jan. 31, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/808,354 mailed Nov. 28, 2023. |
| Non-Final Office Action for U.S. Appl. No. 18/134,857 mailed Jan. 25, 2024. |
| Non-Final Office Action for U.S. Appl. No. 18/140,163 mailed Nov. 9, 2023. |
| Non-Final Office Action for U.S. Appl. No. 18/198,464 mailed Dec. 7, 2023. |
| Notice of Allowance for U.S. Appl. No. 16/369,676 mailed Nov. 14, 2023. |
| Notice of Allowance for U.S. Appl. No. 17/051,550 mailed Feb. 7, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/326,980 mailed Jan. 29, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/453,560 mailed Jan. 31, 2024. |
| Notice of Allowance for U.S. Appl. No. 18/299,788 mailed Nov. 6, 2023. |
| Restriction Requirement for U.S. Appl. No. 18/134,857 mailed Oct. 23, 2023. |
| Submission in Opposition Proceedings for European Application No. 17807547.9 filed Jan. 10, 2024. |
| U.S. Appl. No. 17/451,719, filed Oct. 19, 2021. |
| U.S. Appl. No. 18/294,370, filed Feb. 1, 2024. |
| U.S. Appl. No. 18/294,403, filed Feb. 1, 2024. |
| U.S. Appl. No. 18/389,009, filed Nov. 13, 2023. |
| U.S. Appl. No. 18/415,080, filed Jan. 17, 2024. |
| U.S. Appl. No. 18/426,795, filed Jan. 30, 2024. |
| U.S. Appl. No. 18/556,945, filed Oct. 24, 2023. |
| U.S. Appl. No. 18/558,502, filed Nov. 1, 2023. |
| U.S. Appl. No. 18/562,626, filed Nov. 20, 2023. |
| U.S. Appl. No. 18/563,672, filed Nov. 22, 2023. |
| U.S. Appl. No. 18/569,711, filed Dec. 13, 2023. |
| U.S. Appl. No. 18/569,778, filed Dec. 13, 2023. |
| U.S. Appl. No. 18/681,987, filed Feb. 7, 2024. |
| U.S. Appl. No. 18/682,006, filed Feb. 7, 2024. |
| U.S. Appl. No. 63/596,012, filed Nov. 3, 2023. |
| U.S. Appl. No. 63/608,553, filed Dec. 11, 2023. |
| Wikipedia Article, “Zylinder (Geometrie)”, https://de.wikipedia.org/w/index.php?title=Zylinder (Geometrie)&oldid=154862081, version of Jun. 1, 2016 , 7 pages. |
| Advisory Action for U.S. Appl. No. 16/452,258 mailed Apr. 8, 2024. |
| Advisory Action for U.S. Appl. No. 17/446,654 mailed Apr. 15, 2024. |
| Advisory Action for U.S. Appl. No. 17/450,864 mailed Mar. 21, 2024. |
| Advisory Action for U.S. Appl. No. 17/501,591 mailed Feb. 22, 2024. |
| Advisory Action for U.S. Appl. No. 17/646,771 mailed Feb. 29, 2024. |
| Advisory Action for U.S. Appl. No. 17/661,090 mailed Feb. 26, 2024. |
| Advisory Action for U.S. Appl. No. 17/663,330 mailed Feb. 27, 2024. |
| Advisory Action for U.S. Appl. No. 17/664,487 mailed Mar. 13, 2024. |
| Advisory Action for U.S. Appl. No. 18/139,523 mailed Apr. 24, 2024. |
| Advisory Action for U.S. Appl. No. 18/140,751 mailed Apr. 24, 2024. |
| Corrected Notice of Allowability for U.S. Appl. No. 17/657,474 mailed Mar. 13, 2024. |
| Corrected Notice of Allowability for U.S. Appl. No. 17/657,474 mailed May 14, 2024. |
| Final Office Action for U.S. Appl. No. 16/478,180 mailed Feb. 28, 2024. |
| Final Office Action for U.S. Appl. No. 17/444,792 mailed Apr. 3, 2024. |
| Final Office Action for U.S. Appl. No. 17/447,123 mailed May 14, 2024. |
| Final Office Action for U.S. Appl. No. 17/451,345 mailed Apr. 18, 2024. |
| Final Office Action for U.S. Appl. No. 17/645,821 mailed Apr. 3, 2024. |
| Final Office Action for U.S. Appl. No. 17/808,354 mailed Apr. 10, 2024. |
| Final Office Action for U.S. Appl. No. 18/140,163 mailed Mar. 27, 2024. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/025192 mailed Feb. 7, 2024. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/025939 mailed Feb. 7, 2024. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/030365 mailed Mar. 13, 2024. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/030373 mailed Mar. 13, 2024. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/031433 mailed Mar. 4, 2024. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/031740 mailed Mar. 4, 2024. |
| Issue Notification for U.S. Appl. No. 17/051,550 mailed Mar. 13, 2024. |
| Issue Notification for U.S. Appl. No. 17/051,554 mailed Mar. 6, 2024. |
| Issue Notification for U.S. Appl. No. 18/299,788 mailed Feb. 21, 2024. |
| Non-Final Office Action for U.S. Appl. No. 16/369,676 mailed Feb. 29, 2024. |
| Non-Final Office Action for U.S. Appl. No. 16/433,773 mailed Feb. 26, 2024. |
| Non-Final Office Action for U.S. Appl. No. 16/904,868 mailed Mar. 12, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/179,116 mailed Feb. 26, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/451,354 mailed Apr. 4, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/597,673 mailed Mar. 20, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/646,771 mailed Apr. 24, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/653,920 mailed Mar. 15, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/655,464 mailed Mar. 26, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/661,090 mailed May 22, 2024. |
| Non-Final Office Action for U.S. Appl. No. 18/003,029 mailed Mar. 26, 2024. |
| Non-Final Office Action for U.S. Appl. No. 18/164,800 mailed Mar. 22, 2024. |
| Non-Final Office Action for U.S. Appl. No. 18/389,009 mailed May 24, 2024. |
| Notice of Allowance for U.S. Appl. No. 16/449,039 mailed Mar. 28, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/326,980 mailed Apr. 5, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/453,260 mailed Apr. 8, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/657,474 mailed Mar. 5, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/657,474 mailed May 2, 2024. |
| Notice of Allowance for U.S. Appl. No. 18/198,464 mailed Apr. 17, 2024. |
| Restriction Requirement for U.S. Appl. No. 17/667,097 mailed Mar. 20, 2024. |
| Supplemental Notice of Allowance for U.S. Appl. No. 17/051,550 mailed Feb. 21, 2024. |
| Supplemental Notice of Allowance for U.S. Appl. No. 17/051,554 mailed Feb. 14, 2024. |
| U.S. Appl. No. 17/444,792, filed Aug. 10, 2021. |
| U.S. Appl. No. 18/249,577, filed Oct. 19, 2021. |
| U.S. Appl. No. 18/584,002, filed Feb. 22, 2024. |
| U.S. Appl. No. 18/610,523, filed Mar. 20, 2024. |
| U.S. Appl. No. 18/662,216, filed May 13, 2024. |
| U.S. Appl. No. 18/687,117, filed Feb. 27, 2024. |
| U.S. Appl. No. 18/688,023, filed Feb. 29, 2024. |
| U.S. Appl. No. 18/693,638, filed Mar. 20, 2024. |
| U.S. Appl. No. 18/694,090, filed Mar. 21, 2024. |
| U.S. Appl. No. 63/561,893, filed Dec. 11, 2023. |
| Wikipedia Article, “Decibel”, https://web.archive.org/web/2020041521917/https://en.wikipedia/org/wiki/Decibel last accessed Mar. 11, 2024, 21 pages. |
| Wikipedia Article, “Fiberglass”, https://web.archive.org.web/20200309194847/https://en.wikipedia.org/wiki/Fiberglass last accessed Mar. 11, 2024. |
| Number | Date | Country | |
|---|---|---|---|
| 20220265462 A1 | Aug 2022 | US |
| Number | Date | Country | |
|---|---|---|---|
| 63008112 | Apr 2020 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | PCT/US2021/026607 | Apr 2021 | WO |
| Child | 17662700 | US |
